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1 Introduction 
1.1 Drug Development & Pharmacotherapy 
The existing drug development process1 is regulated by authorities like the US Food 
and Drug Administration (FDA) or the European Medicines Agency (EMA) and it en-
sures that safe and effective medications are made available to the public in an ethically 
rigorous manner. However, the drug development process is hampered by its duration 
and its costs. The average time for a new molecular entity to successfully enter the drug 
market is 13.5 years at costs of 1,778 million US Dollars2. These costs have been steadily 
increasing over the last decades3. This poses not only a threat to pharmaceutical compa-
nies which have to make risky decisions during drug development but also to patients 
for whom safe and effective pharmacotherapy is not available yet. 
Pharmacotherapy (therapy using pharmaceutical drugs) poses further challenges to 
medical professionals as well as patients. All patients have individual anatomical and 
physiological properties such as age and genetics and they can be in different disease 
states with varying co-medications. These factors, among various others, can positively 
or negatively impact a drug’s pharmacokinetics (PK) and pharmacodynamics (PD) and 
thus pharmacotherapy. However, the drug development process can only cover a small 
fraction of the population during the clinical research phases. Hence, the drug therapy is 
not equally safe and effective for all patients treated with the dosing regimens approved 
by the authorities for a new drug, as not all possible patient properties are equally ac-
counted for by these dosing regimens that were determined during the clinical study 
phases. 
A sophisticated solution to reduce the time drug development takes as well as its 
costs and to improve pharmacotherapy is the development and application of mathemat-
ical modeling and simulation. 
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1.2 Pharmacometrics (PMx), Quantitative Systems Pharmacology 
(QSP) & Physiologically-based Pharmacokinetics (PBPK) 
Mathematical models are often used to describe real-life measurements and to pre-
dict non-measured values by simulation of “what-if” scenarios. This approach is common 
practice in natural sciences, engineering and many industries like aerospace or automo-
tive. 
Pharmacometrics (PMx - equivalent to “population pharmacokinetics” or “POP-
PK”) is the science of mathematically and statistically quantifying disease, drug and 
clinical trial characteristics such as dose, biomarkers, endpoints and study design4. Since 
the pioneering development of key concepts of PK and PD in the 1950s5, PMx has evolved 
from a scientific curiosity in literature and academia6–10 to a vital part of regulatory 
guidelines11–18 that has been identified as a strategic component for the Ciritical Path 
Initiative19 with the aim of improving decision making in drug development and pharma-
cotherapy. 
In the past, PMx activities have helped to increase the drug research and develop-
ment efficiency20–23 by enabling approval of unstudied dosing regimens, providing con-
firmatory evidence of effectiveness and deriving model-based primary study endpoints24. 
Furthermore, PMx helped to increase the mechanistic understanding of drugs25,26, deter-
mine first-in-human doses27,28, optimize study designs21,29–31, characterize risks and benefits 
from early clinical responses32–36, select dose schedules and label recommendations37–39 and 
to differentiate between comparator and standard of care drugs40–43. 
Next to PMx, Quantitative Systems Pharmacology (QSP) has emerged as an inno-
vative tool lately44. QSP aims at joining physiologically-based pharmacokinetics (PBPK) 
with in vitro-in vivo correlation of absorption, distribution, metabolism and excretion 
(ADME) data45, often enhanced by complex systems biology models and methodology. 
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PBPK modeling and simulation is one of the main pillars of the modeling and 
simulation (r)evolution in the pharmaceutical sciences46,47. PBPK models where first con-
ceptualized as soon as 1937 by the Swedish physiologist Torsten Teorell48,49 who many 
now attribute as being the father of modern PK50,51. However, computing capacity has 
only started in the 1960s and 1970s to become powerful enough to cope with the mathe-
matical equation systems of PBPK models52. 
PBPK models consist of multiple compartments which are based on real tissue 
characteristics such as volume, surface area and protein expression. The tissue compart-
ments are mechanistically connected via tissue blood flows to simulate in vivo ADME47,53. 
PBPK models can be developed in varying degrees of complexity as minimal54,55, whole-
body56,57, and as whole-body models incorporating even more complex systems biology 
models44,58,59. In minimal PBPK models, organ tissues that show similar PK behavior are 
‘lumped’ together60–62 to reduce model complexity while considering available physiologi-
cal, anatomical and ADME information and the questions to be answered by the model63–
67. Next to these drug-independent physiological and anatomical parameters, PBPK mod-
els build upon drug-dependent parameters such as logP, pKa, molecular weight and drug-
biological parameters such as unbound drug fraction in plasma (fu), metabolism data, 
drug transporter data and pharmacogenetics. 
PBPK modeling was initially applied in the field of toxicology and toxicokinetics68–
70 where it is still used today71. As computing capacity has grown and new in silico and 
in vitro methodologies emerged, PBPK modeling and simulation has expanded to various 
clinically relevant fields during drug development and pharmacotherapy. PBPK has al-
ready made contributions in the prediction and assessment of (i) drug-drug- and drug-
gene-interactions (DDI72–75 and DGI76–79) via metabolic enzymes and drug transporters 
and (ii) the PK of special populations, such as pediatric80–82, geriatric83,84 and pregnant 
individuals85,86 or patients with differing degrees of hepatic87,88 or renal89,90 impairment.  
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1.3 PBPK in Drug Development 
During drug discovery, PBPK modeling and simulation can be applied in the lead 
optimization or candidate drug selection by providing human PK predictions91. The pre-
diction of high necessary drug doses or the need for multiple drug administrations per 
day might already discourage the further development of a candidate drug. At this stage, 
the PBPK model is informed by drug-dependent parameters such as logP, pKa or mo-
lecular weight. 
In preclinical development, the ADME of the candidate drug is assessed by metabolism 
and transporter assays, as well as by PK studies in animal species such as mice, rats, 
rabbits, dogs and monkeys92–94. Here, basic information on relevant drug metabolizing 
enzymes (e.g. cytochrome P-450 (CYP), UDP-glucuronosyltransferase (UGT)), drug 
transporters (e.g. P-glycoprotein (P-gp), organic anion-polypeptide transporters 
(OATP)), drug permeability, distribution and excretion is obtained. At this stage the 
PBPK model gains information on important drug-biological properties. PBPK modeling 
now has the capacity to inform clinical trials and to simulate DDIs. In case enough safety 
margin can be predicted in worst-case simulation scenarios, clinical DDI trials can be 
waivered15. 
In clinical development the so far developed PBPK model can be applied to predict 
clinical phase I safety trials in healthy volunteers. In vivo concentration-time profiles and 
excretion data of the investigational new drug (IND) can then help to improve the PBPK 
model performance for the prediction of clinical phase II trials which assess the drug 
efficacy in patients. Clinical phase III trials that provide a more thorough understanding 
of the effectiveness of the drug, the benefits and the range of possible adverse reactions 
are in many cases also accompanied by PBPK modeling exercises. Fully developed PBPK 
models can be used as part of the regulatory submission to support the market access.  
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With increasing information during the drug development, the confidence in the PBPK 
modeling predictions is increasing. This pushes the candidate drug development process 
forward by enabling the prediction of the drug PK in special populations (e.g. children) 
at strategically important milestones. 
After drug approval by the authorities and market access, PBPK models can be regu-
larly updated to accommodate emerging new scientific information on the drug. After 
the replacement of the drug by more efficacious and/or safer competitors, the obsolete 
drug can still be a valuable part of a PBPK model repository95, for instance, to simulate 
DDI scenarios in order to predict the effect of the obsolete co-administered drugs on 
newly developed medications and vice versa.  
At every stage in the development of a drug, PBPK modeling and simulation helps to 
combine all available drug-dependent and drug-biological in silico, in vitro and in vivo 
information to help answer complex questions in order to move drug candidates from 
their discovery to the market and beyond. 
1.4 PBPK in Pharmacotherapy 
PBPK models and hence the simulations which are based on them are ab initio 
blind for human age, meaning that the models initially do not take into account anatom-
ical or physiological changes, i.e. maturation in the young or functional decline in the 
elderly. In general, human life can be categorized into several age groups, each showing 
physiological and anatomical properties which are specific to the respective age group. 
Commonly, infancy (0-2 years), childhood (2-12 years), adolescence (12-18 years), adult-
hood (20-65 years), the elderly life stage (>65 years) and death are differentiated.  
Age-dependent anthropometric measures such as body height/weight but also or-
gan/tissue weights and volumes as well as varying degrees of organ functions can be 
implemented into PBPK models to simulate age-specific PK from birth to the elderly. 
As already ascertained in the literature: neonates, infants, children and adolescents are 
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not small adults96–99 but demonstrate particular anatomical and physiological properties 
which have the potential to alter the PK of drugs when compared to adults and elderly 
patients100–103. Next to height and body weight104, the body composition105, the cardiac 
output106,107 as well as blood flows108–111 are altered in pediatric patients. Absorption of 
drugs might be different in children by a relatively elevated intra-gastric pH due to 
reduced acid output and decreased volume of gastric secretion112–114, immature conjuga-
tion and transport of bile salts115,116 and immature intestinal motor activity117. Maturation 
of drug transporters118–120, e.g. P-gp and OATP, might impact the absorption, distribution 
and elimination of drugs that are substrates of these transporters. Reduced alpha-1-acid 
glycoprotein (AAG) and human serum albumin (HSA)121,122 quantities can increase the 
free fraction of drugs in pediatric patients and thereby can alter their distribution and 
elimination. Delayed maturation of most drug-metabolizing phase I and II enzymes such 
as CYP 2C9123–125, CYP2C19123,124, CYP3A4126–129, UGT 1A9130 and UGT2B7130–132 can in-
crease or decrease the metabolic clearance and hence decrease or increase the exposure 
of substrates, respectively. Finally, the glomerular filtration rate (GFR) follows a partic-
ular age-dependent maturation with increasing GFR from birth to adulthood133. 
While pediatric patients mostly show immature physiological systems (an exception 
is CYP3A7126,128) which develop towards the adult functionality, elderly patients in many 
aspects show declining physiological functioning. Elderly patients show a loss of muscle 
mass but a relative increase in fat mass134–136, a decrease in liver137–139 and kidney 
weight140,141, a reduction in cardiac index142, which relates the cardiac output (CO) to the 
body surface area (BSA), and reduced kidney blood flow143. All of these parameters have 
the capacity to influence the PK of drugs in the elderly. 
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In summary, PBPK modeling and simulation can be used to describe and predict the 
PK of drugs at all stages of human life by implementing human anatomical and physio-
logical data (drug-independent parameters) and can thereby help to personalize drug 
treatments for more effective and safer pharmacotherapies. 
1.5 PBPK & Drug-Drug-Interactions (DDI) 
While steady scientific progress has been accomplished in various areas of PBPK re-
search, most contributions have been made in the area of DDI modeling, shown by its 
over-proportional use in DDI simulations for regulatory submissions144–146. 
1.5.1 DDI Assessment and Authority Perspective 
In a DDI scenario, the co-administered “perpetrator” drug causes an altered systemic 
and/or local exposure of the “victim drug” which may lead to increased rates of undesir-
able effects due to sub- or supra-therapeutic “victim” drug concentrations. This is espe-
cially important when the PK interaction is large enough in magnitude to produce a 
clinically relevant change on the PD of the “victim” drug, the “victim” exhibits a narrow 
therapeutic index and the variability in the PK of the victim is small enough for the DDI 
to be identifiable147. As DDIs can negatively impact pharmacotherapy, it is important to 
assess and quantify potential DDIs during drug development and beyond market access 
to provide guidance to medical professionals and drug regulatory authorities on how to 
treat clinically relevant DDIs during drug therapy. 
The FDA and EMA provide a systematic, risk-based approach for the assessment of 
the DDI potential of IND14–16. During this assessment there are three major tasks: 1. To 
identify the primary routes of the IND’s elimination; 2. To derive the contribution of 
enzymes and transporters to the IND’s disposition; 3. To characterize the impact of the 
IND on enzymes and transporters. By translating these in vitro observations into in vivo 
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predictions, the PBPK modeling approach is in some cases able to replace clinical in vivo 
studies as stated recently in an updated FDA guideline on DDIs15. 
1.5.2 DDI Management 
The number of patients taking more than one drug at a time has increased over the 
last decade148,149. Hence, the risk of unanticipated, unrecognized, or mismanaged DDIs is 
increasing, which is an important cause of morbidity and mortality150. Therefore, the 
FDA recommends developing DDI management strategies when a clinically significant 
DDI has been identified14.  
These DDI management strategies may include the contraindication and avoidance of 
the concomitant use, the temporary discontinuation and/or dosage modifications of the 
interacting drugs, including staggered drug administration and specific monitoring strat-
egies (e.g. therapeutic drug monitoring (TDM)). 
Especially in the case of successfully marketed drugs, PBPK modeling and simulation 
might either help to catch up on DDI studies which have not been performed in vivo in 
the past or help to reassess already conducted in vivo DDI studies. Hence, formerly 
contraindicated drugs might be eligible for concomitant use with dose modifications 
based on PBPK simulations. In that sense, PBPK modeling and simulation can become 
a valuable tool for DDI management strategies. 
1.6 PBPK & Pharmacodynamics (PD) 
While the PK relates the drug administration to drug concentrations within the body 
over time, the PD relates the response (desired and undesired) to drug concentrations. 
In PBPK models, organs can be explicitly represented with intracellular, interstitial, 
plasma and red blood cell compartments of these organs. Hence, on- and off-target tissue 
exposure to drugs can be directly quantified. Furthermore, drug targets like enzymes or 
other proteins can be distributed in the PBPK model in a tissue-specific manner using 
 1. INTRODUCTION 
 
9 
 
in vitro and in vivo mRNA and/or protein quantification data151–153. Subsequently, 
PBPK/PD models enable the simulation of tissue-specific PD at the actual site of drug 
action. In the literature, PBPK/PD models have been successfully applied to model the 
effect of antibiotics on bacterial growth in the lung154 or to investigate dosing schedules 
for a switch of medication from warfarin to rivaroxaban155. 
PBPK/PD models can offer a unique method to assess and optimize drug treatments 
taking advantage of the high spatial resolution (tissue representation) of PBPK models. 
1.7 Current Obstacles in PBPK Research 
Although there have been successes in PBPK modeling and simulation research over 
the years, there are critical issues that prevent the PBPK approach from being used at 
its full potential.  
Firstly, the DDI potential analysis of drug transporter substrates during drug devel-
opment is a field with a high research demand. Due to the complex model development 
and data integration process, many reliable victim drug models to assess the impact of 
potential perpetrator drugs in coupled PBPK models are not available in the literature. 
Hence, it is crucial to develop these victim drug models but also to find a scientifically 
sound “work-around” to analyze the general DDI potential of perpetrators in case PBPK 
models of victim drugs are missing. 
Secondly, a vividly investigated topic is the implementation of enzyme and transporter 
inhibition models into PBPK models and their application in DDI simulation scenarios. 
Some perpetrator and victim drugs, which are often used in in vitro DDI screenings 
heavily depend on tissue-specific (e.g. intestine, liver, kidney) metabolism and transport. 
A major hurdle preventing easily accessible and usable DDI models is to combine these 
drugs in DDI models while accounting for tissue-specific inhibition, tissue-specific protein 
abundances and half-lives and to simultaneously reflect the literature information on the 
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PK of these drugs. Furthermore, questions on how these DDI models could be applied in 
DDI management and assessment scenarios remain.  
Thirdly, to apply PBPK models for dose specification in pediatric patients, maturation 
functions, describing the expression of enzymes and transporters over time, must be 
available and implemented in pediatric PBPK models. It is only recently that expression 
data of some neglected metabolic enzymes, such as UGT2B17, has become available. 
Hence, pediatric PBPK models and simulations for UGT2B17 substrates are needed for 
the design of future pediatric clinical trials. 
Fourthly, there is a need to develop the existing PBPK software further. Many complex 
induction or inhibition processes of proteins, mediated by drugs, have not yet been im-
plemented into these software packages and can therefore not be accounted for in the 
model simulations. Equally missing are integrated PD models to simultaneously account 
for plasma drug concentrations together with safety and efficacy biomarkers in the target 
tissues. 
Finally, as described in the introduction, PBPK modeling has been applied in several 
patient populations. So far, these applications have been limited to model simulations 
for living patients. As of now, PBPK research tries to push this boundary forward to 
describe and predict the PK of drugs shortly before and after death. Here, PBPK models 
could be applied in the guidance of palliative drug dosing and in cases of legal medicine. 
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2 Aims and Objectives of Projects I-IV 
The aim of this thesis was to overcome some of the major obstacles in current PBPK 
research, to innovate state-of-the-art PBPK modeling and simulation techniques and to 
generate new explanations and hypotheses for future research. The thesis’ aim was real-
ized within the scope of the following projects: 
 
Project I: DDI potential of zoptarelin doxorubicin 
The aim of project I was to support the drug development of the new chemotherapeutic 
drug zoptarelin doxorubicin by evaluating its DDI potential using the PBPK approach. 
The specific objectives of project I were (i) to establish the first whole-body PBPK model 
of zoptarelin doxorubicin and its active metabolite doxorubicin, (ii) to apply the 
zoptarelin doxorubicin model for a general assessment of the DDI potential with 
OATP1B3 and OCT2 victim drugs and (iii) to predict the magnitude of zoptarelin dox-
orubicin DDIs with simvastatin and metformin in worst-case scenarios. 
 
Project II: DDI management of clarithromycin, midazolam and digoxin 
The aim of project II was to support drug development by providing PBPK models of 
clarithromycin, midazolam and digoxin and to support pharmacotherapy by providing 
dosing rationales for midazolam and digoxin during co-medication with clarithromycin. 
Furthermore, the aim was to develop the existing PBPK software further by implement-
ing a mechanism-based inhibition (MBI) model for CYP3A4 and clarithromycin. The 
specific objectives of project II were (i) to develop fully mechanistic PBPK models for 
the single compounds clarithromycin, midazolam and digoxin, (ii) to couple the clarithro-
mycin and midazolam PBPK models to predict the metabolic DDI (via CYP3A4) of 
these drugs and (iii) to couple the clarithromycin and digoxin PBPK models to predict 
the transporter-based DDI (via P-gp) of these two drugs.  
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Project III: Dose specification of vorinostat in adults and children 
The aim of project III was to support pharmacotherapy by specifying pediatric vorinostat 
doses and thereby enabling a rational pediatric pharmacotherapy and by specifying po-
tentially safer and more effective adult dosing regimens than the approved vorinostat 
dosage. Furthermore, the aim was to develop the existing PBPK software further by 
implementing a functional relationship between PD biomarkers and vorinostat plasma 
concentrations. The specific objectives of project III were (i) to build and evaluate an 
adult whole-body PBPK model of the chemotherapeutic agent vorinostat being able to 
describe and predict the PK of varying doses of intravenously and orally administered 
vorinostat, (ii) to develop and evaluate a pediatric PBPK model for vorinostat and esti-
mate vorinostat does for children between 0 and 17 years, (iii) to build and evaluate a 
PBPK/PD model incorporating the vorinostat-mediated histone deacetylase activity in-
hibition and a thrombocytopenia model, (iv) to identify potentially effective vorinostat 
dosing regimens while considering HDAC activity and the number of circulating throm-
bocytes and (v) to perform a parameter sensitivity analysis for the developed whole-body 
PBKP model.  
 
Project IV: Potential morphine overdosing - a palliative legal case 
The aim of project IV was to support pharmacotherapy by simulating the morphine and 
morphine-6-glucuronide PK shortly before a patient’s death by implementing palliative 
medical information using the PBPK approach. The specific objective of project IV was 
to examine a potential overdosing of morphine in a palliative care patient (i) by suggest-
ing which dosing unit (“mg” or “mL”) appeared more likely as no dosing units were 
reported in clinical documentation, (ii) by assessing whether the analytically determined 
 2. AIMS AND OBJECTIVES OF PROJECTS I-IV 
 
13 
 
morphine concentrations could be explained by the clinically documented morphine ad-
ministration and (iii) by exploring potential physiological and mechanistic reasons that 
could explain the documented morphine concentrations. 
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3 Methods 
3.1 PBPK Model Structure 
PBPK models consist of multiple organs which are connected via the circulating blood 
system. A schematic representation of a simple blood-flow limited PBPK model following 
intravenous dosing is shown in Figure 1.  
In the case of a blood-flow limited PK, the ADME processes are rate-limited by the 
arterial and venous blood flow. The rate of change of drug in the non-eliminating tissues 
can then be calculated using (1), 
 VT ∗ dCTdt  = QT ∗ CA − QT ∗ CvT (1) 
where Q is the blood flow [L/h], C is concentration [mg/L], V is volume [L], T is tissue, 
A is arterial, V is venous, CvT is CT/(Kpu/B:P) with Kpu denoting the tissue to plasma 
partition coefficient and B:P the blood to plasma ratio. 
 
 
Figure 1 Schematic of a blood-flow limited PBPK model. The red and blue arrows 
indicate the arterial and venous blood flows, respectively. CLhep hepatic clearance, CLkid 
renal clearance. 
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In eliminating tissues such as the liver or the kidney, the unbound drug concentration 
(CvuT) drives the clearance rate as stated in (2), 
 VT ∗ dCTdt  = QT ∗ CA − QT ∗ CvT − CLint ∗ CvuT (2) 
where CLint is the intrinsic clearance of the drug [L/h] and u denotes “unbound”. The 
intrinsic clearance is a measure of the intrinsic ability of a drug to be metabolized by 
enzymes which is independent on extrinsic factors like the blood flow. 
Kpus are a crucial part of PBPK models which influence the tissue concentrations of 
drugs in addition to the blood flow and the B:P. Among various approaches for the 
prediction of Kpu values156–161, the method by Rodgers and co-workers is the most popular 
one. Derivations of the following equations from this approach are available in the liter-
ature156,157. 
In general, the Kpu for any tissue can be experimentally determined using (3), 
 Kpu = CuT,ss
Cup,ss
 (3) 
where CuT,ss is the steady-state concentration of the drug [mg/L] in a tissue outside of 
the blood perfusing it and the Cup,ss is the corresponding unbound concentration [mg/L] 
in plasma.  
For diprotic moderate-to-strong bases (pKa ≥ 7) electrostatic interactions with tissue 
acidic phospholipids, drug partitioning intro neutral phospholipids and drug dissolution 
in tissue water can be considered by the estimation of the Kpu. Assuming that drugs 
distribute by passive diffusion with the blood flow, electrostatic interactions predominate 
and non-saturating conditions prevail in the tissues, the Kpu can be calculated with (4), 
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Kpu = 
CT
Cup
=
⎣⎢
⎢⎢
⎢⎢
⎡ fEW+ �1+10pKa2−pHIW+10pka1+pka2−2pHIW
1+10pKa2−pHp+10pka1+pka2−2pHp � *fIW
+ � (P*fNL+�(0.3*P+0.7)*fNP�)
1+10pKa2−pHp+10pka1+pka2−2pHp�
+ �(Ka*[AP-]T*(10pKa2−pHIW+10pka1+pka2−2pHIW))
1+10pKa2−pHp+10pka1+pka2−2pHp �⎦
⎥⎥
⎥⎥
⎥⎤
 (4) 
 
where CT is CT,ss [mg/L], Cup,ss is Cup [mg/L], fEW is the fractional tissue volume of 
extracellular water, pHIW is the pH of intracellular tissue water, pHp is the pH of plasma, 
fNL is the fractional tissue volume of neutral lipids, fNP is the fractional tissue volume of 
neutral phospholipids, P is the partition coefficient of the unionized drug and Ka is the 
association constant [M-1] of basic compounds with acidic phospholipids (AP-). P is the 
n-octanol to water partition coefficient for all tissues except adipose where it represents 
the vegetable oil to water partition coefficient. For monoprotic bases the term 
�1+10pKa2−pHIW+10pka1+pka2−2pHIW
1+10pKa2−pHp+10pka1+pka2−2pHp � can be reduced to �1+10pKa−pHIW1+10pKa−pHp �. 
As Ka is not readily available one can rearrange equation (4) and apply it to acidic 
phospholipids containing blood cells (BC) by defining that the extracellular space of 
blood cells is 0. Additionally, the blood cell to plasma water concentration ratio (KpuBC) 
can be experimentally determined from the B:P, the fraction of drug unbound in plasma 
or the hematocrit. Equation (5) gives the calculation of KaBC for a diprotic base, 
 
 
KaBC = ⎝⎜
⎜⎜⎜⎛
Kpu
BC
-�1+10pKa2−pHBC+10pka1+pka2−2pHBC
1+10pKa2−pHp+10pka1+pka2−2pHp *fIW,BC�
-� (P*fNL,BC+(0.3P+0.7)*fNP,BC
1+10pKa2−pHp+10pka1+pka2−2pHp� ⎠
⎟⎟⎟⎟
⎞
* � 1+10pKa2−pHp+10pka1+pka2−2pHp[AP-]BC*10pKa2−pHBC+10pka1+pka2−2pHBC�
 (5) 
 
where pHBC and pHp are the pH values in blood cells and plasma, respectively. The 
parameter fIW,BC denotes the fractional tissue volume of neutral lipids in blood cells, fNL,BC 
 3. METHODS 
 
17 
 
denotes the fractional tissue volume of intracellular water in blood cells and fNP,BC denotes 
the fractional tissue volume of neutral phospholipids in blood cells. 
In a generalized form, (4) can be simplified to (6), 
 
 
Kpu = 
⎣⎢
⎢⎢
⎢⎢
⎡ fEW+�1+X1+Y *fIW�
+�(P*fNL+�(0.3*P+0.7)*fNP�)
1+Y
�
+�(Ka*[AP-]T*X)
1+Y
� ⎦⎥
⎥⎥
⎥⎥
⎤
 (6) 
 
and (5) can be simplified to (7), 
 
 
Ka = ⎝⎜
⎜⎜⎜⎛ KpuBC − �
1+Z
1+Y *fIW,BC�
− �(P*fNL,BC+(0.3P+0.7)*fNP,BC
1+Y �⎠⎟
⎟⎟⎟⎞
* � 1+Y[AP-]BC*Z�
 (7) 
 
where X, Y and Z can be replaced by (8-10) for di-basic zwitterions and by (11-13) for 
di-acidic zwitterions. For very weak monoprotic bases X = 1+10pKa-pHIW and Y = 1+10pka-
pH
P; for monoprotic acids X = 1+10pHIW-pKa and Y = 1+10pHP-pKa. For neutral drugs X and 
Y equal 1. 
 
 X = 10pHIW-pKaACID + 10pKa2BASE-pHIW
+10pKa1BASE+pKa2BASE-2pHIW
 (8) 
 Y = 10
pH
P
−pKa
ACID+10pKa2BASE−pHP
+10pKa1BASE+pKa2BASE−2pHP  (9) 
 Z = 10
pH
BC
−pKa
ACID+10pKa2BASE−pHBC
+10pKa1BASE+pKa2BASE−2pHBC  (10) 
 X = 10
pKa1
ACID
−pH
IW+102pHIW-−pKa1ACID−pKa2ACID
+10pKaBASE+pHIW
 (11) 
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 Y = 10pKa1ACID−pH𝑃𝑃 +102pH𝑃𝑃 −pKa1ACID−pKa2ACID
+10pKaBASE+pH𝑃𝑃  (12) 
 Z = 10pKa1ACID−pH𝐵𝐵𝐵𝐵+102pH𝐵𝐵𝐵𝐵−pKa1ACID−pKa2ACID
+10pKaBASE+pH𝐵𝐵𝐵𝐵  (13) 
 
In case of a di-acidic zwitterion that has one or more basic pKa values < 7, equation 
(14) should be used, 
 
 
 
Kpu = X*fIW
Y
+fEW+ �P*fNL+(0.3P+0.7)*fNPY �
+ �� 1
fu
− 1 − �P*fNL+(0.3P+0.7)*fNP,P
Y
�� * [PR]T
[PR]
P
� (14) 
 
where the aforementioned replacement of Y applies and [PR]P and [PR]T refer to the 
binding protein concentration in either the plasma ([PR]P) or the tissue ([PR]T). 
In contrast to blood-flow limited PBPK models, permeability-limited PBPK models 
sub-divide the PBPK organs into further physiological distribution spaces such as the 
plasma, red blood cells, interstitial and intracellular volumes. A schematic of a permea-
bility-limited PBPK model is presented in Figure 2. Further sub-compartments are avail-
able for instance in the kidney which has an additional urine compartment to represent 
the amount of drug excreted into urine. 
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Figure 2 Schematic of a permeability-limited PBPK organ model of the heart. A blood 
flow from the heart to the venous blood compartment, B passive drug transport be-
tween plasma and red blood cells, C blood flow from the arterial blood compartment 
to the heart, D passive drug transport between plasma and interstitial space, E passive 
drug transport between interstitial and intracellular space. 
 
The passive drug transport from plasma to red blood cell (Tpls,rbc) [µmol/min] (Figure 
2 B) is calculated using (15), 
 Tpls,rbc = SArbc*fu*Ppls,rbc*(Cpls − CrbcKrbc ) (15) 
where SArbc is the surface area between red blood cells and plasma [dm2], fu is fraction 
unbound, Ppls,rbc is the cellular permeability from plasma to red blood cell cells and vice 
versa [dm/min], Cpls is the drug plasma concentration [µmol/L], Crbc is the drug red blood 
cell concentration [µmol/L] and Krbc denotes the drug partition coefficient between blood 
cells and plasma . 
In this context SArbc is estimated using (16), 
 SArbc = HCT*AVrbc*0.6*Vrbc,organ*fvas (16) 
where HCT is the hematocrit, AVBC  is the surface/volume ratio of red blood cells 
[1/dm], Vrbc,organ is the red blood cell volume in the respective organ [L] and fvas is the 
vascular fraction of the red blood cells. 
Plasma Red BloodCells
Interstitial Intracellular
A B C
D
E
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The main parameter driving the sub-compartmental distribution is the drug permea-
bility (PD) [dm/min] which is calculated using (17), 
 
PD = �MWEff*109336 �
-6
*
10LogMA
5
*10-5 (17) 
where MWEff is the effective molecular weight [g/mol], which takes into account the 
small contribution of halogens to the molecular volume in relation to their weight and 
LogMA is the membrane affinity which might be replaced by the LogP values. 
The passive drug transport between plasma and interstitial space (Tpls,int) [µmol/min] 
(Figure 2 D) is described using equation (18), 
 Tpls,int = SAint
*fu*Pendothelial*(Cpls − CintKint,rbc ) (18) 
where SAint is the surface area between plasma and interstitial volume [dm2], fu is 
fraction unbound, Pendothelial is the cellular permeability from plasma to interstitial space 
and vice versa [dm/min], Cpls is the drug plasma concentration [µmol/L, Cint is the inter-
stitial drug concentration [µmol/L] and Kint,rbc denotes the drug partition coefficient be-
tween plasma and interstitial space. 
Finally, the passive distribution between interstitial and intracellular space (Tint,cell) 
[µmol/min]  is described by (19), 
 Tint,cell = Kwater,int
*PAint,cell*Cint − Kwater,cell*PAcell,int*Ccell (19) 
where Kwater,int and Kwater,cell denote the drug partition coefficient interstitial to water 
and intracellular to water, respectively. PA is the product of P times SA [dm2/min] and 
C denotes the interstitial (Cint) or intracellular (Ccell) drug concentration. 
3.2 PBPK Implementation of Metabolism and Transport 
Many drugs do not only show passive absorption, distribution and excretion as pre-
sented in the blood-flow limited and permeability-limited PBPK models before, they are 
often actively transported (e.g. substrate of P-gp) and/or metabolized (e.g. substrate of 
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CYP3A). Drug transporters as well as metabolizing enzymes show an organ-specific dis-
tribution and they act in specific sub-compartments of organs. Hence, permeability-lim-
ited PBPK models are often better suited for the description of active processes than 
blood-flow limited models. Figure 3 presents a schematic of a permeability-limited PBPK 
model with active P-gp-mediated drug transport and CYP3A-mediated drug metabolism. 
The organ-specific protein expression can be calculated relatively to the expression in 
the organ with the highest protein concentration (e.g. P-gp, CYP3A), which is the ref-
erence concentration (RF) [µmol/L]. The RF corresponds to an expression level of 100%. 
The organ-specific protein concentrations are then calculated using (20), 
 CP,organ=RF*EXPRP,organ (20) 
where CP,organ is the organ-specific protein concentration [µmol/L] and EXPRP,organ [%] 
is the expression level of the respective protein in the specific organ. Database comprising 
whole genome expression arrays from ArrayExpress162, RT-PCR derived gene expression 
estimates from the literature152,153 and expressed sequence tags (EST) from UniGene163 
are available151,163. Table 1 summarizes EXPRP,organ for CYP3A4 and P-gp for selected 
organs. 
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Figure 3 Schematic of a permeability-limited PBPK organ model of the liver. A blood 
flow from the heart to the venous blood compartment, B passive drug transport be-
tween plasma and red blood cells, C blood flow from the arterial blood compartment 
to the heart, D passive drug transport between plasma and interstitial space, E passive 
drug transport between interstitial and intracellular space and F passive drug transport 
between intracellular space and the gallbladder. In the intracellular compartment in 
yellow: active P-gp-mediated drug transport from the intracellular space to the inter-
stitial space and the gallbladder, in red: active CYP3A-mediated drug metabolism to 
its metabolites M1 and M2. 
 
The absolute protein concentration of CYP3A4 in the liver (CCYP3A4,liver [µmol/L]) can 
be calculated using (21), 
CCYP3A4,liver = MPPGL*WTliver*AbCYP3A4 (21) 
where MPPGL is the amount of microsomal protein per gram of liver [mg/g], AbCYP3A4 
is the CYP3A4 microsomal abundance [pmol/mg] and WTliver is the liver weight [kg] 
assuming the tissue density of the liver to be 1 g/ml. 
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Table 1 Organ-specific expression (EXPRP,organ) of CYP3A4 and P-gp 
Organ Array [%] RT-PCR [%] EST [%] 
CYP3A4 
Bone 4.75 - - 
Brain 3.66 0.42 1.23 
Fat - - - 
Kidney 3.65 0.54 2.87 
Liver 100.00 100.00 100.00 
Lung 3.67 0.04 - 
Muscle 3.14 - 0.80 
Small Intestine 39.99 7.28 40.05 
P-gp 
Bone 8.85 3.42 - 
Brain 30.56 10.73 5.16 
Fat - - - 
Kidney 66.24 100.00 2.49 
Liver 27.28 27.03 5.27 
Lung 14.45 9.27 - 
Muscle 6.48 1.81 1.05 
Small Intestine 100.00 39.60 100.00 
CYP3A4 cytochrome P450 3A4, P-gp P-glycoprotein, RT-PCR reverse transcription 
polymerase chain reaction, EST expressed sequence tags 
3.3 Generic PBPK Modeling and Simulation Strategy 
The PBPK modeling approach uses “bottom-up” information meaning that the model 
is built by mechanistically connecting many different sources of information like drug-
dependent, drug-independent and drug-biological parameters, to predict concentration-
time profiles of a drug without prior provision of in vivo concentration-time profiles. 
However, these models need to be compared and assessed against in vivo profiles as soon 
as these are available. Potential deviations between predictions and observations often 
lead to parameter optimizations, in order to match the predicted to the observed data 
as closely as possible. This means that the model is also based on “top-down” information 
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(concentration-time profiles). Hence, a general PBPK modeling and simulation strategy 
in most cases relies on a combination of “bottom-up” and “top-down” information. Figure 
4 summarizes the modeling and simulation steps for building a PBPK model after ad-
ministration of an orally formulated drug.  
Although there seems to be a clear disconnect between intravenous and oral solution 
and oral formulation model building, in many cases a separation of these modeling steps 
is not possible and hence intravenous and oral in vivo data is often combined to optimize 
parameters simultaneously. Due to the diverse nature of informing data of the PBPK 
models and the wide range of physicochemical and ADME characteristics of compounds, 
deviations from this general modeling strategy are often demanded and indicated. 
3.4 Used Software 
All PBPK modeling and simulation work was accomplished using PK-Sim® (5.3.2 and 
higher) and MoBi® (3.3.2 and higher) provided by Bayer Technology Services, 
Leverkusen, Germany. All statistical analyses and graphics were compiled using Matlab 
and its Statistics Toolbox 2013b (32-Bit, The MathWorks, Inc., Natick, Massachusetts, 
United States). Parameter sensitivity analyses were performed using the model export 
function of MoBi in combination with Matlab. 
Whenever necessary, data, such as concentration-time profiles, were digitized using 
GetData Graph Digitizer 2.25.0.32164. 
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Figure 4 A general PBPK modeling strategy for an orally formulated drug. LogP n-
octanole to water partition coefficient, pKa acid dissociation constant, Vmax maximum 
reaction velocity, KM Michaelis-Menten constant, ADME absorption, distribution, me-
tabolism and excretion, DDI drug-drug-interaction, DGI drug-gene-interaction, PBPK 
physiologically-based pharmacokinetics, PD pharmacodynamics, QSP quantitative sys-
tems pharmacology. “Learn-Confirm-Cycle” adopted from Sheiner165. 
 
 
Introduction of “Top-Down” 
information:
1. In vivo conc.-time profiles after various 
single intravenous doses
2. In vivo conc.-time profiles after multiple 
doses of various intravenous dosages
“Bottom-Up” Information
1. Drug-dependent information 
(e.g. LogP, pKa, solubility)
2. Drug-biological information (e.g. 
enzyme metabolism data, 
transporter data, fraction unbound)
Initial intravenous prediction:
1. In silico conc.-time profiles after 
various single intravenous doses
2. In silico conc.-time profiles after 
multiple doses of various 
intravenous dosages
Optimized intravenous prediction:
1. In silico conc.-time profiles after 
various single intravenous doses
2. In silico conc.-time profiles after 
multiple dosing of various intravenous 
dosages
Initial oral solution prediction:
1. In silico conc.-time profiles after 
various single oral solution doses
2. In silico conc.-time profiles after 
multiple doses of various oral 
solution dosages
Typical parameters eligible 
for optimization:
Kpu calculation, LogP, fraction 
unbound, transporter Vmax / 
Km, enzyme Vmax / Km, biliary 
clearance
Introduction of “Top-Down” 
information:
1. In vivo conc.-time profiles after 
various single oral solution doses
2. In vivo conc.-time profiles after 
multiple doses of various oral 
solution dosages
Typical parameters eligible 
for optimization:
Solubility, specific intestinal 
permeability
Optimized oral solution prediction:
1. In silico conc.-time profiles after 
various single oral solution doses
2. In silico conc.-time profiles after 
multiple doses of various oral solution 
dosages
Initial oral formulation prediction:
1. In silico conc.-time profiles after 
various single oral formulation doses
2. In silico conc.-time profiles after 
multiple dosing of various oral 
formulation dosages
Introduction of “Top-Down” 
information:
1. In vivo conc.-time profiles after various 
single oral formulation doses
2. In vivo conc.-time profiles after multiple 
doses of various oral formulation dosages
Typical parameters eligible 
for optimization:
Dissolution time, dissolution 
shape, lag-time
Optimized oral formulation prediction:
1. In silico conc.-time profiles after 
various single oral formulation doses
2. In silico conc.-time profiles after 
multiple dosing of various oral 
formulation dosages
Final Model:
1. “What-if” simulations
2. Test hypotheses
3. Pediatric scaling
4. Geriatric scaling
5. DDI / DGI
6. PBPK/PD modeling
7. Implementation of QSP models
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4 Results 
 
4.1 Project I: 
Physiologically-based pharmacokinetic (PBPK) analysis of 
zoptarelin doxorubicin drug-drug interaction potential - inte-
grating preclinical, phase I and phase II data. 
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Abstract
Purpose Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-
releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study 
was to establish a physiologically based pharmacokinetic (PBPK) parent-metabolite model of zoptarelin doxorubicin and to 
apply it for drug–drug interaction (DDI) potential analysis.
Methods The PBPK model was built in a two-step procedure. First, a model for doxorubicin was developed, using clinical 
data of a doxorubicin study arm. Second, a parent-metabolite model for zoptarelin doxorubicin was built, using clinical 
data of three different zoptarelin doxorubicin studies with a dosing range of 10–267 mg/m2, integrating the established 
doxorubicin model. DDI parameters determined in vitro were implemented to predict the impact of zoptarelin doxorubicin 
on possible victim drugs.
Results In vitro, zoptarelin doxorubicin inhibits the drug transporters organic anion-transporting polypeptide 1B3 (OATP1B3) 
and organic cation transporter 2 (OCT2). The model was applied to evaluate the in vivo inhibition of these transporters in 
a generic manner, predicting worst-case scenario decreases of 0.5% for OATP1B3 and of 2.5% for OCT2 transport rates. 
Specific DDI simulations using PBPK models of simvastatin (OATP1B3 substrate) and metformin (OCT2 substrate) predict 
no significant changes of the plasma concentrations of these two victim drugs during co-administration.
Conclusions The first whole-body PBPK model of zoptarelin doxorubicin and its active metabolite doxorubicin has been 
successfully established. Zoptarelin doxorubicin shows no potential for DDIs via OATP1B3 and OCT2.
Keywords AEZS-108 · AN-152 · Doxorubicin · PBPK modeling · Drug–drug interaction · Targeted chemotherapy
Introduction
Zoptarelin doxorubicin (also known as AEZS-108, AN-152 
and ZEN-008) is a fusion molecule of the chemotherapeutic 
doxorubicin and an LHRHR agonist [1]. The DNA interca-
lating agent doxorubicin is chemically linked to the carrier 
molecule D-Lys6-LHRH, which enables specific binding 
and selective uptake of zoptarelin doxorubicin by tumors 
expressing receptors for LHRH (“drug targeting”), followed 
by the intracellular release of the active component doxo-
rubicin. The rationale for the synthesis and development of 
this hybrid molecule is to increase the cytotoxic specific-
ity, while decreasing the general toxicity when compared to 
doxorubicin alone.
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In vitro, zoptarelin doxorubicin has shown stronger anti-
proliferative effects in human LHRHR positive ovarian and 
endometrial cancer cells compared to doxorubicin [2], as 
well as higher cytotoxic potency in LHRHR expressing 
human oral and laryngeal carcinoma cells [3]. In nude mice 
bearing subcutaneous human LHRHR positive endometrial 
and ovarian tumors, equimolar doses of zoptarelin doxo-
rubicin were significantly more effective in tumor growth 
inhibition compared to doxorubicin. Furthermore, in the 
high-dose study arm, seven of the ten mice treated with 
doxorubicin died, while all ten mice treated with zoptarelin 
doxorubicin survived [4]. Growth of subcutaneous human 
urinary bladder cell tumors in nude mice was more potently 
inhibited by zoptarelin doxorubicin compared to doxorubicin 
[5].
In clinical Phase I and Phase II studies, zoptarelin doxoru-
bicin has shown therapeutic activity in patients with LHRHR 
positive ovarian and endometrial cancer [6, 7]. The PK prop-
erties of zoptarelin doxorubicin have been assessed in the 
first-in-human, dose escalation Phase I study in patients. 
Plasma half-life and clearance were calculated to be approxi-
mately 2 h and 1 L/(min*m2), with the reservation that in 
this early study the measured plasma concentrations showed 
a high variability [8]. Due to the size and hydrophilicity of 
zoptarelin doxorubicin (decapeptide coupled via a glutaryl 
linker to doxorubicin), passive distribution into tissues is 
limited, but cellular entry is expected to be facilitated by 
target binding to LHRHR, followed by internalization of the 
drug–receptor complex and intracellular cleavage to release 
the doxorubicin moiety within the target cells. In aqueous 
solution and in blood plasma, zoptarelin doxorubicin is sub-
ject to spontaneous and carboxylesterase-mediated hydroly-
sis into doxorubicin and probably D-Lys6-LHRH-glutarate. 
Metabolite profiles in liver microsomal incubations suggest a 
minor role of oxidative metabolism compared to hydrolysis.
Doxorubicin PK studies in patients show that doxorubicin 
follows a multiphasic disposition after intravenous infusion. 
The initial distribution half-life of approximately 5 min 
indicates rapid tissue uptake, while a terminal half-life of 
20–48 h reflects slow elimination from tissues. Steady-state 
distribution volumes exceed 20–30 L/kg revealing extensive 
drug uptake into tissues. Plasma clearance is in the range of 
8–20 mL/min/kg and is governed by metabolism and biliary 
excretion [9–11].
To evaluate the zoptarelin doxorubicin DDI poten-
tial in vitro, a DDI screening on cytochrome P450 (CYP) 
enzymes and recommended drug transporters has been per-
formed. In these assays, zoptarelin doxorubicin showed no 
inhibition or induction of CYP enzymes, but in the trans-
porter studies, zoptarelin doxorubicin inhibited OATP1B3 
and OCT2 with  IC50 values of 16.5 and 3.26  μmol/L, 
respectively. Doxorubicin itself and D-Lys6-LHRH-glu-
tarate inhibited OATP1B3 with  IC50 values > 100 µmol/L 
and OCT2 with  IC50 values > 200 µmol/L. Based on these 
results, in vivo interactions with drugs that are substrates of 
OATP1B3 (e.g. simvastatin) or OCT2 (e.g. metformin) could 
not be ruled out. As these victim drugs are widely used, their 
co-administration with zoptarelin doxorubicin would be very 
likely, creating a need to investigate the impact of these 
potential DDIs. However, clinical DDI studies involving 
DNA intercalating agents are, for ethical reasons, difficult 
to conduct. PBPK modeling offers an excellent alternative 
to dedicated clinical DDI studies and is recommended and 
supported by the FDA (US Food and Drug Administration) 
and EMA (European Medicines Agency) to predict the mag-
nitude of in vivo DDIs from in vitro results [12, 13].
The objectives of this modeling investigation were (1) 
to establish the first whole-body PBPK model of zoptare-
lin doxorubicin and its active metabolite doxorubicin, (2) to 
apply the zoptarelin doxorubicin model for a general assess-
ment of the DDI potential with OATP1B3 and OCT2 victim 
drugs and (3) to predict the magnitude of zoptarelin doxo-
rubicin DDIs with simvastatin and metformin in worst-case 
scenarios.
Materials and methods
Clinical studies used
The results of three different clinical studies with PK blood 
sampling were available for model development (Table 1). 
Study 1 (ZEN-008-Z023) is a Phase I first-in-human sequen-
tial group dose escalation and PK study, performed in 17 
female patients with LHRHR positive tumors. Zoptarelin 
doxorubicin was administered as a 2-h intravenous infu-
sion, once every 21 days, in doses of 10, 20, 40, 80, 160 or 
267 mg/m2 [8]. Data of two patients were excluded due to 
bioanalytical issues. Study 2 (AEZS-108-046) is a combined 
Phase I/II study, with PK sampling performed in a sub-set 
of 14 male or female patients with locally advanced unre-
sectable or metastatic LHRHR positive urothelial carcinoma 
who failed platinum-based chemotherapy. Zoptarelin doxo-
rubicin was administered as a 2-h infusion every 21 days 
in doses of 160, 210 or 267 mg/m2 (results not published, 
yet). Data of four patients were excluded because of sample 
hemolysis. Study 3 (AEZS-108-053) is a Phase I cardiac 
safety and PK study comparing zoptarelin doxorubicin and 
doxorubicin therapy in 21 and 11 female patients, respec-
tively, with locally advanced recurrent or metastatic cancer. 
Zoptarelin doxorubicin was administered as a 2-h infusion of 
267 mg/m2. Doxorubicin was administered as a 1-h infusion 
of 60 mg/m2 (results not published, yet). Data of two patients 
were excluded due to sampling issues. Details on the patient 
demographics of these studies (age, weight, body surface 
area) are listed in Table 1.
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To supplement the measurements of the doxorubicin arm 
of Study 3, published human in vivo data of doxorubicin 
in plasma, white blood cells, urine and feces were added, 
to build the “training dataset” for the development and 
 parameter optimization of the doxorubicin model. As train-
ing data for zoptarelin doxorubicin model development and 
parameter optimization, the four lowest dose applications 
of Study 1 (10, 20, 40, 80 mg/m2) plus the measurements 
of Study 3 (267 mg/m2, highest clinical dose) were chosen. 
Evaluation of the zoptarelin doxorubicin model was carried 
out with the clinical data of the remaining dosing groups of 
Study 1 as well as the complete clinical Study 2 as the “test 
dataset”.
Software
PBPK modeling was performed with PK-Sim® and MoBi® 
(Open Systems Pharmacology Suite, Version 7.0.0, Bayer 
AG, Leverkusen, Germany). Parameter optimization was 
accomplished using the Monte Carlo algorithm of the 
“Parameter Identification Toolbox” in MATLAB® (Version 
R2013b, The MathWorks, Inc., Natick, MA, USA). Sensitiv-
ity analysis was performed within PK-Sim®. Graphics and PK 
parameter analyses were compiled with MATLAB® R2013b.
Doxorubicin model development
Model development was started with the establishment of 
a model of the active metabolite doxorubicin. To limit the 
parameters to be optimized during model development, the 
minimal number of processes necessary was implemented 
into the model. For the doxorubicin model these are (1) 
doxorubicin binding to DNA, (2) an unspecific metabolic 
hepatic clearance and (3) an unspecific elimination to bile. 
Glomerular filtration and enterohepatic cycling were ena-
bled, as they are active under physiological conditions. A 
diagram of the PBPK model structure is given in Zoptare-
lin Doxorubicin Supplementary Fig. 1.
To model the binding of doxorubicin to DNA as the 
cause of the extensive distribution into and slow elimi-
nation from body tissues, a binding partner was imple-
mented into the DNA-rich organs, with published values 
for Kd and koff [14]. In the literature, there are reports of 
doxorubicin concentration measurements in plasma and 
white blood cells [15, 16] that were utilized to inform the 
distribution (cellular permeability, see below) and DNA 
binding processes. As there is no white blood cell (WBC) 
compartment in PK-Sim, the red blood cell (RBC) com-
partment was used as a substitute to represent the nucle-
ated white blood cells. The volume of this red blood cell 
compartment is larger than the physiological volume of 
the white blood cells; therefore, a relative concentration 
of DNA binding sites (that are absent in the anucleate 
RBCs) was implemented into the RBC compartment and 
estimated. The DNA binding site reference concentration 
(concentration in the tissue with the highest concentration 
of binding sites) was also optimized.
Table 1  Studies used for zoptarelin doxorubicin PBPK model development and evaluation
Values given for age, weight and BSA are arithmetic means, minima and maxima
a Assumed, BSA: body surface area, iv: intravenous, n: number of individuals studied, QD: once daily, SD: single dose, test: test dataset (model 
evaluation), training: training dataset (model development and parameter optimization)
Dose (mg/m2) Administration n Women (%) Age (years) Weight (kg) BSA  (m2) Dataset Study references
Doxorubicin
 36 iv (96 h), SD 7 50a 30.0a 64.0a 1.73a Training [15]
 30 iv (bolus), QD 7 50a 30.0a 64.0a 1.73a Training [16]
 60a iv (1 h),  SDa 3a 100a 71.0 (67–74)a 67.0 (58–84)a 1.64 (1.57–1.77)a Training [18]
 60 iv (1 h), SD 9 100 59.9 (44–74) 64.1 (41–84) 1.63 (1.28–1.81) Training Study 3 (AEZS-108-053)
Zoptarelin doxorubicin
 10 iv (2 h), SD 1 100 58.0 84.0 1.89 Training Study 1 (ZEN-008-Z023)
 20 iv (2 h), SD 1 100 48.0 65.0 1.70 Training Study 1 (ZEN-008-Z023)
 40 iv (2 h), SD 1 100 69.0 145.0 2.48 Training Study 1 (ZEN-008-Z023)
 80 iv (2 h), SD 1 100 44.0 55.0 1.63 Training Study 1 (ZEN-008-Z023)
 160 iv (2 h), SD 6 100 59.3 (55–69) 83.2 (58–107) 1.89 (1.60–2.12) Test Study 1 (ZEN-008-Z023)
 267 iv (2 h), SD 5 100 48.8 (31–63) 66.9 (59–85) 1.73 (1.64–1.89) Test Study 1 (ZEN-008-Z023)
 160 iv (2 h), SD 3 0 64.0 (63–65) 78.3 (69–90) 1.97 (1.84–2.07) Test Study 2 (AEZS-108-046)
 210 iv (2 h), SD 3 29 66.0 (55–83) 89.6 (64–121) 2.02 (1.71–2.38) Test Study 2 (AEZS-108-046)
 267 iv (2 h), SD 4 25 69.0 (62–87) 70.0 (52–86) 1.81 (1.51–1.98) Test Study 2 (AEZS-108-046)
 267 iv (2 h), SD 21 100 61.6 (46–78) 71.4 (45–108) 1.73 (1.35–2.13) Training Study 3 (AEZS-108-053)
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To account for hepatic metabolism to doxorubicinol and 
other metabolites, an unspecific metabolic first-order clear-
ance was implemented into the liver and optimized.
To model biliary excretion, an unspecific first-order trans-
port from liver to bile was implemented and estimated. As 
the lipophilicity of doxorubicin is very low (logP = 1.27), 
calculated passive cellular permeability is low. However, 
doxorubicin has been reported to be a substrate of diverse 
transporters, including the human isoforms of OATP1A and 
OATP1B [17]. To accurately describe the available clinical 
data, passive cellular permeability was increased, to com-
pensate for active transport processes that have not been 
implemented into the model.
To obtain values for the parameters that could not be 
adequately informed from literature or in-house preclinical 
studies, optimization was performed by simultaneously fit-
ting the model to the data of the doxorubicin arm of Study 3 
(9 patients), measured doxorubicin plasma and white blood 
cell intracellular concentration–time profiles of Speth et al. 
[15, 16] (two studies with mean values of 7 patients each) 
and published fraction of doxorubicin dose administered 
excreted unchanged to urine and feces information [18].
Zoptarelin doxorubicin model development
The final doxorubicin model was then used in the estab-
lishment of the zoptarelin doxorubicin model, together 
with clinically observed plasma concentration–time pro-
files of zoptarelin doxorubicin and doxorubicin following 
intravenous administration of zoptarelin doxorubicin. The 
following processes were implemented into the zoptarelin 
doxorubicin model: (1) zoptarelin doxorubicin binding to the 
LHRHR target, (2) internalization of zoptarelin doxorubicin 
by LHRHR and (3) hydrolysis of zoptarelin doxorubicin to 
release the active doxorubicin moiety within blood plasma 
as well as intracellularly. A diagram of the PBPK model 
structure is given in Zoptarelin Doxorubicin Supplementary 
Fig. 1.
To model the binding of zoptarelin doxorubicin to its 
target LHRHR, this receptor was implemented and values 
for Kd, koff as well as the LHRHR reference concentration 
were estimated. Expression of LHRHR is described in the 
literature to occur in non-malignant pituitary, ovary, testis, 
prostate and breast cells, as well as in cancer cells of diverse 
origin [19, 20]. In the model, LHRHR was implemented 
into the gonadal compartment (approximate organ volume of 
0.013 L). To compensate for the missing pituitary, prostate, 
breast and, most notably, cancer cell expression, as these 
tissues are not represented in standard PK-Sim individuals, 
LHRHR expression was further added at a 50% expression 
level to the lung compartment (approximate organ volume of 
1 L). The lung was chosen as a well perfused organ with no 
special pharmacokinetic function in this analysis (as would 
have been the case with liver or kidney). Implementation of 
zoptarelin doxorubicin binding to LHRHR into the model 
clearly improved the shape of the simulated zoptarelin doxo-
rubicin plasma concentration–time curves.
Internalization of zoptarelin doxorubicin was imple-
mented as a cellular uptake facilitated by LHRHR (into 
gonads and lung), followed by intracellular hydrolysis to 
release the doxorubicin moiety. As KM value of this uptake 
process an  IC50 value of 7.45 nmol/L was used, measured 
in a radio ligand displacement assay with very low concen-
trations of the radiolabeled ligand [21]. Therefore, it was 
assumed that  IC50 = Ki and this value was used as KM value 
for the internalization process. A very similar  IC50 value of 
10 nmol/L has been described in the literature for the bind-
ing of the endogenous agonist LHRH to LHRHR [22]. The 
internalization turnover number was estimated.
To model the hydrolysis of zoptarelin doxorubicin to 
D-Lys6-LHRH-glutarate and doxorubicin, a hydrolytic clear-
ance was implemented into blood plasma, gonads and lung. 
The hydrolysis rate in plasma was optimized, informed by 
the measured concentrations of zoptarelin doxorubicin being 
hydrolyzed and of doxorubicin resulting from this hydroly-
sis. The hydrolysis rate in gonads and lung was assumed to 
be the same as in plasma.
Parameter optimization was performed by simultaneously 
fitting the model to measured zoptarelin doxorubicin and 
doxorubicin plasma concentration–time profiles after admin-
istration of zoptarelin doxorubicin obtained in Study 1 (10, 
20, 40, 80 mg/m2) and Study 3 (267 mg/m2).
Virtual population characteristics
To predict the variability of the simulated plasma concen-
tration–time profiles, virtual populations of 100 individuals 
were generated according to the population demographics of 
each respective dosing group of the Studies 1, 2 and 3. The 
ICRP (International Commission on Radiological Protec-
tion) database in PK-Sim [23] was used for generation of 
virtual Caucasian populations. In the generated virtual popu-
lations, age, height, weight, corresponding organ volumes, 
tissue compositions, blood flow rates, etc. are varied by an 
implemented algorithm within the limits of the ICRP data-
base. In addition, the zoptarelin doxorubicin hydrolysis rate, 
the reference concentrations of the binding partners LHRHR 
and DNA, as well as the doxorubicin hepatic and biliary 
clearance rates were set to be log-normally distributed with 
variabilities of 25%CV (relative standard deviation). To cre-
ate a virtual population for the DDI predictions, reflecting 
an even larger demographic variability and representing the 
target cancer patient population, preliminary demographics 
of a large clinical Phase III study (Study 4, AEZS-108-050 
[24]) were used.
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Model evaluation
Model performance was evaluated by comparison of the pre-
dicted concentration–time profiles of the virtual populations 
to the plasma concentrations observed in the clinical studies, 
which had not been used during parameter optimization (test 
dataset). All population predictions compared to observed 
plasma concentration–time profiles are documented in the 
“Results” section or in the supplementary material, together 
with predicted compared to observed  AUClast and Cmax val-
ues of all studies. Furthermore, the biological plausibility of 
optimized parameters was checked and sensitivity analyses 
were conducted for the doxorubicin and zoptarelin doxoru-
bicin models.
Sensitivity of the final models to single parameters (local 
sensitivity analysis) was investigated, measured as changes 
of the AUC extrapolated to infinity  (AUCinf) of a simula-
tion of the highest applied dose. All parameters relevant to 
the respective model were included into the analysis, opti-
mized parameters as well as parameters fixed to literature 
values. Parameters were defined as relevant if they have 
been optimized (see Zoptarelin Doxorubicin Supplementary 
Tables 4 and 5), if they might have a strong influence due to 
calculation methods used in the model (lipophilicity, frac-
tion unbound), if they are related to optimized  parameters 
(doxorubicin-DNA Kd, doxorubicin-DNA koff, doxorubicin 
blood/plasma ratio) or if they had significant impact in for-
mer models (solubility, intestinal permeability, EHC con-
tinuous fraction, cellular permeability, blood/plasma ratio, 
GFR fraction). A sensitivity value of − 1.0 signifies that 
a 10% increase of the examined parameter causes a 10% 
decrease of the simulated  AUCinf.
General assessment of the zoptarelin doxorubicin 
DDI potential
To obtain a general statement on the DDI potential of zop-
tarelin doxorubicin, the final model was applied to predict 
the in vivo inhibition of OATP1B3 and OCT2 in a generic 
manner (independent of the victim drug affected by this inhi-
bition), by calculating the relative change of these transport-
ers’ KM values due to inhibition by zoptarelin doxorubicin.
Assuming a competitive inhibition and Michaelis–Menten 
kinetics, we expect a change in the KM value of the transport 
of the affected victim drugs, but not of the maximal trans-
port rate, as competitive inhibition can be overcome by high 
victim drug concentrations. Therefore, the inhibition is char-
acterized by the relative change of KM according to Eq. 2: 
(1)
KM apparent, victim drug (μmol∕L)
= KM victim drug ∗
(
1 +
inhibitor concentration
inhibitor K
i
)
Simulations to assess the DDI potential of zoptarelin 
doxorubicin were performed for the highest clinical dose 
of 267 mg/m2 zoptarelin doxorubicin as intravenous infu-
sion over 2 h. OATP1B3 is predominantly expressed at 
the basolateral membranes of hepatocytes located around 
the central vein, facilitating the uptake of organic anions 
for hepatic clearance [25]. To estimate the effect of zop-
tarelin doxorubicin on OATP1B3, predicted population 
interstitial unbound concentrations of zoptarelin doxo-
rubicin in the liver were used as input for Eq. 2. OCT2 
is mainly expressed at the basolateral membrane of renal 
tubule cells, facilitating the uptake of organic cations from 
the blood for subsequent renal secretion [26]. To estimate 
the impact of zoptarelin doxorubicin on OCT2, predicted 
population interstitial unbound concentrations of zoptare-
lin doxorubicin in the kidney were employed.
The zoptarelin doxorubicin Ki values for inhibition of 
OATP1B3 and OCT2 were calculated from  IC50 values 
determined in vitro (16.5 and 3.26 µmol/L), the substrate 
concentrations applied in these assays (0.05 µmol/L estra-
diol-17beta-glucuronide and 10.0 µmol/L metformin) and 
the OATP1B3 and OCT2 transport KM values for these 
substrates (15.8 [27] and 990.0 µmol/L [28]), according 
to the Cheng-Prusoff equation for competitive inhibition 
[29]: 
Ki values for pure competitive inhibition are independent of 
the affected victim substrate, the substrate concentration and 
the assay conditions [30]. Therefore, the relative changes 
of KM calculated from Eq. 2 are in theory applicable to all 
putative zoptarelin doxorubicin victim drugs transported by 
OATP1B3 and OCT2.
Specific assessment of the zoptarelin doxorubicin 
DDI potential
To evaluate the in vivo interaction potential of zoptarelin 
doxorubicin with actual OATP1B3 and OCT2 victim drugs, 
the model was coupled to PBPK models of simvastatin and 
metformin (for details on the simvastatin and metformin 
PBPK models see the Simvastatin and Metformin Supple-
mentaries). Simvastatin acid, the pharmacologically active 
metabolite of the prodrug simvastatin, is recommended by 
the FDA as a victim drug for the clinical investigation of 
OATP1B1/1B3 DDIs [31]. Metformin is recommended 
by the FDA as well-established substrate of the cationic 
(2)
KM apparent, victim drug (%)
= 100% ∗
(
1 +
inhibitor concentration
inhibitor K
i
)
(3)Ki =
IC
50
1 + substrate concentration∕ K
M
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transport system for the use in clinical studies of DDIs 
involving OCT2/MATE [31].
Simvastatin is administered in the form of the inac-
tive lactone that is hydrolyzed after ingestion to the active 
 simvastatin acid. Only the acid form is transported by 
OATP1B1 and OATP1B3 from blood plasma into hepato-
cytes. The model applied for DDI prediction is a whole-body 
parent-metabolite PBPK model of simvastatin lactone and 
simvastatin acid. Because of the overlapping substrate spe-
cificities of OATP1B1 and OATP1B3, it is difficult to pin-
point the exact contribution of each isoform to simvastatin 
acid transport [32]. As the goal of this analysis was to assess 
worst-case scenarios, a combined OATP1B1/3 transport was 
modeled and this whole transport was inhibited with the 
zoptarelin doxorubicin  Ki determined for OATP1B3, even 
though OATP1B1 was not affected in vitro. This approach 
results in an overprediction of the impact of OATP1B3 inhi-
bition, but avoids underprediction of the DDI potential due 
to misspecification of the OATP1B3 contribution.
As worst-case co-administration scenarios, simultaneous 
administrations of 267 mg/m2 zoptarelin doxorubicin with 
80 mg simvastatin (once daily, day 5) or 1000 mg metformin 
(three times daily, day 5) were simulated, and victim drug 
plasma concentrations with and without co-administration 
of zoptarelin doxorubicin were assessed in population pre-
dictions. Different time intervals between the start of zop-
tarelin doxorubicin infusion and the day 5 morning dose of 
the victim drugs were simulated, to find the administration 
schemes resulting in highest drug–drug interaction impact 
for worst-case scenario assessment.
Results
A comprehensive parent-metabolite PBPK model for the 
prediction of zoptarelin doxorubicin and doxorubicin con-
centrations following different intravenous doses of zoptare-
lin doxorubicin has been successfully developed.
A schematic representation of the parent-metabolite 
model structure is shown in Zoptarelin Doxorubicin Supple-
mentary Fig. 1. All drug-dependent parameters of the final 
model, taken from literature or preclinical studies as well 
as all optimized parameter values, are given in Zoptarelin 
Doxorubicin Supplementary Table 4. All system-dependent 
parameters of the final model, particularly expression levels 
of the implemented binding partners in the different tissues 
with their geometric standard deviations of lognormal distri-
bution in virtual populations, are given in Zoptarelin Doxo-
rubicin Supplementary Table 5. No other system-dependent 
parameters were changed or adjusted.
PBPK model development and performance
The established doxorubicin and zoptarelin doxorubicin 
PBPK models show excellent descriptive and predictive 
performance.
The data used for doxorubicin model development con-
sisted of individual plasma concentration–time profiles fol-
lowing application of 60 mg/m2 of doxorubicin to a total of 
nine patients. These measurements were supplemented by 
literature data of white blood cell concentrations and excre-
tion to urine and feces information (Table 1). Predicted and 
observed doxorubicin plasma concentrations of Study 3 
as well as fractions excreted to urine and feces following 
administration of doxorubicin are presented in Zoptarelin 
Doxorubicin Supplementary Fig. 2 (training dataset). Pre-
dicted and observed doxorubicin plasma and white blood 
cell concentrations following administration of doxorubicin 
as published by Speth et al. are shown in Zoptarelin Doxo-
rubicin Supplementary Fig. 3 (training dataset). These con-
centrations were fitted with lower weight compared to the 
measurements of Study 3, given the age of the data and the 
assumption underlying the blood cell concentrations that  109 
cells equal a volume of 1 mL, knowing that white blood 
cells are very divers in size and shape. Prediction of the 
doxorubicin concentrations resulting from administration of 
zoptarelin doxorubicin is presented in Figs. 1 and 2 as well 
as in Zoptarelin Doxorubicin Supplementary Figs. 4 and 5.
The data used for zoptarelin doxorubicin model estab-
lishment included individual plasma concentration–time 
profiles collected in three clinical trials, following applica-
tion of seven different doses of zoptarelin doxorubicin in a 
range of 10–267 mg/m2. Plasma concentrations of zoptarelin 
doxorubicin and doxorubicin were collected in a total of 46 
patients (Table 1). Model performance of the final zoptarelin 
doxorubicin model is demonstrated in Fig. 1 and Zoptarelin 
Doxorubicin Supplementary Fig. 4 for the studies used dur-
ing parameter optimization (training dataset) and in Fig. 2 
and Zoptarelin Doxorubicin Supplementary Fig. 5 for the 
independent clinical data (test dataset).
As can be seen in Fig. 1, the inter-individual variabil-
ity of the measured concentrations is wider for zoptare-
lin doxorubicin than for doxorubicin. This is unexpected, 
as the variability of its main ADME mechanism, namely 
the hydrolysis of zoptarelin doxorubicin to doxorubicin, 
affects both analytes. The more pronounced variability 
of the parent compound concentrations in blood plasma, 
where zoptarelin doxorubicin and doxorubicin are sam-
pled, might result from its very low permeability com-
pared to doxorubicin, which extensively distributes into 
body tissues [11]. The predicted variability in the popula-
tion simulations is also wider for zoptarelin doxorubicin.
Furthermore, the variance of the measured concentra-
tions in the very first clinical Study 1 is higher than in the 
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following trials (see Zoptarelin Doxorubicin Supplemen-
tary Fig. 5, test dataset). This high variability might be the 
result of errors in sampling time or of hydrolytic cleavage 
of zoptarelin doxorubicin prior to freezing of some of the 
blood samples [8]. These issues could be resolved and, 
therefore, did not affect later measurements.
Precision of model parameter estimates is shown in the 
tables listing the drug-dependent and system-dependent 
zoptarelin doxorubicin PBPK model parameters (Zoptarelin 
Doxorubicin Supplementary Tables 4 and 5).
Using the final model, pharmacokinetic parameters 
 (AUClast and Cmax) of all dosing groups have been cal-
culated from population simulations as mean values with 
standard deviation and compared to observed values (see 
Zoptarelin Doxorubicin Supplementary Tables 1 and 2). 
Prediction errors for  AUClast and Cmax values are also 
Fig. 1  Training dataset: a Population simulations (semilog scale) 
compared to observed data of zoptarelin doxorubicin (blue) and doxo-
rubicin plasma concentrations (red) following intravenous adminis-
tration of 267 mg/m2 zoptarelin doxorubicin. Clinical data (Study 3, 
n = 21) are shown as dots. Population simulation medians are shown 
as lines; the shaded areas depict the 5th−95th percentile popula-
tion prediction intervals. b Goodness of fit (GOF) plots (log scale) 
demonstrating the correlation of individual predicted with observed 
zoptarelin doxorubicin (blue) and doxorubicin plasma concentrations 
(red) of the study shown above. The solid lines represent the line of 
unity; the dashed lines indicate twofold deviation
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given in Zoptarelin Doxorubicin Supplementary Tables 1 
and 2. Plots of predicted versus observed  AUClast and Cmax 
values with twofold prediction success limits are shown in 
Zoptarelin Doxorubicin Supplementary Fig. 6.
PBPK model sensitivity analysis
Sensitivity analyses were conducted for the doxorubicin 
and the zoptarelin doxorubicin model, with simulations of 
Fig. 2  Test dataset: Population simulations (semilog scale) compared 
to observed data of zoptarelin doxorubicin (blue) and doxorubicin 
plasma concentrations (red) following intravenous administration of 
160, 210 or 267 mg/m2 zoptarelin doxorubicin. Clinical data (Study 
2, n = 3, n = 3 and n = 4) are shown as dots. Population simulation 
medians are shown as lines; the shaded areas depict the 5th–95th per-
centile population prediction intervals
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single intravenous administrations of 60 mg/m2 doxoru-
bicin (1-h infusion) and of 267 mg/m2 zoptarelin doxoru-
bicin (2-h infusion), respectively. The investigated model 
parameters and results are listed in Fig. 3. The doxorubicin 
model is sensitive to the values of fraction unbound in 
plasma (sensitivity value of − 0.6) and cellular permeabil-
ity (sensitivity value of − 0.3). The zoptarelin doxorubicin 
model is sensitive to the values of fraction unbound in 
plasma (sensitivity value of − 1.0) and zoptarelin doxoru-
bicin hydrolysis rate (sensitivity value of − 1.0).
General assessment of the zoptarelin doxorubicin 
DDI potential
To obtain a general assessment of the in vivo DDI potential 
of zoptarelin doxorubicin via OATP1B3 and OCT2, inde-
pendently of the substrate affected by this inhibition, the 
relative changes of the apparent KM values for these two 
transporters were calculated according to Eq. 2. As input 
inhibitor concentrations, predicted population interstitial 
unbound concentrations of zoptarelin doxorubicin in the 
liver and the kidney, respectively, were used (267 mg/m2 
zoptarelin doxorubicin, 2-h infusion). Zoptarelin doxo-
rubicin Ki values were calculated to be 16.45 µmol/L for 
Fig. 3  Doxorubicin and zoptare-
lin doxorubicin model sensitiv-
ity analysis results. Conc: con-
centration, EHC: enterohepatic 
circulation, GFR: glomerular 
filtration rate, kcat: catalytic 
rate constant, Kd: dissociation 
constant, koff: dissociation rate 
constant, LHRHR: luteinizing 
hormone-releasing hormone 
receptor, rel expr: relative 
expression, normalized to tissue 
with highest expression
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OATP1B3 and 3.23 µmol/L for OCT2 (see “Materials and 
methods”). The resulting relative changes of apparent KM 
values amount to less than 0.5% for OATP1B3 and to less 
than 2.5% for OCT2, as illustrated in Fig. 4.
To rate the impact of a 2.5% change in KM, the relation of 
initial reaction velocity v0 and KM can be applied: 
For substrate concentrations significantly below KM 
and unchanged maximal reaction velocity Vmax (competi-
tive inhibition assumed), a 2.5% increase of KM results in 
a 2.5% decrease of initial reaction velocity. For higher sub-
strate concentrations, the influence of increased KM will be 
even smaller.
DDI potential of zoptarelin doxorubicin 
with simvastatin and metformin
For specific DDI predictions with simvastatin and met-
formin, victim drug steady-state plasma concentrations 
after administration of the highest common doses of 80 mg 
simvastatin (once daily, day 5) or 1000 mg metformin (three 
times daily, day 5) with and without co-administration of 
267 mg/m2 zoptarelin doxorubicin were simulated.
Testing of different time intervals between the start of 
zoptarelin doxorubicin infusion and administration of the 
victim drugs showed highest DDI impact on simvastatin 
acid, when the zoptarelin doxorubicin infusion is started 2 h 
after the administration of simvastatin (zoptarelin doxoru-
bicin Cmax at the time of simvastatin acid Cmax); and highest 
DDI impact on metformin, when the zoptarelin doxorubicin 
(4)v0 =
V
max
∗ substrate concentration
K
M
+ substrate concentration
infusion is started 1 h before the administration of metformin 
(zoptarelin doxorubicin Cmax at the time of metformin Cmax).
The identified administration regimens for maximum 
DDI impact and the resulting plasma concentrations of 
zoptarelin doxorubicin, simvastatin acid and metformin 
are illustrated in Fig. 5a, b. Victim drug plasma concentra-
tions of simvastatin acid and metformin, with and without 
co-administration of zoptarelin doxorubicin are presented 
in Fig. 5c, d. DDI impact on victim drug AUC and Cmax 
values, simulated with the different tested dosing regimens 
is shown in Zoptarelin Doxorubicin Supplementary Table 3. 
The identified worst-case co-administration scenarios result 
in a 0.114% increase of the plasma  AUC96–120 of simvastatin 
acid and a 0.096% increase of the  AUC96–104 of metformin, 
due to liver and kidney uptake inhibition.
Discussion
Doxorubicin model
The presented doxorubicin model is the first whole-body 
PBPK model developed with clinical data from humans and 
a mechanistic implementation of the binding of doxorubicin 
to DNA. This binding is essential to describe the pharma-
cokinetics of doxorubicin, as it is the driving force behind 
the unusual distribution behavior of this drug [33]. The 
developed model accurately describes doxorubicin plasma 
concentrations following direct administration of doxoru-
bicin and also very successfully predicts the concentrations 
of doxorubicin released following administration of a variety 
of different doses of zoptarelin doxorubicin.
Fig. 4  Zoptarelin doxorubicin DDI potential: Maximum impact of 
zoptarelin doxorubicin on OATP1B3 and OCT2. a Relative change 
of OATP1B3 apparent KM during inhibition by 267 mg/m
2 zoptarelin 
doxorubicin. b Relative change of OCT2 apparent KM during inhibi-
tion by 267  mg/m2 zoptarelin doxorubicin. Population simulation 
medians are shown as lines; the shaded areas depict the 5th–95th per-
centile population prediction intervals
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The sensitivity of the doxorubicin model to the value of 
fraction unbound is to be expected, as this parameter deter-
mines the doxorubicin concentration available for all phar-
macokinetic processes. The value used in the model has been 
carefully determined in vitro at Aeterna Zentaris and has not 
been optimized. The doxorubicin fraction unbound meas-
ured in-house (26.3%) is in very good accordance with the 
literature (25%, [34]). The moderate sensitivity of the model 
to the cellular permeability value underlines the influence 
of this parameter. Adjustment of this value greatly improved 
the model performance and, therefore, it has been included 
into the set of optimized parameters.
Several other PBPK models of doxorubicin have been 
developed so far, mostly established from animal data with 
the benefit of measured doxorubicin concentrations in dif-
ferent tissues [35–38]. Among those is a very nice model of 
doxorubicin in mice, that has been extrapolated to humans 
including evaluation of the predicted serum concentrations 
with actual clinical data, as well as mechanistic modeling 
of DNA binding to describe the tissue distribution of doxo-
rubicin [35]. The only other model directly developed from 
Fig. 5  Zoptarelin doxorubicin DDI potential: Specific DDI worst-
case scenario predictions with simvastatin acid and metformin as 
OATP1B3 and OCT2 victim drugs. a Predicted zoptarelin doxoru-
bicin (blue), doxorubicin (red), simvastatin (green) and simvastatin 
acid (pink) plasma concentrations (semilog scale) of a typical indi-
vidual during administration of 80  mg simvastatin every 24  h, plus 
267  mg/m2 zoptarelin doxorubicin once, on the morning of day 5. 
The last administration of simvastatin is at 96 h; zoptarelin doxoru-
bicin infusion (2 h) is started 2 h later at 98 h, resulting in simulta-
neous peak plasma concentrations of zoptarelin doxorubicin and 
simvastatin acid at 100 h. b Predicted zoptarelin doxorubicin (blue), 
doxorubicin (red) and metformin (dark yellow) plasma concentra-
tions (semilog scale) of a typical individual during administration of 
1000  mg metformin every 8  h, plus 267  mg/m2 zoptarelin doxoru-
bicin once, on the morning of day 5. The last administration of met-
formin is at 96 h; zoptarelin doxorubicin infusion (2 h) is started 1 h 
earlier, at 95 h, resulting in simultaneous peak plasma concentrations 
of zoptarelin doxorubicin and metformin at 97  h. c Overlay of pre-
dicted simvastatin acid plasma concentrations using the administra-
tion protocol shown in a, without (pink) and during co-administration 
of zoptarelin doxorubicin (dashed black line). d Overlay of predicted 
metformin plasma concentrations using the administration protocol 
shown in b, without (dark yellow) and during co-administration of 
zoptarelin doxorubicin (dashed black line)
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human data lacks a mechanistic implementation of the tissue 
binding, but features a physiologically based description of 
the effects of aging on the distribution clearance of doxo-
rubicin [36].
In the presented doxorubicin model, DNA binding sites 
have so far only been implemented into 8 of the 22 model 
compartments, resulting in an overestimation of the doxo-
rubicin accumulation in these tissues and an underestima-
tion of the doxorubicin concentration in the tissues without 
binding partner (not counting the blood cell compartment, 
as the DNA concentration within this volume has been sepa-
rately adjusted to match literature data). Although the DNA 
binding site reference concentration of the virtual patients 
has been optimized (Kd and koff have been fixed to litera-
ture values), the obtained value is biologically plausible. A 
rough estimate of the number of DNA base pairs per human 
is 6.0 × 1022 (6.0 × 109 base pairs per cell, 1.0 × 1013 cells 
per human). This equals 0.1 mol of base pairs per human. 
As the doxorubicin binding partner was implemented only 
into the 8 most important tissues of the model patient, these 
DNA binding sites are distributed into 4 L of tissue with 
equal expression of this binding partner, resulting in a refer-
ence concentration of 0.025 mol/L. The optimized value of 
0.046 mol/L is in the same order of magnitude. Furthermore, 
there are reports of binding of doxorubicin not only to DNA, 
but (with a lower affinity) also to cardiolipin and DNA-asso-
ciated enzymes, which have not been implemented into the 
model [9, 39]. To predict the doxorubicin concentrations and 
pharmacodynamics within a distinct organ, the distribution 
of the DNA binding sites will have to be implemented in an 
anatomically correct way, as has been proposed by Gustaf-
son et al. [35].
Despite minor limitations, this model is a suitable basis 
for further refinement and subsequent extrapolation to vul-
nerable populations receiving doxorubicin treatment such as 
children, elderly and patients with organ impairment.
Zoptarelin doxorubicin model
The presented zoptarelin doxorubicin model is the first 
PBPK model of zoptarelin doxorubicin and accurately 
describes and predicts plasma concentrations of zoptarelin 
doxorubicin and its active metabolite doxorubicin following 
infusion of different doses of zoptarelin doxorubicin. This 
is remarkable, as the model has been developed with data 
collected in three clinical trials investigating patients with 
different types of cancer.
As for the doxorubicin model, the sensitivity of the zop-
tarelin doxorubicin model to the value of fraction unbound 
was to be expected and the value used in the model has also 
been carefully measured in-house. The relatively high sensi-
tivity of the model to the zoptarelin doxorubicin hydrolysis 
rate value emphasizes the impact of this parameter on the 
elimination of zoptarelin doxorubicin and on the predicted 
AUC.
The primary aim of this PBPK analysis was to 
assess the DDI potential of zoptarelin doxorubicin with 
OATP1B3 and OCT2 victim drugs. Future applications 
of the presented model could include the implementation 
of a tumor compartment to enable the prediction of zop-
tarelin doxorubicin and doxorubicin concentrations in the 
target tissue and to answer questions regarding efficacy 
and pharmacodynamics of zoptarelin doxorubicin. For a 
first estimate, the model can be employed to simulate the 
internalization and intracellular concentrations of zopta-
relin doxorubicin as well as the resulting concentrations of 
doxorubicin in the gonads. The lack of a tumor compart-
ment (compensated by a low expression of LHRHR in the 
lung) does not impact the results and interpretation of the 
presented PBPK analysis of the interaction with OATP1B3 
and OCT2, as these DDIs are determined by the concentra-
tions in liver and kidney.
Zoptarelin doxorubicin DDI potential
Zoptarelin doxorubicin shows no inhibition or induction 
of cytochrome P450 enzymes in vitro, as well as no inhi-
bition of investigated transporters other than OATP1B3 
 (IC50 = 16.5 µmol/L) and OCT2  (IC50 = 3.26 µmol/L). P-gly-
coprotein (P-gp), breast cancer resistance protein (BCRP), 
organic anion transporter 1 (OAT1), OAT3 and OATP1B1 
are not inhibited in vitro  (IC50 values > 200 μmol/L). The 
predicted maximum relative changes of transport rate during 
treatment with the highest clinical dose of zoptarelin doxoru-
bicin are 0.5% for OATP1B3 and 2.5% for OCT2 at the end 
of the infusion. In line with this general interaction potential 
assessment, no impact of zoptarelin doxorubicin on plasma 
concentrations of the OATP1B3 and OCT2 victim drugs 
simvastatin acid and metformin was found in worst-case sce-
nario simulations. These results are in accordance with the 
expectations due to low interstitial concentrations of zopta-
relin doxorubicin in relation to the zoptarelin doxorubicin K
i
 
values for inhibition of OATP1B3 and OCT2. As zoptarelin 
doxorubicin (MW = 1893.06 g/mol) is a 10-amino acid poly-
peptide linked to doxorubicin and positively charged at two 
amino groups at physiological pH, its passive permeability 
is low, leading to low interstitial concentrations.
This example demonstrates that PBPK modeling is a val-
uable technique to analyze the risk of investigational drugs 
suspected to cause drug–drug interactions in vivo. In vitro 
results and pharmacokinetic data from early clinical studies 
are used to establish mechanistic and physiologically based 
models that allow the in vivo prediction of drug–drug inter-
actions. This approach is supported by drug approval agen-
cies [12, 13] and can help to minimize patient risk, costs 
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and time needed for drug development. Furthermore, PBPK 
modeling has the capability to generate information when-
ever the conduct of clinical trials is not ethical, as is the case 
in all frail populations such as children, elderly and patients.
Conclusion
This is the first report of a whole-body PBPK model of zop-
tarelin doxorubicin and its active metabolite doxorubicin. 
The model was applied for the evaluation of the zoptarelin 
doxorubicin drug–drug interaction potential (1) by a general 
assessment of the OATP1B3 and OCT2 inhibition poten-
tial of zoptarelin doxorubicin in vivo and (2) by specific 
DDI simulations of the impact of zoptarelin doxorubicin 
on  simvastatin acid and metformin exposure in worst-case 
scenarios. No DDI potential of zoptarelin doxorubicin was 
detected in these analyses.
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Abstract. Clarithromycin is a substrate and mechanism-based inhibitor of cytochrome
P450 (CYP) 3A4 as well as a substrate and competitive inhibitor of P-glycoprotein (P-gp) and
organic anion-transporting polypeptides (OATP) 1B1 and 1B3. Administered concomitantly,
clarithromycin causes drug–drug interactions (DDI) with the victim drugs midazolam
(CYP3A4 substrate) and digoxin (P-gp substrate). The objective of the presented study
was to build a physiologically based pharmacokinetic (PBPK) DDI model for clarithromycin,
midazolam, and digoxin and to exemplify dosing adjustments under clarithromycin co-
treatment. The PBPK model development included an extensive literature search for
representative PK studies and for compound characteristics of clarithromycin, midazolam,
and digoxin. Published concentration-time proﬁles were used for model development
(training dataset), and published and unpublished individual proﬁles were used for model
evaluation (evaluation dataset). The developed single-compound PBPK models were linked
for DDI predictions. The full clarithromycin DDI model successfully predicted the metabolic
(midazolam) and transporter (digoxin) DDI, the acceptance criterion (0.5≤AUCratio,predicted/
AUCratio,observed≤ 2) was met by all predictions. During co-treatment with 250 or 500 mg
clarithromycin (bid), the midazolam and digoxin doses should be reduced by 74 to 88% and
by 21 to 22%, respectively, to ensure constant midazolam and digoxin exposures (AUC).
With these models, we provide highly mechanistic tools to help researchers understand and
characterize the DDI potential of new molecular entities and inform the design of DDI
studies with potential CYP3A4 and P-gp substrates.
KEY WORDS: clarithromycin; digoxin; dose; drug interaction; midazolam; PBPK.
INTRODUCTION
Pharmacokinetic (PK) drug–drug interactions (DDIs)
can cause negative clinical effects, either by decreasing
therapeutic efﬁcacy or by enhancing toxic side effects of
drugs. DDIs play an important role in reported adverse
events (1) and are a major cause of market withdrawal of
drugs due to safety reasons (2). To cope with the increasing
DDI risks associated with polypharmacy, the European
Medicines Agency (EMA) (3) and the US Food and Drug
Administration (FDA) (4) published guidance documents to
help researchers understand and characterize the DDI
potential of new molecular entities. A prominent feature of
these guidances is the recommendation of well-established
perpetrator and victim drugs for clinical DDI studies.
Perpetrators of metabolic DDIs inhibit or induce, e.g.,
cytochrome P450 (CYP) enzymes. CYP enzymes are an
important source of clinically relevant DDIs, among which
CYP3A4 is the most common enzyme for the metabolic
clearance of drugs (5,6). Consequently, the inhibition or
induction of CYP3A4 is a frequent cause of DDI.
Until 2013, ketoconazole has been the CYP3A inhibitor
of choice in clinical DDI studies (7). Due to the risk of serious
hepatic toxicity, the EMA and the FDA advised against the
further use of ketoconazole in clinical DDI studies (8).
Clarithromycin has been proposed as a useful clinical
alternative (9).
Clarithromycin is a widely prescribed antibiotic (10) that is
mainly metabolized via CYP3A4 (11). It forms a non-covalent
metabolic-intermediate complex with CYP3A4 (12) leading to a
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mechanism-based inhibition (MBI). This MBI is characterized
by a non-linear, dose-dependent and irreversible degradation of
CYP3A4. Thus, the MBI by clarithromycin leads to a
mechanism-based auto-inhibition of metabolism and results in
a non-linear increase of clarithromycin exposure after ascending
doses of clarithromycin (13). Clarithromycin is also a substrate
(14) and competitive inhibitor of P-glycoprotein (P-gp) (15) as
well as a substrate (16,17) and competitive inhibitor of human
organic anion-transporting polypeptides (OATP) 1B1 and 1B3
(18).
One of the recommended and most suitable victim drugs
to investigate CYP3A4-mediated DDIs is midazolam. Mid-
azolam is a short-acting, widely used sedative approved as
premedication before medical interventions that is almost
exclusively metabolized by CYP3A4 (19).
Digoxin is a prominent victim drug to investigate P-gp-
mediated DDIs, as its disposition is mainly governed by P-gp.
Any metabolism via phase I or II enzymes seems to be
negligible. The primary route of digoxin elimination (∼75%) is
renal excretion via glomerular ﬁltration and active tubular
secretion (mainly via P-gp) of unchanged drug (20,21). Digoxin
binds to and inhibits several subunits of the (Na+,K+-)ATPase, in
particular the subunit alpha 2, which leads to the desired positive
inotropic effects of digoxin in the heart (22).
OBJECTIVE
The aims of this work were as follows:
1. To develop fully mechanistic physiologically based
pharmacokinetic (PBPK) models for the single com-
pounds clarithromycin, midazolam, and digoxin
2. To couple the clarithromycin and midazolam PBPK
models to predict the metabolic DDI (via CYP3A4) of
these two drugs
3. To couple the clarithromycin and digoxin PBPK
models to predict the transporter-based DDI (via P-
gp) of these two drugs
Exemplarily, it is shown how dosing recommendations
for midazolam and digoxin during co-administration with
various doses of clarithromycin can be derived.
METHODS
PBPK Model Development
The PBPK model development consisted of (i) an
extensive literature search for representative PK studies and
(ii) for compound characteristics (physicochemical and
ADME) of clarithromycin, midazolam, and digoxin. For the
model development, the available, published, and unpub-
lished individual PK data were divided into a Btraining^
dataset for model development and an Bevaluation^ dataset
for model qualiﬁcation. The training dataset was used to
optimize model parameter values to ﬁnd the best overlap
between observed and simulated concentration-time proﬁles.
First, intravenous concentration-time proﬁles were used to
determine clearance and distribution parameters. Second,
oral concentration-time proﬁles were used to determine
absorption and dissolution parameters, keeping the formerly
optimized parameters ﬁxed. Model qualiﬁcation with the
evaluation dataset was carried out using visual predictive
checks. The ﬁnal single-compound models were then coupled
to predict the pharmacokinetic effects of clarithromycin on
midazolam and digoxin. The PBPK models for
clarithromycin, midazolam, and digoxin were developed
independently of each other. This also includes the parame-
terization of the CYP3A4 MBI, which has been achieved with
multiple-dose studies of clarithromycin only. The parameters
for the inhibition of P-gp have been taken from in vitro
experiments without optimization. DDI PK studies were used
to qualify the DDI prediction performance of the coupled
clarithromycin–midazolam and clarithromycin–digoxin
models. Forty-four concentration-time proﬁles were used in
the model development process (Table I).
PBPK modeling software PK-Sim® 5.3.2 (Bayer Tech-
nology Services, Leverkusen, Germany) and MoBi 3.3.2
(Bayer Technology Services, Leverkusen, Germany) were
used. Statistical analysis of the results and graphics were
compiled with Matlab 2015a. Data was digitized using
GetData Graph Digitizer 2.25.
PBPK Model Structure
The PBPK models of clarithromycin, midazolam, and
digoxin are based on a generic 22-organ PBPK model,
including the arterial and venous blood pools and the portal
vein. Each organ is further divided into sub-compartments,
characterizing the blood plasma, the red blood cells (RBC),
the interstitial space, and the intracellular space. The mass
transfer between compartments is based on a generic
distribution model (passive processes). Herein, substance-
speciﬁc parameters (e.g. lipophilicity) are used to determine
permeabilities across membranes and partition coefﬁcients
between compartments. Active processes (binding, metabo-
lism, and transport) are additionally implemented, depending
on the PK behavior of the substance.
For clarithromycin, implemented active processes are
metabolism via CYP3A4 and transport via OATP 1B3. An
unspeciﬁc renal clearance of clarithromycin was assumed. As
P-gp substrate, the intestinal absorption of clarithromycin is
reduced by intestinal P-gp. The impact of this efﬂux transport
of clarithromycin from intestinal mucosa to intestinal lumen
was implemented by reducing the net transcellular intestinal
permeability of clarithromycin (55). The midazolam model
assumes metabolism by CYP3A4 with negligible renal
clearance. The digoxin model incorporates active efﬂux
transport via P-gp with a renal clearance of digoxin consisting
of glomerular ﬁltration and tubular secretion by P-gp.
The PBPK modeling software calculates the organ-
speciﬁc protein expression relative to the expression in the
organ with the highest concentration of the respective protein
(reference concentration). The reference concentration cor-
responds to an expression level of 100%. Hence, organ-
speciﬁc transporter protein concentrations of P-gp and OATP
1B3 used in simulations were calculated based on Eq. 1,
CT;organ ¼ TREF  EXPRorgan ð1Þ
where CT,organ denotes the molar transporter concentration in
the speciﬁc organ, TREF is the transporter reference
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concentration, and EXPRorgan denotes the transporter ex-
pression relative to the organ with the highest concentration
(56–58).
In our models, CYP3A4 is expressed in the liver and the
intestinal mucosa. The CYP3A4 reference concentration used
in the simulations was set to 3.47 μmol/L (59) in the liver.
OATP 1B3 is expressed in, e.g., the bone, liver, lung, muscle,
and intestine, with the highest OATP 1B3 expression (276
nmol/L (60)) in the intestinal mucosa according to published
expression databases (56,57). P-gp was expressed in, e.g., the
brain, kidney, liver, and intestine, with the highest expression
in the kidney (61) (101 nmol/L (62)). ATPase (subunit alpha
2), as digoxin binding partner, is implemented, e.g., in the
brain, heart, and muscle with the highest expression in the
brain (57,58), with a ﬁtted reference concentration of
99.5 μmol/L.
Table I. Clinical Study Data of Clarithromycin, Midazolam, and Digoxin in Healthy Volunteers
Substrate Route of
administration
Dose
[mg]
Number Age range
(mean) [years]
Weight range
(mean) [kg]
Height range
(mean) [cm]
BMI range
(mean) [kg/m2]
Ref.
Clarithromycin iv (inf, 0.5 h, SD) 0.1 30 18–55 – – 18–30 (23)
iv (inf, 0.5 h, SD) 250 22 18–40 (29) 57.7–87.7 (71.5) 164–188 (175) – (24)
po (tab, SD) 100–1200 36 19–36 (25.3) 55.9–96.6 (71.4) 158–191 (175) – (13)
po (tab, MD) 250 17 18–40 (29) 57.7–87.7 (70.8) 164–188 (174.9) – (25)
po (tab, MD) 250 12 21–39 (28) 68–98 (80) – 22–28 (24) (26)b
po (tab, MD) 250, 500 12 24–38 (26.5) 65–88 (79.5) 168–197 (182) – (27)
po (tab, MD) 500 17 20–39 (31) 63.9–86.8 (72.2) 160–183 (174.1) – (25)
po (sol, MD) 500 12 19–41 (28) 45.1–86.1 (66.5) 150–186 (168.4) – (28)
Midazolam iv (inf, 0.5 h, SD) 0.05/kg 16 (34) (78) – – (29)
iv (bolus, SD) 0.13/kg 5 28–49 70–80 – – (30)
iv (bolus, SD) 1.0 12 18–50 – – 18–30 (31)
iv (bolus, SD) 1.0 19 (22.9) (68.1) (174) – (32)
iv (bolus, SD) 5.0 6 21–22 66.3–77.0 – – (33)
iv (bolus, SD) 5.0 12 20–45 (29)a – – 20–26 (23)a (34)
iv (bolus, SD) 11.42 6 22–27 55–77 – – (35)
po (sol, SD) 2.0 12 18–50 – – 18–30 (31)
po (sol, SD) 3.0 11 (31.2) – – (23) (36)
po (tab, SD) 4.0 16 (34) (78) – – (29)
po (sol, SD) 5.0 24 – – – – (37)
po (tab, SD) 7.5, 15, 30 12 24–52 54.9–92.5 – – (38)
po (tab, SD) 10.0 6 21–22 66.3–77.0 – – (33)
po (tab, SD) 15.0 12 24–53 54–93 – – (39)
po (tab, SD) 10.0, 20.0 6 22–27 55–77 – – (35)
Digoxin iv (inf, 0.08 h, SD) 0.01/kg 12 21–39 (28) 68–98 (80) – 22–28 (24) (26)
iv (bolus, SD) 1.0 12 – – – – (40)
iv (bolus, SD) 0.5 6 – 66–96 – – (41)
iv (bolus, SD) 0.015/kg 6 22–29 (24) – – – (42)
iv (inf, 0.08 h, SD) 0.5 12 (28) (74) – (23) (43)
iv (inf, 0.5 h, SD) 1.0 8 (29) (84) – – (44)
iv (inf, 1 h, SD) 0.5 9 (27.9) (66.6) (169.7) – (45)
iv (inf, 1 h, SD) 0.75 8 – – – – (20)
iv (inf, 1 h, SD) 0.5, 1.0, 1.5 9 23–37 (31.3) 69–90 (77.7) – – (46)
iv (inf, 1, 3 h, SD) 0.5 6 – 66–96 – – (41)
po (tab, SD) 0.5 12 22–35 (26) – – 19–28 (22) (47)
po (tab, SD) 0.25 18 (30) (77.5) – – (48)
po (na, SD) 0.25 16 20–43 (39)a (72.5)a (174)a (24)a (49)
po (tab, SD) 0.75 12 21–39 (28) 68–98 (80) – 22–28 (24) (26)
po (tab, SD) 1.0 8 (29) (84) – – (44)
po (tab, SD) 1.0 10 19–27 (24)a 61–92 (73)a – – (50)
po (sol, SD) 0.5 6 – 66–96 – – (41)
po (tab, MD) 0.5, 0.25c 8 (32.4) (74.8) (178.5) – (51)
po (na, MD) 0.125 12 18–55 (37.8) 70–95 (87.8) (179) 23–30 (27) (52)
po (tab, MD) 0.25 20 23–49 (74.8) (171) (25) (53)
po (na, MD) 0.25 22 18–45 (50) – – (54)
inf infusion, iv intravenous, MD multiple doses, na information not available, po per oral, SD single dose, sol solution, tab tablet,
aMedian given
b Individual concentration-time proﬁles are unpublished in-house data
c 0.5 mg bid for 3 days followed by 0.25 mg bid for 2 weeks
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MBI of CYP3A4 Metabolism
The metabolic clearance (CLmet) of clarithromycin and
midazolam via CYP3A4 was incorporated using Eq. 2,
CLmet ¼ Vmax  Ct= KM;CYP3A4 þ Ct
 
with Vmax ¼ kcat;CYP3A4  Et
ð2Þ
where C t denotes the unbound concentration of
clarithromycin or midazolam in the respective intracellular
organ compartment and KM,CYP3A4 denotes the Michaelis-
Menten constant of CYP3A4 for the respective substrate. The
parameter kcat,CYP3A4 is the turnover number and Et is the
amount of CYP3A4 at time point t available for metabolizing
processes.
The MBI of CYP3A4 by clarithromycin was imple-
mented and the organ-speciﬁc de novo synthesis rates were
described by Eq. 3,
R0 ¼ E0  kdeg ð3Þ
where R0 is the de novo protein synthesis rate of
CYP3A4, E0 is the enzyme amount at baseline at time
point 0, and kdeg denotes the 1st-order degradation rate
constant of CYP3A4.
The rate of change of CYP3A4 amount due to the
inactivation via clarithromycin in the intracellular compart-
ments was described by Eq. 4,
dEt= dt ¼ R0 kdeg  Et kinact  CLRt= KI þ CLRtð Þð Þ  Et
ð4Þ
where the maximum rate of enzyme inactivation (kinact)
and the concentration required for half-maximal enzyme
inactivation (KI) of clarithromycin are used to describe
the enzyme inactivation due to the intracellular, unbound
clarithromycin concentration at time point t (CLRt). Value
selection for kinact and KI (Table II) was based on the
descriptive performance of the auto-inhibition in multiple-
dose studies of clarithromycin.
Competitive Inhibition of P-gp Transport
The P-gp efﬂux transport of digoxin (Jefﬂux) was de-
scribed by Eq. 5,
Jefflux ¼ Jmax  DIGt= KM;Pgp þ DIGt
 
with Jmax ¼ kcat;Pgp  Pt
ð5Þ
where DIGt denotes the unbound concentration of digoxin in
the respective intracellular organ compartment and KM,Pgp
denotes the Michaelis-Menten constant of P-gp for digoxin.
The parameter kcat,Pgp is the turnover number and Pt is the
amount of P-gp at time point t available for transporting
processes.
The competitive inhibition of P-gp-mediated digoxin
transport by clarithromycin was implemented using Eq. 6,
KM;Pgp;app ¼ KM;Pgp  1 þ I = Kið Þ ð6Þ
where KM,Pgp denotes the digoxin Michaelis-Menten constant
in the absence of clarithromycin, I is the unbound
clarithromycin concentration, and Ki denotes the dissociation
constant of the clarithromycin–transporter complex. Using
the assumptions of Cheng and Prusoff (88), a P-gp Ki value
for clarithromycin of 3.78 μmol/L was used in the simulations,
based on a published IC50 of 4.1 μmol/L (15).
Drug–Drug Interaction
The AUCratio (AUCinhibition/AUCnormal) between the
victim drug AUC with clarithromycin co-treatment
(AUCinhibition) and without clarithromycin co-treatment
(AUCnormal) was determined. The AUCratio derived from
the DDI model prediction was compared to AUCratio
literature values observed in clinical DDI studies. A ratio of
0.5≤AUCratio,predicted/AUCratio,observed≤ 2 was used as the
acceptance criterion for a successful DDI prediction.
Virtual population characteristics
Interstudy variabilities of the investigated DDIs were
assessed using 10 virtual populations with the same number of
study individuals as described in the respective study. In
virtual populations, CYP3A4 was log-normally distributed
with a geometric mean reference concentration of 3.47 μmol/
L and a geometric standard deviation (GSD) of 1.6, based on
a coefﬁcient of variation of 53% (89). The standard CYP3A4
half-life in liver and intestinal mucosa was set to 36 and 23 h,
respectively (90). In virtual populations, the CYP3A4 half-life
was uniformly distributed within 10–140 h in the liver and 12–
33 h in the intestine (91). P-gp was normally distributed with a
mean reference concentration of 101 nmol/L and a standard
deviation (SD) of 40% of the mean (92).
Dosing Recommendations of Midazolam and Digoxin for
Clinical Practice
Dosing recommendations for midazolam and digoxin
under bid (twice a day) clarithromycin co-treatment were
determined as percentage of the midazolam and digoxin dose
without co-medication. In the scenario of clarithromycin co-
administration, doses of midazolam and digoxin were reduced
until the AUCinhibition equaled the AUCnormal. For the DDI
studies, mean individuals were created (mean of the study
age, weight, height, and BMI) to calculate the adapted doses
during clarithromycin administration of 25, 50, 100, 200, 300,
400, 500, 600, 700, 800, 900, and 1000 mg bid. For the
clinically most relevant clarithromycin doses of 250 and
500 mg, virtual population simulations were performed using
the adapted doses of midazolam and digoxin.
Moj et al.
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PBPK DDI Modeling of Clarithromycin, Midazolam, and Digoxin
Parameter Sensitivity Analysis
Parameter sensitivity analyses have been performed to
assess the impact of critical model parameters on the
predicted AUCratios for the co-treatment regimens showing
the highest observed AUCratios. Co-treatment regimens were
(i) 500 mg oral clarithromycin at steady state (bid) with a
single oral dose of 4 mg midazolam and (ii) 250 mg oral
clarithromycin at steady state (bid) with a single oral dose of
0.75 mg digoxin. Assessed parameters were: clarithromycin
blood cell permeabilities (one permeability for each direc-
tion), CYP3A4 KI, CYP3A4 kinact, midazolam CYP3A4 kcat,
CYP3A4 half-lives in the liver and intestine, digoxin P-gp kcat,
digoxin P-gp Ki, and digoxin ATPase koff. All parameters
were varied individually over a wide range of values (via
multiplication by factors between 0.1 and 10.0) and the
change in AUCratio was documented. If a 10% change of a
single parameter leads to a >1% change in AUCratio, the
model is considered sensitive to this parameter.
RESULTS
PBPK models of clarithromycin, midazolam, and digoxin
have been successfully developed using the given parameters
in Table II. Best simulation results for all compounds were
obtained using tissue-to-plasma partition coefﬁcients calcu-
lated by the method of Rodgers and Rowland (93,94).
For clarithromycin, it was not possible to adequately
describe the concentration-time proﬁle after intravenous
administration using standard input parameters (e.g., logP)
and calculation methods (e.g., partition coefﬁcients). Simu-
lated concentration-time proﬁles over-predicted Cmax and
under-predicted the observed data for time > Tmax. Accord-
ing to literature, clarithromycin accumulates in mononuclear
(MN) and polymorphonuclear (PMN) leukocytes, probably
via active transport (95). This process was implemented, and
it improved the model signiﬁcantly. Due to limited knowledge
on this transport (unknown transporter, unknown Vmax, and
KM value), an adjustment of the clarithromycin permeability
between plasma and RBC compartments was applied. The
clarithromycin permeability optimization (Pplasma→RBC,
PRBC→plasma) led to an asymmetric permeability ratio
Pplasma→RBC/PRBC→plasma of 13, indicating that clarithromycin
can more easily enter than exit the RBC compartments.
Using the optimized permeability values, the clarithromycin
model successfully described the training dataset’s
concentration-time proﬁles after different doses of intrave-
nous (supplementary Fig. 1) and oral clarithromycin applica-
tion (Fig. 1). The prediction of the evaluation dataset’s
individual concentration-time proﬁles was successful for
multiple dosing with 250 and 500 mg clarithromycin (Fig. 2)
and reasonably well for single rising doses of 100–1200 mg
(supplementary Fig. 2). The MBI of CYP3A4 by
clarithromycin was successfully implemented. The reported
loss of CYP3A4 activity in the liver and intestine (96) during
treatment with 500 mg clarithromycin could be accurately
simulated (supplementary Fig. 3). Our model predicts a
duodenal intracellular mucosa clarithromycin concentration,
after oral treatment, which is about 20 times higher than the
concentration reached in the intracellular liver compartment
Fig. 1. Predicted concentration-time proﬁles of clarithromycin after multiple doses of
clarithromycin (a, b: ref. (25), c, d: ref. (27)) in comparison with the observed mean data
(±standard deviation (SD)). Solid line, predicted mean; dashed-dotted line, predicted median; gray
shaded area, predicted SD; dashed line, predicted minimum/maximum; gray circles observed mean
data (±SD)
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(Cmax,intestine, 621 mg/L; Cmax,liver, 31 mg/L). The maximum
loss of intestinal CYP3A4 activity was about 80% whereas
the hepatic loss was about 55% during simulated treatment
with 500 mg clarithromycin bid.
The developed midazolam model appropriately de-
scribed the training dataset (supplementary Figs. 4 and 5)
and predicted the evaluation dataset’s concentration-time
proﬁles (Fig. 3, supplementary Figs. 4 and 5), of both,
intravenously and orally administered midazolam.
The digoxin model also adequately described the
training dataset (supplementary Figs. 6–8) and predicted
the evaluation dataset’s concentration-time proﬁles (Fig. 4,
supplementary Figs. 6–8) for intravenous and oral
administration.
The clarithromycin–midazolam model accurately pre-
dicted the clinically observed DDI after oral clarithromycin
pretreatment and intravenously or orally administered mid-
azolam (Fig. 5). Hence, the MBI parameter values (kinact, KI)
of the clarithromycin model could be successfully used to
predict the clarithromycin–midazolam DDI without further
adjustments to these parameters. The clarithromycin–digoxin
model adequately predicted the clinically observed DDI after
oral clarithromycin pretreatment and intravenously or orally
administered digoxin (supplementary Fig. 9, Fig. 6). The
predicted mean AUCratios of the clarithromycin–midazolam
DDI, intravenous and oral, were comparable to the observed
mean AUCratios. Dividing predicted by observed AUCratios
gives ratios of 0.8 (minimum) to 1.0 (maximum) (Table III).
The predicted mean AUCratios of the intravenous
clarithromycin–digoxin DDI were also comparable to the
observed mean AUCratios. Dividing predicted by observed
AUCratios of the intravenous clarithromycin–digoxin DDI
gives values of 0.9 (minimum) to 1.0 (maximum). The
predicted mean AUCratios of the oral clarithromycin–digoxin
DDI were over-predicted by a factor of 2.0. The predicted
SDs of all AUCratios (midazolam and digoxin DDI) were
close to the observed SDs except for the SD of the
clarithromycin–digoxin DDI after intravenous application,
which was under-predicted (SDpred = 0.01 vs. SDobs = 2.22).
To assess the impact of the parameters used to model the
DDI processes, a sensitivity analysis was conducted which
showed that 10% changes in CYP3A4 kinact, CYP3A4 KI,
liver CYP3A4 half-life, digoxin P-gp kcat, and midazolam
CYP3A4 kcat (5 out of 10 tested parameters) lead to 13, 11,
Fig. 2. Predicted concentration-time proﬁles of clarithromycin after multiple doses of
clarithromycin (a: ref. (26), b: ref. (28)) in comparison with the observed individual data. Solid
line, predicted mean; dashed-dotted line, predicted median; gray shaded area, predicted 5th–95th
percentile; dashed line, predicted minimum/maximum; gray circles, observed individual data
Fig. 3. Predicted concentration-time proﬁles of midazolam after intravenous and oral doses of
midazolam (a: ref. (31), b: ref. (37)) in comparison with the observed individual data. Solid line,
predicted mean; dashed-dotted line, predicted median; gray shaded area, predicted 5th–95th
percentile; dashed line, predicted minimum/maximum; gray circles, observed individual data
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11, 9, and 5% changes in AUCratios, respectively (supplemen-
tary Fig. 10). The other half of the assessed parameters had
no crucial impact on the predicted AUCratios.
Dosing recommendations for midazolam and digoxin
under clarithromycin co-medication were calculated using
mean study individuals. An overview of the recommended
oral midazolam and digoxin doses with the corresponding
oral clarithromycin doses from 25 to 1000 mg bid at steady
state is presented in Fig. 7. At clarithromycin steady state
with orally administered 500 mg bid, the intravenous midazo-
lam dose had to be reduced by 62% to achieve a similar
midazolam exposure as without co-treatment. At
clarithromycin steady state with orally administered 250 or
500 mg bid, the oral midazolam doses had to be reduced by
74 and 88%, respectively. During clarithromycin treatment
with orally administered 250 or 500 mg bid, the oral digoxin
doses had to be reduced by 21 or 22%, to prevent elevated
digoxin concentrations.
The identiﬁed adjusted midazolam and digoxin doses for
co-medication with the clinically most relevant clarithromycin
doses of 250 and 500 mg bid were applied in virtual
populations (supplementary Table 1). In both DDI scenarios,
the number of virtual individuals who experience a relevant
increase in the AUC of the victim drug is signiﬁcantly
reduced when applying the adjusted doses. In other words,
DDIs take place in all virtual individuals, but the AUCs of
the victim drugs stay approximately the same. In the
clarithromycin–midazolam DDI, the decline in the number
of experienced DDIs is much higher than in the
clarithromycin–digoxin DDI using the calculated dose
adaptation.
DISCUSSION
For the ﬁrst time, a whole-body PBPK model of
clarithromycin has been developed. The model was able to
predict a metabolic and a transporter DDI with the victim
drugs midazolam and digoxin.
Apart from our presented whole-body PBPK model, two
semi-physiological models of clarithromycin and a commen-
tary on a clarithromycin PBPK model have been published to
date (9,85,97). For the semi-physiological models, empirically
accentuated approaches were used, focusing exclusively on
the prediction of the impact of clarithromycin on CYP3A4,
which was reasonably well predicted. However, the MBIs
used in these publications were either available in the liver
only or not active at clarithromycin doses ≤100 mg. Further-
more, these models are not developed for prediction of
intravenous application of clarithromycin. In the case of the
commentary, no model development was presented, the
model structure remains unclear (full or minimal PBPK),
and the parameterization was not published.
Our clarithromycin model overcomes these limitations
and was built in a more comprehensive and mechanistic
approach. The MBI is available in all tissues with CYP3A4
expression and active at all clarithromycin doses after
intravenous and oral application. Furthermore, the DDI is
not only limited to the level of CYP3A4 but also describes
clarithromycin DDIs via P-gp. All three PBPK models
(clarithromycin, midazolam, and digoxin) were developed
and evaluated independently of each other. Hence, the
prediction of the DDIs of clarithromycin with midazolam
and digoxin were done without any adaptation of the
parameters used in the implemented processes mediating
the DDIs. The presented mechanistic models can easily be (i)
coupled to other victim or perpetrator models or (ii)
expanded by addition of further DDI processes (e.g., OATP
inhibition). This comprehensive whole-body PBPK approach
was used in the conviction that mechanistic models are better
suited for the scaling to special populations like geriatric,
pediatric, or diseased populations.
The MBI of CYP3A4 is crucial to understand the
non-linear pharmacokinetics of clarithromycin (12). Our
model adequately predicts the observed loss of duodenal
and hepatic CYP3A4 activity due to the MBI (96).
Although CYP3A activity encompasses CYP3A4 and
CYP3A5, whose substrate speciﬁcities cannot be distin-
guished (6), we neglected CYP3A5 in our clarithromycin
and midazolam models, since it was reported that
CYP3A5 plays a negligible role in the PK of both CYP3A
substrates (32,98,99).
The PK of clarithromycin further depends on the
distribution into MN and PMN in vivo. Since the standard
Fig. 4. Predicted concentration-time proﬁles of digoxin after intravenous and oral doses of digoxin
(a: ref. (40), b: ref. (51)) in comparison with the observed mean data (±standard deviation (SD)).
Solid line, predicted mean; dashed-dotted line, predicted median; gray shaded area, predicted SD;
dashed line, predicted minimum/maximum; gray circles, observed mean data (±SD)
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whole-body PK-Sim model does not offer MN or PMN cell
compartments, we used the RBC compartments (with ad-
justed permeability values) as surrogate compartments for
RBC + (MN + PMN) cells to adequately describe the PK of
clarithromycin. In a clinical study with 250 mg bid dosing, the
observed peak concentrations (Cmax) of clarithromycin in MN
and PMN cells were 29 and 17 μg/mL, respectively, leading to
a Cmax concentration ratio Cmax,MN+PMN/Cmax,plasma of 10 to
30 in healthy volunteers (27). The observed Cmax values
correspond to an amount of 17 mg of clarithromycin. The
Fig. 5. Left column: predicted concentration-time proﬁles of intravenous and oral doses of
midazolam (a, b: ref. (29), c: ref. (39), d: ref. (36)) with and without prior clarithromycin
regimens in comparison with observed mean data (±standard deviation (SD)). Solid line,
predicted midazolam mean without prior clarithromycin; dashed line, predicted midazolam
mean with prior clarithromycin; gray circles, observed mean midazolam without prior
clarithromycin; gray triangles, observed mean midazolam with prior clarithromycin. Right
column: predicted midazolam AUCratio (AUCinhibition/AUCnormal) in 10 virtual populations
of intravenous and oral doses of midazolam in comparison with observed mean data
(±SD). Horizontal lines, predicted midazolam AUCratio median; triangles, predicted
midazolam AUCratio mean; gray circles, predicted individual midazolam AUCratios; filled
circles, observed mean midazolam AUCratio (±SD). Clarithromycin was administered orally
(bid) with 250 mg (36,39) and 500 mg (29). WB whole blood
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predicted, additional amount of clarithromycin in the RBC
compartments, due to the optimized asymmetrical permeabil-
ity ratio of 13, was 36 mg, which is reasonably close.
In the ﬁnal digoxin model, digoxin is binding to the
ATP1A2 ATPase. The ATPase concentration was ﬁtted to a
reference concentration in the brain of 99.5 μmol/L. ATPase
measurements of [3H]-ouabain binding, enzyme activity and
maximum transport capacity suggest that the concentration of
Na+-K+ pumps (ATPase) inmammalian skeletal muscle is about
300–800 pmol/g wet tissue (100), which translates to 0.4–
1.1 μmol/L, assuming a tissue density of 1 g/mL and an
expression level of 0.7 inmuscle. The reason for this discrepancy
Fig. 6. Left column: predicted concentration-time proﬁles of digoxin after single oral doses of
digoxin (a: ref. (48), b: ref. (26)) with and without prior clarithromycin regimens in comparison with
observed mean data (±standard deviation (SD)). Solid line, predicted digoxin mean without prior
clarithromycin; dashed line, predicted digoxin mean with prior clarithromycin; gray circles, observed
mean digoxin without prior clarithromycin; gray triangles, observed mean digoxin with prior
clarithromycin. Right column: predicted digoxin AUCratio (AUCinhibition/AUCnormal) in 10 virtual
populations of oral digoxin in comparison with observed mean data (±SD). Horizontal lines,
predicted digoxin AUCratio median; triangles, predicted digoxin AUCratio mean; gray circles,
predicted individual digoxin AUCratios; filled circles, observed mean digoxin AUCratio (±SD).
Clarithromycin was administered orally (bid) with 250 mg (26) and 500 mg (48)
Table III. Comparison Predicted vs. Observed AUC Ratio
Application and dose
[mg] of clarithromycin
Application and dose
[mg] of victim drug
Number Females
[%]
Predicted mean
AUCratio
a ± STD
Observed mean
AUCratio ± STD
AUCratio,predicted/
AUCratio,observed
Ref.
Midazolam
po (tab, MD), 500 iv (inf, 30 min), 0.05/kg 16 50 2.2 ± 1.2 2.8 ± 1.6 0.8 (29)
po (tab, MD), 250 po (sol, SD), 3.0 11 10 5.8 ± 3.7 5.6 ± 2.0 1.0 (36)b
po (tab, MD), 500 po (tab, SD), 4.0 16 50 5.9 ± 4.6 7.0 ± 4.2 0.8 (29)
po (tab, MD), 250 po (tab, SD), 15.0 12 66 3.2 ± 1.5 3.6 ± 1.7 0.9 (39)
Digoxin
po (tab, MD), 400 iv (inf, 60 min), 0.5 9 0 1.01 ± 0.01 0.98 ± 2.22 1.0 (45)
po (tab, MD), 250 iv (inf, 4 min), 0.01/kg 12 0 1.02 1.2 0.9 (26)
po (tab, MD), 500 po (tab, SD), 0.25 18 50 2.91 ± 2.74 1.47 ± 2.50 2.0 (48)
po (tab, MD), 250 po (tab, SD), 0.75 12 0 3.37 ± 2.86 1.7 ± 3.05 2.0 (26)
inf infusion, iv intravenous, MD multiple doses, po per os, SD single dose, sol solution, STD standard deviation, tab tablet
aAUCratio =AUCinhibition/AUCnormal
b Individual concentration-time proﬁles are unpublished in-house data
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is unknown and probably reﬂects further mechanisms of digoxin
distribution that we have not understood so far.
The performance of the clarithromycin–midazolam
model is very good over the full range of administered doses
and administration protocols including the predicted mean
AUCratios and corresponding standard deviations. Conse-
quently, this model can help to replace ketoconazole by
guiding clinical DDI study designs with clarithromycin as a
strong mechanism-based inhibitor of CYP3A4. Although a
secondary objective, the clarithromycin–digoxin model shows
very good performance. Nevertheless, the predicted mean
AUCratio of oral digoxin (0.25, 0.75 mg) with and without
clarithromycin pretreatment is over-predicted by a factor of 2.
Interestingly, the predicted median AUCratio is close to the
observed mean. Virtual population simulations revealed a
wide range of individual AUCratios between 1 and 10 (Fig. 6).
There is no over-prediction using a single mean study
individual, instead of a population, to predict the AUCratio
for, e.g., 0.25 mg digoxin (predicted, 1.33; observed, 1.47).
The reason for the over-prediction lies in the combination of
intestinal permeability of digoxin together with the mucosal
P-gp activities along the intestinal tract within the virtual
populations. This combination leads to a high sensitivity to P-
gp transport for some individuals which in turn leads to the
skewed distribution of concentration-time proﬁles (predicted
median AUCratio < predicted mean AUCratio). Further,
knowledge on tissue-speciﬁc P-gp expression and its variabil-
ity would greatly improve the DDI population predictions.
This may also include genetic information because P-gp
polymorphisms have been related to differences in digoxin
distribution (101) and also to important clinical endpoints in
digoxin users (102). It could also be speculated that unbound
tissue concentrations of clarithromycin and/or digoxin are not
adequately predicted.
Our dose adaptation analysis identiﬁed that the
recommended digoxin dose is constant at ∼80% across
the investigated dose range, whereas the dose of midazo-
lam is declining from 60 to 10% for clarithromycin doses of
25 to 500 mg bid, respectively. For higher clarithromycin
doses (>500 mg), no further reduction of the midazolam
dose seems to be required. For oral digoxin, the
competitive DDI with clarithromycin occurs predominantly
in the mucosa where clarithromycin reaches local concen-
trations high enough to signiﬁcantly inhibit the P-gp
transport of digoxin even at clarithromycin doses of
25 mg. In contrast, 500 mg clarithromycin at steady state
are necessary to reach the maximum MBI for CYP3A4.
For clinical practice, this could imply that a single dose
adaptation is sufﬁcient for digoxin but a number of
midazolam dose adaptations might be needed, depending
on the given clarithromycin dose. There are several
approved oral formulations and strengths available for
midazolam and digoxin in the USA. According to the
FDA BOrange Book,^ midazolam is approved and available
as an oral syrup (2 mg base/mL) and digoxin is available as
oral solution (0.05 mg/mL) and tablet (0.125 and 0.25 mg).
The accurate administration of the adapted doses of
midazolam and digoxin is feasible with the oral solution
formulations. Training in appropriate dosing of the oral
solutions might be needed for the patients.
Since DDIs are a major reason for adverse events during
commonplace pharmacotherapy, the FDA labels would
beneﬁt from dosing guidance to prevent avoidable DDIs with
clarithromycin, midazolam, and digoxin. To assess the impact
of dose adaptations on DDIs in a population, simulations
could help to close this gap in the respective labels. The
virtual population simulations with the adapted victim drug
doses in supplementary Table 1 show that a dose adaptation
is especially helpful and necessary during the MBI
(clarithromycin–midazolam). Although the adapted doses
prevent digoxin overdosing during the competitive inhibition
(clarithromycin–digoxin) in a signiﬁcant number of individ-
uals, the reduction of individuals experiencing strong and
moderate AUC changes is improvable. However, as a drug
with a narrow therapeutic index, digoxin is a typical candidate
drug for therapeutic drug monitoring which implies that the
individualization of the digoxin dose during clarithromycin
co-treatment in this study especially revolves around the
determination of the digoxin starting dose. A clinical study
should be considered to evaluate and add more conﬁdence to
these model predictions established in a virtual population.
Fig. 7. Left: predicted concentration-time proﬁles of midazolam after single oral doses of
midazolam (MDZ) with and without oral clarithromycin (CLR) pretreatment. Solid line, 100%
midazolam dose without clarithromycin; dashed line, 100% midazolam dose with clarithromycin;
dashed-dotted line, adapted 26% midazolam dose with clarithromycin. Right: victim drug dose
recommendations in percent depending on the co-administered clarithromycin dose at
clarithromycin steady state (bid). Solid line, adapted digoxin dose; dashed-dotted line, adapted
midazolam dose
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Comprehensive and mechanistic whole-body PBPK
models are complex and require the input of many parame-
ters. For some of these parameters, no values are available
from the literature or the reported values differ strongly. The
parameter sensitivity analysis shows that the predicted DDI
AUCratios are sensitive to 5 out of 10 assessed parameters.
Among these 5 parameters, especially CYP3A4 liver half-life
but also CYP3A4 KI and CYP3A4 kinact cannot be reliably
derived from the literature. The liver half-life of CYP3A4 is
reported with values from 10 to 140 h. We found that a half-
life of 36 h was optimal to describe the effects of the MBI by
clarithromycin. The same value has been reported as most
appropriate in a dedicated modeling study by Rowland Yeo
et al. using several CYP3A4 mechanism-dependent inhibitors
and victim drugs (103). For CYP3A4 KI and kinact, the values
used in the simulations were the only ones to result in an
accurate description of the clinical clarithromycin data.
Additional impactful parameters were the midazolam
CYP3A4 kcat and the digoxin P-gp kcat. Both values have
been optimized very carefully using a multitude of clinical
studies spanning large dosing ranges of intravenous and oral
application. In addition, the digoxin model has been devel-
oped including data on the fraction of digoxin excreted in
urine, to increase our conﬁdence in the optimized P-gp kcat
value. However, this sensitivity analysis demonstrates that the
MBI of clarithromycin with CYP3A4 is strongly inﬂuenced by
3 different parameters (CYP3A4 liver half-life, CYP3A4 KI,
and CYP3A4 kinact). We will continue to evaluate our DDI
model by expanding it to the interactions with other victim
drugs and the scientiﬁc community will probably carry on to
investigate these parameters until a good validation is
reached. On the in vivo side, these results suggest that
interindividual differences in CYP3A4 and P-gp activity,
CYP3A4 turnover in the liver and clarithromycin concentra-
tions available to cause the MBI of CYP3A4 will lead to large
interindividual differences in the observed AUCratios during
this DDI. If this is true, DDI modeling should strive to
account for these variabilities for accurate dose recommen-
dations and study design.
In summary, our work shows that the sub-
compartmentalization of blood into plasma and red blood
cell compartments is not sufﬁcient to account for important
distribution processes found in vivo for clarithromycin. This
might also hold true for other eligible compounds. As models
will become more mechanistic in the future and the spatial
and temporal resolution will be continuously improved, a
more detailed compartmentalization of the blood will be part
of a general trend for more accurate descriptions of organs
important for absorption, disposition, action, and toxicity
(gut, liver, kidney, brain, etc.).
Further direction for future work is the measurement
and the interplay of many important parameters needed
as inputs for model building which are not (publicly)
available yet, starting with physicochemical parameters,
activity levels of drug metabolizing enzymes and trans-
porters throughout the body and other parameters to
inform ADME and DDI processes. Also, the characteri-
zation of the interindividual variability of these parame-
ters would greatly help to understand individual
differences in observed plasma concentrations and could
be considered during model building.
CONCLUSION
In this paper, we present the ﬁrst published whole-body
PBPK model of clarithromycin. Our clarithromycin model
was linked to PBPK models of the paradigm victim drugs
midazolam and digoxin and was capable to predict the
resulting DDIs. With the presented model, we provide a
valuable, publicly available tool for drug development and
clinical practice. The presented models can help researchers
understand and characterize the DDI potential of new
molecular entities and inform the design of DDI studies with
potential CYP3A4 and P-gp substrates.
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Results The PBPK/PD model suggests dosages of 80 
and 230 mg/m2 for children of 0–1 and 1–17 years of age, 
respectively. In comparison with the approved standard treat-
ment, in silico trials reveal 11 dosing regimens (9 oral, and 2 
intravenous infusion rates) increasing the HDAC inhibition 
by an average of 31%, prolonging the HDAC inhibition by 
181%, while only decreasing the circulating thrombocytes 
to a tolerable 53%. The most promising dosing regimen pro-
longs the HDAC inhibition by 509%.
Conclusions Thoroughly developed PBPK models enable 
dosage recommendations in pediatric patients and integrated 
PBPK/PD models, considering PD biomarkers (e.g., HDAC 
activity and platelet count), are well suited to guide future 
efficacy trials by identifying dosing regimens potentially 
superior to standard dosing regimens.
Keywords Vorinostat · Pediatrics · Physiologically 
based pharmacokinetics · Histone deacetylase · 
Thrombocytopenia · Pharmacodynamics
Introduction
Histone deacetylases (HDACs) regulate gene transcrip-
tion and cell signaling pathways. Changes in the structure, 
activity, or expression of HDACs can result in abnormal 
gene transcription and cell signaling leading to cancer [1]. 
HDAC inhibitors (HDACi), such as vorinostat, show anti-
neoplastic effects in vitro and in vivo, and offer therefore 
a new approach in chemotherapy [2]. Vorinostat is a fast, 
light-binding inhibitor with short residence time at the target 
that inhibits the enzymatic activity of Class I (HDACs 1–3) 
and Class II (HDAC 6) HDACs at nanomolar concentra-
tions  (IC50 = 30–86 nM) [3, 4]. It was approved by the U.S. 
Food and Drug Administration (FDA) for the treatment of 
Abstract 
Purpose This study aimed at recommending pediatric dos-
ages of the histone deacetylase (HDAC) inhibitor vorinostat 
and potentially more effective adult dosing regimens than 
the approved standard dosing regimen of 400 mg/day, using 
a comprehensive physiologically based pharmacokinetic/
pharmacodynamic (PBPK/PD) modeling approach.
Methods A PBPK/PD model for vorinostat was developed 
for predictions in adults and children. It includes the matu-
ration of relevant metabolizing enzymes. The PBPK model 
was expanded by (1) effect compartments to describe vori-
nostat concentration–time profiles in peripheral blood mono-
nuclear cells (PBMCs), (2) an indirect response model to 
predict the HDAC inhibition, and (3) a thrombocyte model 
to predict the dose-limiting thrombocytopenia. Parameteri-
zation of drug and system-specific processes was based on 
published and unpublished in silico, in vivo, and in vitro 
data. The PBPK modeling software used was PK-Sim and 
MoBi.
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cutaneous manifestations in patients with cutaneous T-cell 
lymphoma (CTCL) who have progressive, persistent, or 
recurrent disease on, or following two systemic therapies 
[4, 5].
Vorinostat shows a dose-proportional exposure increase 
after oral or intravenous doses of 100–800 mg or 75–900 mg/
m2, respectively, with an absorption rate-limited drug dispo-
sition in the gastrointestinal tract after oral dosing, leading 
to flip-flop pharmacokinetics (PK) [6]. Elimination primar-
ily comprises metabolism, involving glucuronidation and 
hydrolysis followed by β-oxidation without the contribution 
of CYP enzymes [7]. Renal excretion is negligible account-
ing for ~ 1% of total body clearance [8]. While the UDP-glu-
curonosyltransferases (UGTs) 1A9, 2B7, and 2B17 are the 
major enzymes of vorinostat glucuronidation, the enzyme 
responsible for hydrolysis and β-oxidation remains uniden-
tified [7]. These enzymes exhibit nonlinear age-dependent 
maturations completed within 10 years after birth [9–14]. 
Genetic polymorphisms of UGT 2B17 might play a role in 
the clearance of vorinostat and in clinical outcomes [15–17]. 
In general, vorinostat exhibits a short half-life of 1 (intrave-
nous) to 2 h (oral) and multiple-dose PK similar to single-
dose administration [7].
Clinical studies of vorinostat in patients with stage Ib and 
higher CTCL and in patients with refractory CTCL demon-
strated overall objective responses of 30 and 31%, respec-
tively [18, 19]. The most common adverse reactions, with 
an incidence ≥ 10%, associated with vorinostat treatment are 
anorexia, diarrhea, dysgeusia, fatigue, nausea, and thrombo-
cytopenia, with thrombocytopenia being the most common 
hematologic event [5, 20]. In pediatric studies, vorinostat 
was well tolerated at 230 mg/m2/day (alone or in combina-
tion with bortezomib) or 300 mg/m2/day (in combination 
with temozolomide) and showed a drug disposition similar 
to that observed in adults [21–23].
While in vitro experiments suggest that vorinostat con-
centrations of 2.5 µmol/l lead to the maximum accumulation 
of acetylated histones, it has also been shown that the HDAC 
inhibition has to be maintained over a significant period of 
time to show antitumor activity [24, 25]. Furthermore, vori-
nostat enhances the effect of other chemotherapeutics such 
as cisplatin and gemcitabine at concentrations > 2 µmol/l, 
which is, nevertheless, inconsistently achieved in patients 
at the approved 400 mg/day (qd) dose [6, 26, 27]. Little 
is known about the impact of different dosing regimens on 
its efficacy [6]. Hence, Dickson and co-workers attempted 
to achieve maximum vorinostat concentrations (Cmax) of 
> 2.5 µmol/l by an intermittent oral pulse dosing protocol of 
vorinostat in combination with the cyclin-dependent kinase 
inhibitor flavopiridol [28]. In this attempt, the Cmax of vori-
nostat could be increased, but unfortunately the incidence 
of myelosuppression was also increased. However, these 
promising results demand further assessment of alternative 
vorinostat dosing strategies that might show more effective-
ness and still tolerable toxicity compared to the vorinostat 
standard treatment.
Here, physiologically based pharmacokinetic and phar-
macodynamic (PBPK/PD) modeling and simulation enable 
the assessment of dosing regimens in in silico trials, while 
also being able to test clinical trial designs.
Objectives
1. Build and evaluate an adult whole-body PBPK model of 
vorinostat able to describe and predict the PK of vary-
ing doses of intravenously and orally administered vori-
nostat.
2. Develop and evaluate a pediatric PBPK model for 
vorinostat and estimate vorinostat doses for children 
between 0 and 17 years.
3. Build and evaluate a PBPK/PD model incorporating (1) 
a HDAC inhibition model and (2) a thrombocytopenia 
model.
4. Identify potentially effective vorinostat dosing regimens 
while considering HDAC activity and the number of 
circulating thrombocytes.
5. Perform parameter sensitivity analysis for the developed 
whole-body PBPK model of vorinostat.
Materials and methods
Model development and evaluation
A schematic overview of the PBPK model development 
and evaluation steps is shown in supplemental Fig. S1. The 
detailed steps of the model building are outlined in the fol-
lowing sections. In brief, PBPK modeling was performed 
in a stepwise procedure. First, an intravenous model of 
vorinostat was developed for adults. Second, an oral PBPK 
model for adults was established. Third, age-dependent 
physiological and anatomical changes were implemented 
enabling pediatric predictions and dose estimations. Fourth, 
PD models were incorporated into the PBPK model to 
describe HDAC inhibition and thrombocytopenia. Fifth, the 
PBPK/PD model was used to identify new dosing regimens. 
Finally, a parameter sensitivity analysis was performed.
Experimental datasets from 13 published and unpublished 
clinical studies were used to support the PBPK model devel-
opment and evaluation (Table 1). The experimental data-
sets were split into an internal development (n = 4 trials) 
dataset and an external evaluation dataset (n = 9), such that 
wide dose ranges were covered in both datasets. The PBPK 
model was fitted to the development dataset and the predic-
tion quality of the model was assessed by predicting the 
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evaluation dataset. Parameter optimizations were carried 
out using either a Monte-Carlo or Nelder–Mead method 
[29]. An overview of fitted parameters and the applied opti-
mization method is given in supplemental Table S1. The 
Monte-Carlo approach was used if no initial information on 
parameter values was available.
Model evaluation was carried out using (1) comparison 
of observed and simulated PK parameters and the fraction 
of vorinostat dose excreted unchanged into urine, (2) mean 
prediction errors (MPE) of pharmacokinetic profiles [37] 
and (3) visual predictive checks (VPC), which are tools for 
evaluating the performance of PK and PD models, where 
percentiles of experimental and simulated data are compared 
[38]. PK parameter comparisons were deemed successful 
when they satisfied the twofold acceptance criterion.
Simulations were carried out using virtual PBPK individ-
uals and populations. Virtual PBPK populations were cre-
ated as described by Willmann and co-workers using ranges 
for age, height, and weight reported in the internal and exter-
nal datasets [39]. In this approach, the organ weights and 
the cardiac output (CO) of a target individual are allometri-
cally scaled with height and the organ blood flows are scaled 
to the total CO [39]. To assess the inter-study variability 
of PK parameters, 10 virtual populations were created for 
each study. Applied dosing schedules and doses were used as 
published. The parameters of anatomy and physiology were 
varied as pre-defined in PK-Sim [40–43], parameters of the 
pharmacodynamic models were varied with a coefficient of 
variation (CV) of 20%.
An overview of important assumptions made during 
model development and evaluation is given in supplemen-
tal Table S2.
PBPK simulations were carried out using PK-Sim and 
MoBi (Version 6.3.2, Bayer Technology Services, Lev-
erkusen, Germany). Statistical analyses of the results and 
graphics were compiled using MATLAB (Version R2013b, 
The MathWorks Inc., Natick, MA, USA).
Adult PBPK model—intravenous
Intravenous concentration–time profiles were used to estab-
lish a PBPK model for vorinostat. The partition coefficients 
for vorinostat were calculated using the PK-Sim standard 
model [44, 45]. To describe the distribution phase correctly, 
the cellular permeability of vorinostat was estimated. The 
reference concentrations for UGT 1A9, 2B7, and 2B17 were 
kept at the PK-Sim default values of 1 µmol/l, respectively. 
The UGT  Vmax values were gathered from the literature. The 
PK-Sim gene expression database was used to distribute the 
enzymes to the specific organs [46, 47]. To fit the vorinostat 
half-life and concentration–time profiles, the unidentified 
hydrolytic and oxidative enzyme were implemented as a 
generic enzyme with a reference concentration of 1 µmol/l 
assuming similar availability across organs. The clearance 
value for hydrolysis and oxidation was fitted. All meta-
bolic reactions were modeled as first-order processes. The 
unbound vorinostat was assumed to be filtered and excreted 
with the glomerular filtration rate (GFR).
Adult PBPK model—oral
The developed intravenous PBPK model of vorinostat was 
expanded by an oral formulation. The particle dissolution 
module of PK-Sim was used to describe vorinostat drug 
Table 1  Clinical study data of vorinostat
iv intravenous, inf infusion, po per oral, sd single dose, qd once daily
a Unpublished
Route of administration Dose (mg) Dosing 
schedule
n Male 
patients (%)
Age median 
(range) (years)
Internal (in) or exter-
nal (ex) dataset
Ref.
iv (inf. 2 h) 75, 150, 300, 600, 900 /m2 sd 39 65 19–81 in [30]
iv (inf. 2 h) 200, 400 sd 20 – – ex [4]
po 400, 600, 800, 1000 qd 24 68 59 (31–85) ex [28]
po 100, 200, 400, 500 qd 18 83 58 (25–72) in [8]
po 200, 300, 400, 600 qd 73 69 (20–79) ex [6]
po 400 sd 10 50 62 (31–73) in [60]
po 400 qd 27 44 (46–80) ex [31]
po 800 sd 24 52 (29–78) ex [32]
po 400 qd 28 75 64 (30–77) ex [33]
po 400 qd 23 48 (39–84) ex [34]
po 400 qd 6 100 53.5 (34–75) ex [35]
po 180, 230, 300 /m2 sd 13 60 14 (5–22) ex [21]a
po 400 qd 63 49 64 (29–82) in [36]
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release in the intestine. This module calculates the dis-
solution kinetics of spherical particles with a predefined 
particle size distribution based on the Noyes–Whitney 
approach [48]. To describe the absorption of vorinostat 
correctly, the intestinal permeability coefficient was esti-
mated. To capture the whole-blood-to-plasma ratio of 
2.87, the red blood cell permeability was estimated [50].
Model evaluation of the intravenous and oral adult 
PBPK model was carried out comparing observed and 
predicted PK parameters and concentration–time profiles 
of the external evaluation dataset.
Pediatric PBPK model and dosage recommendations
The developed oral PBPK model of vorinostat was 
expanded by importing available age-dependent anatomi-
cal and physiological changes in human development from 
the PK-Sim databases [40]. The age-dependent maturation 
of UGT 1A9 and 2B7 was already available in PK-Sim, 
whereas the UGT 2B17 maturation was implemented using 
a Hill function (Eq. 1) based on recently published mRNA 
data [14], 
where  OFmin denotes the intercept with the y-axis, and  OFmax 
and  OF50 represent the maximum adult ontogeny factor 
(= 1) and the post-menstrual age needed to reach 50% of 
the maximum ontogeny factor, respectively. Age denotes the 
post-menstrual age in years and γ denotes the Hill factor. 
The unidentified enzyme responsible for the hydrolysis and 
oxidation of vorinostat was assumed to be fully developed 
from birth on.
Model evaluation of the pediatric PBPK model was car-
ried out comparing observed and predicted PK parameters 
and concentration–time profiles of the external evaluation 
dataset that consisted of 13 individual vorinostat plasma 
concentration–time profiles with individual ages ranging 
from 4.7 to 22 years.
The developed pediatric PBPK model of vorinostat 
was used to identify age-stratified mg/m2/day doses for 
children and adolescents from birth to 17 years of age. 
Pediatric doses were selected when the 25th, 50th, and 
75th percentiles of predicted  AUC0 − inf or Cmax values for 
the pediatric age groups were comparable to the values of 
the adult population dosed with the approved oral dose of 
400 mg/day. Two virtual populations were generated, first, 
for adults (age ≥ 18, n = 500) and second, for children (age 
0–17, n = 10,000). The body surface areas were calculated 
using the DuBois equation [49].
(1)
UGT 2B17 ontogeny factor (OF) = OFmin +
OFmax × Age
훾
OF
훾
50
+ Age훾
Adult PBPK model—HDAC activity
The oral PBPK model of vorinostat was expanded by an 
indirect response model to describe the HDAC activity in 
peripheral blood mononuclear cells (PBMCs) during vori-
nostat treatment [6]. PBMCs are not offered as physiologi-
cal compartments in the default PK-Sim PBPK model [50]. 
Therefore, two PBMC effect compartments were imple-
mented in the default model (Fig. 1). First, the rate constants 
keffect,1, keffect,2, keffect,deep,1, and keffect,deep,2 of the PBMC effect 
compartmental model were estimated. Second, the HDAC 
activity in the central PBMC compartment was modeled 
using an indirect response model, where the HDAC activity 
R was described by Eq. 2 [51], 
where  kin is the apparent zero-order rate constant for the 
production of the activity, kout represents the first-order rate 
constant for activity loss, and R is assumed to be stationary 
with an initial value of R
0
(
=
k
in
k
out
)
. The  SC50 value repre-
sents the PBMC vorinostat concentration (CV,PBMC) produc-
ing 50% of the maximum kout stimulation achieved at the 
effect site, whereas Smax is the maximum kout stimulation 
achieved at the effect site. Predictions of HDAC activity fol-
lowing multiple oral vorinostat doses were carried out using 
intracellular vorinostat concentrations of the bone instead of 
PBMC vorinostat concentrations.
Model evaluation of the HDAC activity was carried out 
by comparing the observed and simulated HDAC activity-
time profiles of the internal development dataset using a 
virtual population.
Adult PBPK model—platelet count
Thrombocytopenia was def ined as  a  platelet 
count < 150 × 109 cells/l [52]. The adult PBPK model of 
vorinostat was expanded by a thrombocytopenia model 
as a pharmacodynamic toxicity biomarker. The platelet 
model was first published and comprehensively described 
by Friberg and co-workers and refined by du Rieu and co-
workers [53, 54]. The refined thrombocytopenia model was 
used in the presented PBPK modeling approach (Fig. 1).
In brief, the thrombocytopenia model consists of five 
compartments (cmts) describing proliferating cells (1 cmt), 
developing thrombocytes (3 transit cmts) and circulating 
thrombocytes (1 cmt). Both, the mean transit time (MTT) 
of the developing thrombocytes and the proliferation rate 
constant are influenced by the number of circulating throm-
bocytes by a feedback mechanism. Vorinostat reduces the 
proliferation or induces cell loss of thrombocytes.
(2)
dR
dt
= kin − kout ×
(
1 +
Smax × CV, PBMC
SC50 + CV, PBMC
)
× R
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Parameter values of the thrombocytopenia model were 
gathered from the literature (suppl. Table S3), except for the 
slope parameter of vorinostat, which was estimated using 
clinical study data of thrombocytosis patients [36].
The thrombocytopenia model was evaluated by compar-
ing the observed and predicted fraction of patients with nor-
mal platelet counts that develop thrombocytopenia during a 
24-week treatment with 400 mg vorinostat per day.
Identification of new vorinostat dosing regimens
The adult PBPK/PD model of vorinostat, including the 
HDAC activity and the thrombocytopenia model was used in 
in silico trials to identify vorinostat doses and dosing sched-
ules that are potentially more effective than the standard dos-
ing regimen of 400 mg qd, where ‘more effective’ is defined 
as causing a larger decrease in HDAC activity. Tested dos-
ing regimens were chosen from a range of potential dosing 
frequencies per day (qd, bid, tid) and week (e.g. every 2nd 
week, 3 consecutive days per week). Intravenous and oral 
routes of administration were considered.
In silico trials—part 1
25 dosing regimens with varying administration routes, 
administered doses, and dosing schemes of vorinostat were 
tested. New regimens were declared potentially more effec-
tive when they showed higher maximum  (HDACactivity,bone 
[%]) and longer HDAC inhibition than the standard treat-
ment during a 10-week treatment period without decreasing 
the thrombocyte count  [109 cells/l] more than the standard 
dosing regimen. A simulation time of 10 weeks was nec-
essary to ensure that the circulating thrombocytes were at 
steady-state (MTT ~ 95 h).
In silico trials—part 2
Maximum doses were estimated for 15 dosing schedules 
from in silico trials – part 1. In trial 2, the minimum throm-
bocyte count was set at 50 ×  109 cells/l and the maximum 
possible single vorinostat dose was set to 3000 mg.
All trial results were compared to the standard treatment 
based on the change of HDAC activity (%), the change in 
the accumulated time of HDAC activity < 50% (%), and the 
change in the thrombocyte count (%).
Parameter sensitivity analysis
A parameter sensitivity analysis of the adult PBPK model 
was performed to assess the impact of estimated model 
parameters on the predicted values of  AUC0 − inf, Cmax, half-
life, and Tmax. Assessed parameters were: hydrolysis and 
β-oxidation clearance, intestinal permeability, cellular per-
meability, red blood cell permeabilities, and the unstirred 
layer of the particle dissolution. All parameters were varied 
individually over a wide range of values (via multiplication 
Fig. 1  Schematic structural PBPK/PD model representation. a 
PBMC effect compartment model. b Schematic default PBPK model. 
c Thrombocytopenia model. d HDAC activity indirect response 
model. PBMC peripheral blood mononuclear effect compartment, 
PBMCdeep peripheral blood mononuclear deep effect compartment, 
keffect,1/2 and keffect,deep,1/2 concentration transfer rate constants, Q spe-
cific organ blood flow, CL clearance, Prol proliferating cells, Tran-
sit 1/2/3 cells in transit state, Circ circulating cells, Circ0 circulating 
cells baseline, kprol proliferation rate constant, ktr transit rate constant, 
kcirc elimination rate constant, MTT mean transit time, slope slope 
parameter, Drugconc vorinostat concentration, Edrug vorinostat effect 
on the proliferating cells, FBP circulating cells feedback on prolifer-
ating cells, FBM circulating cells feedback on MTT, kin HDAC activ-
ity synthesis rate, and kout HDAC activity degradation rate
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by factors between 0.1 and 10.0) and the changes in 
 AUC0 − inf, Cmax, half-life, and Tmax was documented [55]. If 
a 10% change of a single parameter led to a > 1% change in 
 AUC0 − inf, Cmax, half-life, and Tmax, the model was consid-
ered sensitive to this parameter [56].
Results
A comprehensive PBPK model for the prediction of vori-
nostat concentrations after different intravenous and oral 
doses of vorinostat has been successfully developed. The 
model can be applied in adult and pediatric patients and 
has been used to recommend doses for children from 0 to 
17 years. Furthermore, the PBPK model has been expanded 
by (1) PBMC effect compartments and (2) pharmacody-
namic models of HDAC activity and thrombocytopenia. 
Finally, the vorinostat PBPK/PD model has been success-
fully used to identify new vorinostat dosing regimens that 
are potentially more effective than the approved standard 
treatment.
The developed vorinostat PBPK model shows good 
descriptive and predictive performance. In summary, 90 
and 96% of the predicted  AUC0 − inf and Cmax values satisfy 
the twofold acceptance criterion, respectively (Fig. 2, suppl. 
Fig. S2). The MPE of the simulated and predicted adult and 
pediatric pharmacokinetic profiles is 44%. Trial-specific 
MPEs are summarized in supplemental Table S4. The final 
model parameters on the drug release, absorption, distribu-
tion, metabolism, and excretion of vorinostat are shown in 
Table 2.
Adult PBPK model—intravenous
The intravenous model is able to describe and predict 
vorinostat concentration–time profiles in close agreement 
with the observed values over a wide range (75–900 mg/
m2) of intravenous single dosages (Fig. 3, suppl. Fig. S3). 
The mean observed dose-independent half-life of vorinostat 
across available doses and studies is 0.65 h [4, 30] where 
the PBPK model predicts 0.75 h, a slight over-prediction of 
15%. The Cmax and the  AUC0 − inf have been predicted with 
mean deviations of 4 and 25% from the observed values, 
respectively [4, 30]. The simulated fraction of unchanged 
vorinostat dose excreted in urine (fe) has been consistently 
below 1% over all doses, which is also in good agreement 
with observed values [4].
Adult PBPK model—oral
The oral PBPK model also shows a good descriptive and 
predictive performance (Fig.  3, suppl. Fig. S3). The 
 AUC0 − inf, Cmax, and Tmax have been predicted with mean 
deviations of 5, 1 and 22% from the observed values across 
available doses, respectively [6, 8, 28, 31–35, 50]. The 
absorption rate-limited PK is well predicted. The observed 
oral half-life is 1.75 h [6, 8, 28, 31–35, 50], where the PBPK 
model predicts a half-life of 1.66 h. The predicted bioavail-
ability 
(
Fpred =
AUCoral,pred
AUCIV,pred
×
Doseoral,pred
DoseIV,pred
)
 is comparable to the 
observed bioavailability (Fobs) with Fpred = 30% and Fobs = 
40% [6]. The contribution of the implemented metabolic 
clearance processes via UGT 1A9, 2B7, 2B17, and hydroly-
sis/oxidation to the overall metabolized fraction (fm) has 
been estimated at 3, 56, 11, and 30%, respectively.
Pediatric PBPK model and dosage recommendations
The age-dependent maturation of UGT 2B17 has been 
successfully described and implemented using a Hill 
function with final parameter values of  OFmax = 0.46, 
 OF50 = 6.0 years, and γ = 1.63, and  OFmin = 0.58 (suppl. 
Fig. S4). The maturation time of the primary metabolizing 
enzymes of vorinostat can be ranked as follows: UGT 2B17 
Fig. 2  Predicted versus observed PK parameters. a  AUC0 − inf in adults (n = 52). b  Cmax in adults (n = 52). c  AUC0 − inf in children (n = 19). Cir-
cles indicate adults and triangles children. Dashed line: twofold acceptance limits
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(longest) > 1A9 > 2B7. Given that there is (1) no clear rela-
tionship between pediatric doses and exposures and (2) no 
inter-individual variability estimated, the individually pre-
dicted vorinostat concentration–time profiles are in adequate 
agreement with the observed data in the age range between 
4.7 and 22.0 years (suppl. Fig. S5).
Because the, so far, proposed pediatric dosage of 230 mg/
m2/day leads to very high exposure in children between 0 
and 1 years (suppl. Fig. S6a), the pediatric PBPK model 
has been used to identify dosages for all age groups from 
0 to 17 years leading to  Cmax values similar to the ones in 
adults. The recommended dosages are 80 mg/m2 for children 
from 0 to 1 year and 230 mg/m2 for children and adolescents 
between 1 and 17 years (suppl. Fig. S6b).
Adult PBPK model—HDAC activity
The default PK-Sim PBPK model has been successfully 
expanded by two effect compartments describing PBMC 
concentrations and by an indirect response model of HDAC 
activity. The PBMC concentration–time profiles are best 
described using a two-compartment model (Fig.  4a). A 
comparison between vorinostat PBMC concentration–time 
profiles simulated using a 1- or 2-compartmental model 
is depicted in supplemental Fig. S7. The observed half-
life of oral vorinostat in PBMCs is 5.30 h, 3.0-fold longer 
than observed in plasma, and the predicted half-life in 
PBMCs (2-cmt) is 5.66 h, 3.4-fold longer than predicted in 
plasma [60]. The indirect response model is able to accu-
rately describe the HDAC inhibition caused by a single dose 
of 400 mg vorinostat (Fig. 4b). The minimum observed and 
predicted HDAC activities are 21.6 and 26.6%, respec-
tively [60]. The final model parameters of both the PBMC 
effect compartment model and the HDAC indirect response 
model are given in supplemental Table S5. The structural 
model alterations of the default PK-Sim PBPK model are 
depicted in Fig. 1.
Adult PBPK model—platelet count
The PBPK model has been successfully expanded by the 
thrombocytopenia model. The integrated PBPK/PD model 
is able to capture the thrombocyte count over a 36-week 
standard vorinostat treatment period in a thrombocytosis 
population (Fig. 4c). In a population with normal thrombo-
cyte counts, the model has successfully predicted the throm-
bocytopenia prevalence of 27.9% which is in close agree-
ment with the published observed value of 25.6% [61]. The 
Table 2  Vorinostat physicochemical and ADME parameters
NA not available
a Mean of 2 reported values
b Mean of 7 reported values
c Mean of 3 reported values
d Fitted
Parameter Unit Literature value Ref. Value used for 
simulations
Parameter description
MW g/mol 264.32 – 264.32 Molecular weight
logP – 0.89 [57] 0.89 Lipophilicity
fu [%] 28.8 ± 2.9 [4] 28.8 Fraction unbound
pKa – 9.2 [4] 9.2 Acid dissociation constant
Solubility mg/ml 0.1–0.4 [4, 58] 0.2 Solubility
UGT 1A9  CLin−vitro µl/min/mg 38.55 [15, 16]
a 38.55 UGT 1A9 in vitro metabolic clearance
UGT 2B7  CLin−vitro µl/min/mg 580 [16] 580 UGT 1A9 in vitro metabolic clearance
UGT 2B17  CLin−vitro µl/min/mg 53 [15, 16]
a 53 UGT 1A9 in vitro metabolic clearance
UGT 1A9 content pmol/mg 30.11 [59]b 30.11 Microsomal UGT 1A9 liver content
UGT 2B7 content pmol/mg 78.49 [59]b 78.49 Microsomal UGT 2B7 liver content
UGT 2B17 content pmol/mg 22.17 [59]c 22.17 Microsomal UGT 2B17 liver content
CLhydr.,β−ox l/h NA NA 1.8
d Clearance via hydrolysis and β-oxidation
Pintest dm/min 1.56E-07 [4] 2.20E-07
d Intestinal permeability
Pcell dm/min 6.55E-5 PK-Sim 9.60E-06
d Cellular permeability
PRBC−>PLS dm/min 6.48E-5 PK-Sim 4.20E-06
d Blood-plasma permeability
PPLS−>RBC dm/min 6.45E-5 PK-Sim 1.00E-04
d Plasma-blood permeability
B:P – 2.87 [50] 2.87 Blood-to-plasma concentration ratio
LayerPD,unstirred,water µm 20 PK-Sim 108
d Particle dissolution unstirred water layer
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model parameter values used in the simulations are compiled 
in supplemental Table S3. The manually estimated slope 
parameter for vorinostat is 0.22 µM− 1.
Identification of new vorinostat dosing regimens
The adult PBPK/PD model of vorinostat including the 
HDAC activity and the thrombocytopenia model has been 
successfully used in in silico trials to identify new vorinostat 
doses and dosing schedules which are potentially more effec-
tive than the standard dosing regimen of 400 mg qd.
Although part 1 suggests that none of the tested 25 dos-
ing regimens offers a higher maximum and/or prolonged 
HDAC inhibition when the target thrombocyte count is that 
of the approved standard treatment (~ 193 × 109 cells/l), the 
alternative treatment D (800 mg, every 2nd day) might be a 
replacement of the standard treatment showing a 14% higher 
maximum HDAC inhibition but a 10% shorter HDAC inhibi-
tion time (suppl. Table S6).
However, part 2 reveals that 11 (9 oral, and 2 infusions) 
out of the 15 tested dosing schedules offer higher maximum 
and prolonged HDAC inhibitions (suppl. Table S7). Com-
pared to the standard treatment, the potentially beneficial 
dosing regimens exhibit a mean maximum HDAC inhibi-
tion that is 27% higher (min: 16%, max: 62%) and the mean 
accumulated time of the HDAC inhibition being > 50% is 
180% longer (min: 6%, max: 509%). Based on the accumu-
lated time of HDAC inhibition, trial C with three daily doses 
of the maximum 3000 mg dose has shown the best results 
with a HDAC inhibition time increase of 509% and a platelet 
decrease of − 72% which is close to the lower thrombocyte 
limit at − 74%.
Fig. 3  Concentration–time profiles after intravenous (a) and oral administration of vorinostat single doses (b) [30, 50]. Simulated data are repre-
sented as median (black lines), 90% prediction interval (gray shaded area), and minimum and maximum values (dotted lines)
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Parameter sensitivity analysis
The parameter sensitivity analysis (suppl. Fig. S8) reveals 
that, among the tested parameters, the intestinal perme-
ability, the clearance via hydrolysis and oxidation, and the 
unstirred layer of the particle dissolution have the biggest 
impact on the tested vorinostat PK parameters  AUC0 − inf, 
Cmax, half-life, and Tmax.
Discussion
A PBPK model for the prediction of vorinostat concentra-
tions after different intravenous and oral vorinostat doses 
has been successfully developed. The model was able to 
accurately predict vorinostat concentrations in adult and 
pediatric patients and to recommend dosages for different 
pediatric age groups. After successful implementation of 
PBMC effect compartments, PD models of HDAC activity 
(measured in PBMCs) and thrombocytopenia were inte-
grated in the PBPK model. The final integrated PBPK/
PD model of vorinostat was successfully applied in in 
silico trials, thereby identifying potentially more effective 
vorinostat dosing regimens in comparison with standard 
treatment.
The cellular permeability drives the permeation rate of 
vorinostat across the interstitial—intracellular membrane 
in the PK-Sim PBPK model. The permeability was ini-
tially calculated within PK-Sim according to an empirically 
derived formula, using logMA and molecular weight as 
Fig. 4  PBPK/PD model results. a PBMC concentration–time profiles 
[50]. b HDAC activity over time [50]. c Thrombocyte count in throm-
bocytosis patients during a 24-week vorinostat treatment with 400 mg 
qd [36]. d Thrombocyte count in patients with normal thrombocyte 
counts. Simulated data are represented as median (black line), 90% 
prediction interval (gray shaded area) and minimum and maximum 
values (dotted lines). The red dotted line represents the thrombocyte 
counts justifying the diagnosis of thrombocytopenia (= 150  ×  109 
cells/l). Single doses: sd, repeated once daily doses: qd
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input variables, based on the procedure presented by Kawai 
and co-workers [62]. However, using the calculated cellular 
permeability value, the plasma concentration–time profiles 
of vorinostat were under-predicted. With the estimated per-
meability value, the model successfully predicted the intra-
venous profiles of the evaluation dataset.
In vitro tests found that UGT 2B17 is the major metabo-
lizing enzyme of vorinostat. However, by compiling all 
available metabolic data of UGT 1A9, 2B7, and 2B17 in 
the model, the PBPK analysis suggested that UGT 2B17 
is only of minor importance for the vorinostat clearance 
in vivo. This has important implications for the evaluation 
of other studies aiming to assess the impact of UGT 2B17 
polymorphisms on survival of patients treated with vori-
nostat. Furthermore, it was reported that the UGT 2B17*2 
polymorphism, which leads to reduced vorinostat glucu-
ronidation, was associated with a longer progression-free 
survival in Asian breast cancer patients [17]. Although, this 
polymorphism is present in 92% of Asian populations, based 
on the presented modeling results, it seems unlikely that the 
reported results are mainly due to the low glucuronidation 
capacity of UGT 2B17*2 as only a small fraction of the 
administered vorinostat dose is metabolized by UGT 2B17 
(fm = 11%) [63, 64]. The PBPK analysis suggests that UGT 
2B7 (fm = 56%) polymorphisms, for instance, could play a 
vital role in the elimination, which is in accordance with the 
literature [16]. It is important to point out, that the clinical 
trial populations used in model development and evaluation 
were not tested for their UGT genotypes. Hence, additional 
information on their genotypes might alter the interpretation 
of these modeling results.
The PBPK analysis suggests that hydrolysis and oxidation 
are responsible for 30% of vorinostat metabolism and there-
fore more important than UGT 2B17 that accounts for 11%. 
Additionally, the sensitivity analysis underlined that the 
vorinostat PBPK model is sensitive to changes to the hydro-
lytic and oxidative clearance. In the model, it was assumed 
that both hydrolysis and oxidation would be carried out by 
a single enzyme available in all tissues. Unfortunately, we 
do not know the contribution of either hydrolysis or oxi-
dation to the metabolized fraction, which means that the 
tissue-specific expression of hydrolytic or oxidative enzymes 
cannot be accounted for in the model. It is known that car-
boxylesterases, responsible for the hydrolysis of other drugs, 
are not equally expressed in all tissues [65]. In the model, 
it was further assumed that hydrolysis and oxidation would 
be fully developed from birth in all tissues, whereas studies 
have shown that the developmental regulation of esterases 
occurs in a gene, organ, and age-dependent manner [65–68]. 
As no details on the oxidative enzymes are available, it was 
decided to assume a scenario in which children would have 
adult enzyme levels for hydrolysis and oxidation available, 
and thus the highest possible clearance via this metabolic 
pathway. This might lead to an over-prediction of hydrolytic 
and oxidative clearance. Thereby, the recommended dose of 
80 mg/m2 for children from 0 to 1 year of age might be over-
predicted and should therefore be viewed as a maximum 
recommended dose.
The maturation of the UGTs should have the biggest 
impact on the pediatric vorinostat PK between the age 0 
and 3 years as the maturation progresses considerably. The 
youngest observed pediatric patient was 4.7 years old, thus it 
was not possible to evaluate the model prediction quality in 
the critical age below 3 years. Although there is uncertainty 
in the recommended doses for an age < 4.7 years, the PBPK 
methodology has demonstrated for several other drugs that 
the pediatric PK can be successfully predicted below the 
age of 5 [69, 70].
Both, the PBMC concentration–time profiles and the 
HDAC inhibition could be very well described. Yet, the 
effect compartment model and the indirect model were 
based on a single 400 mg dose only. Hence, there is some 
uncertainty to the in silico trials that were carried out using 
a wide range of doses. While most parameters of the throm-
bocytopenia model were gathered from the literature, the 
slope parameter of vorinostat had to be estimated. Because 
no other data were available, this parameter was estimated 
using a thrombocytosis population. It was assumed that all 
gathered parameters (e.g. MTT) but the baseline cell counts 
(proliferating (Prol) and circulating (Circ) cells) were similar 
in patients with and without thrombocytosis, which might 
not be true. Nevertheless, the integrated PBPK/PD model 
was able to accurately predict the prevalence of thrombocy-
topenia in patients with normal thrombocyte counts.
Recommended doses for children were determined by 
targeting an exposure  (AUC0 − inf) in children similar to 
the one observed in adults assuming the same efficacy and 
safety in these populations. Although data on the impact of 
vorinostat on the HDAC activity over time or the platelet 
count over time was not available in children, the assumption 
appears reasonable. First, the pediatric dose of 230 mg/m2 
and the comparable approved standard dose of 400 mg/day 
for adults both led to significant accumulation of acetylated 
H3 histones in PBMCs in children and adults, respectively 
[21]. Second, dose-limiting toxicities at comparable doses 
in children and adults are similar [21].
In part 2 of the in silico trials, the lower thrombocyte 
limit was set to 50 × 109 cells/l (part 1: 193 × 109 cells/l) 
since platelet counts ≥ 50 × 109 cells/l typically do not lead 
to clinical interventions; for instance, prophylactic platelet 
transfusions are recommended for thrombocyte counts of 
≤ 10 × 109 cells/l [71]. The upper vorinostat dose limit 
of 3000 mg was defined by two factors. First, the high-
est vorinostat dose administered in vivo was 1000 mg 
(suppl. Fig. S3). As the PBPK model could not be evalu-
ated above doses of 1000 mg, there is some uncertainty in 
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simulations above doses of 1000 mg. Second, vorinostat is 
typically available in 100 mg capsules, which makes dos-
ing of high doses (> 400 mg) difficult in clinical practice. 
However, there are already promising new formulations 
under research that should simplify higher vorinostat dose 
administrations [72, 73].
Finally, the parameter sensitivity analysis has shown 
that the vorinostat half-life mainly depends on the intes-
tinal permeability and the unstirred water layer param-
eter of the particle dissolution, which underlines that 
the absorption rate-limited flip-flop PK of vorinostat has 
been correctly implemented. Although the absorption was 
adequately predicted with the particle dissolution module, 
there might be other reasons responsible for the limited 
absorption such as drug-disease interactions or transport-
ers. Vorinostat was found to be a substrate of P-gp and 
BCRP as well as an inducer of P-gp at the blood–brain 
barrier [58, 74, 75].
Despite some limitations, the presented work clearly 
demonstrates the applicability and usefulness of PBPK and 
PBPK/PD models in pediatric dose identification and in in 
silico trials. The PBPK modeling approach helps to integrate 
and leverage all available in vitro, in vivo, and in silico infor-
mation while potentially reducing the number of clinical 
trials and study participants. Still, future clinical trials are 
needed to evaluate efficacy and safety of the newly proposed 
dosing regimens.
Conclusion
For the first time, a comprehensive PBPK/PD model of vori-
nostat has been developed which can predict (1) vorinostat 
concentration–time profiles in adults and (2) the impact of 
vorinostat on its major PD biomarkers, the HDAC inhibition 
and the dose-limiting decrease in thrombocytes. The PBPK/
PD model was used to recommend (1) pediatric doses from 0 
to 17 years and (2) potentially more effective vorinostat dos-
ing regimens for adults. However, further research on (1) the 
yet unidentified enzymes involved in vorinostat metabolism, 
(2) the vorinostat PK in pediatric patients < 5 years of age, 
and (3) the PK/PD relationship in pediatric patients is nec-
essary to increase the confidence in the model predictions. 
These results exemplify a mechanistic modeling approach 
that might help researchers to design clinical studies and to 
potentially improve dosing regimens of newly developed and 
already established drugs.
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Abstract
In forensic medicine, expert opinion is often required concerning dose and time of intake of a substance, especially in the context
of fatal intoxications. In the present case, a 98-year-old man died 4 days after admission to a hospital due to a femur neck fracture
following a domestic fall in his retirement home. As he had obtained high morphine doses in the context of palliative therapy and
a confusion of his supplemental magnesium tablets with a diuretic by the care retirement home was suspected by the relatives, a
comprehensive postmortem examination was performed. Forensic toxicological GC- and LC-MS analyses revealed, besides
propofol, ketamine, and a metamizole metabolite in blood and urine, toxic blood morphine concentrations of approximately
3 mg/l in femoral and 5 mg/l in heart blood as well as 2, 7, and 10 mg/kg morphine in brain, liver, and lung, respectively. A
physiologically based pharmacokinetic (PBPK) model was developed and applied to examine whether the morphine concentra-
tions were (i) in agreement with the morphine doses documented in the clinical records or (ii) due to an excessive morphine
administration. PBPKmodel simulations argue against an overdosing of morphine. The immediate cause of death was respiratory
and cardiovascular failure due to pneumonia following a fall, femur neck fracture, and immobilization accompanied by a high
and probably toxic concentration of morphine, attributable to the administration under palliative care conditions. The presented
case indicates that PBPKmodeling can be a useful tool in forensic medicine, especially in question of a possible drug overdosing.
Keywords Palliative care . Morphine . Physiologically based pharmacokinetic modeling . Forensic medicine
Introduction
In forensic medicine, profound knowledge on the pharmacoki-
netic (PK) properties of various drugs and drugs of abuse is
necessary when interpreting analytical data in the context of po-
tential intoxications. If expert opinion is required regarding dose
and time of intake of a specific pharmaceutical, the toxicologist
can draw on PK data examined in clinical studies, at least to give
a vague assessment [1, 2]. As far as illicit drugs are concerned,
only few controlled clinical and forensic toxicological studies
dealing with the determination of PK models in order to answer
the abovementioned issues have been performed [3–5]. These
studies have been conducted with healthy individuals.
However, when attempting to estimate antemortem drug concen-
trations and the consumed dose from postmortem analyses, pro-
cesses occurring during agony and postmortem have additionally
to be taken into consideration [6].
In model-informed drug discovery and development, phys-
iologically based (PB) PK modeling has become a useful tool
to predict drug concentrations and consequently optimize drug
therapy in particular patient populations [7–13]. Absorption,
distribution, metabolism, and excretion parameters are calcu-
lated by implementing anatomical structures such as organ
volumes and physiological processes in distinct body
systems/organs such as blood flow rates and pH values at
different locations [14]. These drug-independent data are sup-
plemented with drug-dependent data such as lipophilicity, mo-
lecular weight, and protein binding.
The PK properties of morphine, commonly administered in
palliative therapy [15], are well studied bymeans of various PK
models in healthy volunteers after different routes of adminis-
tration [16, 17]. Morphine is metabolized by cytochrome P450
(CYP) 3A4 [18] and several UDP-glucuronosyltransferases
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(UGTs). The highly potent morphine metabolite morphine-6-
glucuronide is exclusively formed by UGT2B7 [19].
Several models investigating a possible influence of age
[7], impaired renal [20, 21] or hepatic function [22, 23], or
even terminal illness [24] on the PK of morphine have been
developed. Requested expert opinion on a probable
overdosing of morphine in a palliative care patient initiated
the development of a PBPK model comprising morphine and
its major metabolite morphine-6-glucuronide.
Case report
A 98-year-old man (height 170 cm, weight 73 kg) who had
lived in a care retirement home was admitted to the hospital
due to a femur neck fracture following a domestic fall. Because
of incipient pneumonia after clinical immobilization and severe
pre-existing cardiac insufficiency, operative treatment of the
fracture was not indicated and a palliative therapy with mor-
phine (intravenous (i.v.) infusion, dose 200 mg/50 mL) and
oxycodone (peroral, dose 5 mg) was applied. The documented
clinical doses of morphine and oxycodone are listed in Table 1.
Three days after admission, anuresis was observed (for
laboratory findings including values of creatinine and
glomerular filtration rate, see Table 2) and the patient died on
day 4. His daughter accused the care retirement home of having
replaced his magnesium tablets by a diuretic, because she had
recognized an increasing impairment of her father’s mental
health for 3 months. Furthermore, he had wet himself with
increasing frequency and had always been thirsty. According
to the allegation of the daughter, the suspected replacement of
the tablets had been responsible for the fall and the following
death. In addition, it could not unequivocally be deduced from
the clinical patient record, whether the documented morphine
doses (see Table 1) were administered in milligrams or millili-
ters. To examine a probable overdosing of morphine, a com-
prehensive postmortem examination was performed and a
PBPK model was developed and applied.
Autopsy
Autopsy was performed 6 days after death. The following
essential autoptic findings were assessed:
– sufficient dietary and care condition
– frontal cephalhematoma
– fracture of the right femur neck without relevant loss of
blood
– findings indicative of recurrent strokes
– severe aspiration pneumonia
– coronary atherosclerosis and pathological cardiac
enlargement
– chronic blood congestion of inner organs indicative of
chronic heart failure
The autopsy report concluded that the cause of death was
respiratory and cardiovascular failure due to pneumonia fol-
lowing a fall, fracture of femur neck, and immobilization.
Methods
Toxicological analyses
At first, an enzyme immunoassay screening (EIA, Bio-Rad
Laboratories GmbH, Muenchen, Germany) was performed in
heart blood (collected from the inlet of the V. cava inferior to the
right atrium) including opiates, methadone, buprenorphine,
benzodiazepines, amphetamines, methamphetamines, cannabi-
noids, and cocaine. Afterwards, aliquots of heart blood and
urine (0.5 mL each) were extracted liquid-liquidly (diethyl
ether/ethyl acetate; 1:1 v/v) with 50 μL of trimipramine-D3
(0.5 μg/mL, LGC, Wesel, Germany) as internal standard (IS)
Table 1 Clinically documented doses of morphine and oxycodone; no
dosing unit of morphine given
Therapy day Time (h) Morphine i.v.a Oxycodone p.o.
1 16:00 5 mg
20:00 5 mg
24:00 5 mg
2 04:00 5 mg
08:00 5 mg
13:00 5 mg
18:00 1
19:00 2 5 mg
21:00 4
3 06:00 6
09:00 6
13:00 6
17:30 4
20:00 6
21:00 6
21:30 8
4 03:00 8
09:00 8
12:30 8
14:00 8
18:00 10
18:45 10
20:00 13
22:46 death
i.v. intravenous; p.o. per os
aMSI (200 mg/50 mL infusion; bolus assumed)
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and analyzed (with and without acetylation) by gas
chromatography-mass spectrometry (GC-MS; GC: 6890 N,
Agilent Technologies (AT), Waldbronn, Germany; MS: AT
5975 B) in full scan mode. Furthermore, an aliquot was ana-
lyzed by liquid chromatography (LC)-MS/MS (LC: Shimadzu
prominence, Duisburg, Germany; MS: AB Sciex 3200
QTRAP, Darmstadt, Germany) for pharmaceutical drugs such
as benzodiazepines, antidepressants, and neuroleptics. For the
detection of oxycodone, a solid-phase extraction (SPE) was
applied using 1.0 mL of heart blood (IS: 50 μL oxycodone-
D6, 1 μg/mL, LGC, Wesel, Germany) and AT HCX cartridges
(130 mg/3 mL) with a subsequent analysis by LC-MS/MS
(Shimadzu prominence LC, AB Sciex 3200 QTRAP MS).
For quantification of free morphine in blood and tissue
specimens, a fully validated GC-MS method after SPE was
performed. SPE was carried out using AT HCX cartridges
(130 mg/3 mL). They were conditioned with 2 × 3 mL of
methanol and 3 mL of potassium dihydrogen phosphate
(pH 6). Aliquots of blood (1.0 mL of heart blood, 0.5 mL of
femoral blood) as well as homogenized liver, lung, and brain
tissue (cerebrum) specimens (1:5 with H2O; 0.5 mL each)
were mixed with 1.0 mL of potassium dihydrogen phosphate
(pH 6) and 50 μL of morphine-D3 (2 μg/mL; LGC, Wesel,
Germany), respectively. After vortexing, the specimens were
centrifuged at 3200g for 8 min and loaded to the cartridges.
Subsequently, two washing steps with 1.5 mL of potassium
dihydrogen phosphate (pH 6) and 3 mL of hydrochloric acid
(0.01 M) were applied. After adding 1.5 mL of methanol, the
columns were dried under maximum vacuum for 2 min.
Analyte elution was then performed with 1.75 mL of dichlo-
romethane/methanol/ammonia (30/15/1.5, v/v/v). The eluates
were evaporated under a stream of nitrogen at 45 °C. The dry
residues were dissolved in 100 μL of pentafluoropropionic
acid and 75 μL of pentafluoropropanol and incubated for
45 min at 60 °C. Then, the derivatized extracts were evapo-
rated under a stream of nitrogen at 45 °C and reconstituted in
30 μL of ethyl acetate. The extracts were analyzed by GC-MS
(GC: AT 6890; MS: AT 5973 N) using an Optima 1 MS
column (Macherey-Nagel, Duren, Germany) and the follow-
ing temperature gradient: 70 °C kept for 1.5 min, increase up
to 220 °C (30 °C/min), then increase up to 285 °C (8 °C/min),
and further increase up to 315 °C (30 °C/min), kept for
12.37 min. The limit of detection of the validated method
was calculated as 0.9 ng/mL, the limit of quantification as
2.2 ng/mL, and the calibration ranged from 5 to 200 ng/mL.
The supposedly replaced tablets delivered by the daughter
were macerated in ethanol and analyzed by GC-MS (GC: AT
5890; MS: AT 5972) in scan mode (with and without
acetylation).
PBPK modeling
PBPK modeling and subsequent simulations were performed
in a stepwise procedure. First, i.v. models of morphine and
morphine-6-glucuronide were developed. Second, the previ-
ously developed models of morphine and morphine-6-
glucuronide were coupled in a parent-metabolite PBPK mod-
el. Finally, the coupled PBPKwas applied to (i) suggest which
dosing unit (Bmg^ or BmL^) appeared more likely, (ii) assess
whether the analytically determined morphine concentrations
could be explained by the clinically documented morphine
administration, and (iii) explore potential physiological and
mechanistic reasons that could explain the documented mor-
phine concentrations.
Experimental datasets from two published clinical studies
were used to support the PBPK model development and eval-
uation (Table 3). The experimental datasets were split into an
internal development dataset (n = 1 trial) and an external
Table 2 Laboratory parameters
Therapy day Time (h) Creatinine (mg/dL) GFR (mL/min) GOT (U/I) γ-GT (U/I) GPT (U/I)
0 20:18 30 26 17
1 15:48 1.1 60
2 04:00 1.2 54
GFR glomerular filtration rate, GOT glutamate oxaloacetate transaminase, γ-GT gamma-glutamyl transferase,
GPT glutamate pyruvate transaminase
Table 3 Clinical study data of morphine
Route of
administration
M dose
(mg)
M6G dose
(mg)
Dosing
schedule
Matrix Measured
compound
n Male
patients (%)
Age mean (range)
(years)
Internal (in) or external
(ex) dataset
Ref.
i.v. bolus 5.64 1.0 sd Plasma M, M6G, M +M6G 8 50 26 (23–30) in [16]
i.v. inf. 20 min 7.59 – sd Plasma M +M6G 14 79 (20–39) ex [41]
i.v. intravenous, inf infusion, sd single dose, M morphine measured only, M6G morphine-6-glucuronide measured only, M+M6G morphine and
morphine-6-glucuronide measured after morphine dosing
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evaluation dataset (n = 1), such that morphine and its major
metabolite morphine-6-glucuronide were covered. The PBPK
model was fitted to the development dataset, and the predic-
tion quality of the model was assessed by predicting the eval-
uation dataset. Parameter optimizations were carried out using
a Monte-Carlo method.
Model evaluation was carried out using (i) comparison
of observed and simulated PK parameters and the fraction
of morphine dose excreted unchanged into urine and (ii)
visual predictive checks, which is a tool for evaluating the
performance of PK and pharmacodynamic models, where
percentiles of experimental and simulated data are com-
pared [26].
Simulations were carried out using virtual PBPK indi-
viduals and populations. Virtual PBPK populations were
created as described by Willmann and co-workers using
ranges for age, height, and weight reported in the internal
and external datasets [27]. In this approach, the organ
weights and the cardiac output (CO) of a target individual
are allometrically scaled with height and the organ blood
flows are scaled to the total CO [27]. Applied dosing
schedules and doses were used as published. The param-
eters of anatomy and physiology were varied as pre-
defined in PK-Sim [28–31].
PBPK simulations were carried out using PK-Sim and
MoBi (Version 5.6.5, Bayer Technology Services,
Leverkusen, Germany). Statistical analyses of the results and
graphics were compiled using MATLAB (Version R2013b,
The MathWorks Inc., Natick, MA, USA).
iI.v. concentration-time profiles were used to establish
PBPK models of morphine and morphine-6-glucuronide. The
partition coefficients of both compounds were calculated using
the PK-Sim standard model, and the cellular permeabilities
were fitted [32, 33]. The reference concentrations of CYP3A4
and UGT2B7 were kept at the PK-Sim default values of
1 μmol/L, respectively, and the metabolic reactions were
modeled as first-order processes. The PK-Sim gene expression
database was used to distribute the enzymes to the specific
organs [34, 35]. The unbound morphine was assumed to be
filtered and excreted with the glomerular filtration rate (GFR).
The unboundmorphine-6-glucuronide was assumed to be elim-
inated solely by the kidney. This elimination consisted of filtra-
tion via the GFR and an additional tubular secretion that was
modeled and fitted as a first-order process [36].
In the PBPK model, morphine was always administered as
the free base; hence, the morphine sulfate or hydrochloride
trihydrate doses stated in the clinical study publications were
converted to the free base.
Results
Toxicological analyses
The EIA analysis tested positive for opiates. GC-MS and LC-
MS/MS screenings revealed the presence of propofol, keta-
mine, and a metabolite of metamizole in blood and urine. No
oxycodone could be detected in heart blood. The concentra-
tions of free morphine amounted to approximately 3 and
5 mg/L in femoral and heart blood, respectively, to 2, 7, and
10 mg/kg morphine in brain, liver, and lung tissue. In the
Table 4 Physicochemical and
ADME (absorption, distribution,
metabolism, excretion)
parameters of morphine and
morphine-6-glucuronide
Parameter Unit Literature value Ref. Value used for
simulations
Parameter description
Morphine
MW g/mol 285.34 – 285.34 Molecular weight
logP – 0.9 [37] 0.9 Lipophilicity
fu (%) 65 [38] 65 Fraction unbound
pKa – 8.21 a 8.21 Acid dissociation constant
Solubility mg/L 149.0 a 149.0 Solubility
CLUGT 2B7 L/min 4.6 [25, 39] 1.47 Intrinsic UGT 2B17 clearance
CLCYP 3A4 L/min 22.7 [18, 25] 0.64 Intrinsic CYP 3A4 clearance
GFR fraction – – – 1 b
Pcell dm/min [PK-Sim] 7.82E−5 Cellular permeability
Morphine-6-glucuronide
MW g/mol 461.50 – 461.50 Molecular weight
logP – 0.79 [40] 0.79 Lipophilicity
fu (%) 83 [40] 83 Fraction unbound
pKa – 8.22 [40] 8.22 Acid dissociation constant
Solubility mg/mL 9.19 a 9.19 Solubility
GFR fraction – – – 1 b
TSkidney L/min 1.14 [40] 0.35 Tubular secretion
Pcell dm/min [PK-Sim] 1.84E−6 Cellular permeability
a Information obtained from DrugBank (http://www.drugbank.ca)
b Fraction of glomerular filtration rate (GFR) used for passive renal elimination
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supposedly replaced tablets, delivered by the daughter, no
central nervous acting or diuretic drugs could be detected.
PBPK modeling
The final model parameters on the absorption, distribution,
metabolism, and excretion of morphine and its metabolite
morphine-6-glucuronide are shown in Table 4. The mor-
phine and the morphine-6-glucuronide PBPK models were
able to describe and predict the internal (Fig. 1a–c) and
external (Fig. 1d) model development datasets. The simu-
lated fraction of the administered i.v. dose of morphine
excreted unchanged into urine was 6% which is in close
agreement with the literature value of 5% [40]. The simu-
lated and observed half-lives of morphine (predicted 2 h,
observed 1.9 h [16, 41]) and morphine-6-glucuronide (pre-
dicted 1.5 h, observed 1.2 h [16]) were also in close agree-
ment. The area under the curve (0—infinity) of morphine-
6-glucuronide formed from administered i.v. morphine
could be well predicted (predicted 277 nmol/L h−1, ob-
served 248 nmol/L h−1 [16]).
Assuming the dosing unit BmL^ led to threefold higher
morphine concentrations than the Bmg^ dosing, however,
the coupled PBPK model underestimated the observed
morphine concentrations irrespective of the applied dosing
unit (Fig. 2).
Renal clearance was disabled after 26 h of the simula-
tion because the patient was anuretic from that time point
on. Hence, the predicted morphine concentrations in-
creased but did not match the observed concentrations
(Fig. 3a, c). Disabling additionally the metabolism of mor-
phine improved the model performance (Fig. 3b, d).
Providing these conditions, the predicted femoral model
concentration (2.9 mg/L) matched the observed femoral
morphine concentration (3.0 mg/L). Nevertheless, the
model underestimated the concentrations of morphine in
heart blood as well as in brain, liver, and lung tissue (Fig.
3c, d). The predicted free morphine concentrations for
heart blood, brain, liver, and lung were 2.9 mg/L,
0.82 mg/kg, 2.1 mg/kg, and 2.5 mg/kg, respectively,
whereas the observed concentrations were 5.1 mg/L,
2.6 mg/kg, 10 mg/kg, and 7.8 mg/kg, respectively.
Fig. 1 a Morphine concentration-time profile [16]. b Morphine-6-
glucuronide concentration-time profile [16]. c Morphine-6-glucuronide
formation after intravenous morphine dose [16]. d Morphine
concentration-time profile and morphine-6-glucuronide formation [41].
Simulated data are represented as median (black lines), 90% prediction
interval (gray-shaded area), and minimum and maximum values (dotted
lines). Observed data are presented as circles and triangles
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Fig. 2 The impact of switching dosing units (Bmg^ or BmL^) on
morphine concentrations following repeated morphine administrations.
Morphine (black) and morphine-6-glucuronide (red) concentration-time
profiles after multiple intravenous morphine doses with regard to the
documented doses a in Bmg^ and b in BmL.^ Simulated data are repre-
sented as median (black line: morphine, red line: morphine-6-glucuro-
nide), 90% prediction interval (shaded areas), and minimum and maxi-
mum values (dotted lines)
Fig. 3 The impact of disabled renal clearance and/or metabolism on
morphine concentrations following repeated morphine administrations.
a, b Simulation of morphine concentrations in heart (black) and veins
(purple). c, d Simulation of morphine concentrations in brain (blue), liver
(red), and lung (green) tissue. Simulations were carried out applying
repeated morphine administrations with regard to the documented doses
(assuming BmL^ dosing)
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Discussion
The therapeutic morphine blood concentrations are within
0.01–0.1 mg/L [42]. The quantified free morphine concentra-
tions in both femoral and heart blood were present in toxic
concentrations of 3.0 and 5.1 mg/L, respectively [42], and
have been detected in morphine- or heroin-related deaths
[43]. However, in the treatment of cancer pain, morphine ad-
ministration (dosing amount, dosing interval) is often individ-
ually adjusted for each patient [44]. In this context, intrave-
nously administered morphine resulted in blood concentra-
tions of 1.59–11.4 mg/L [45]. It is important to notice that
the PK of high-dose morphine is similar to smaller doses [46].
Regarding the two possible dosing units Bmg^ and BmL,^
the mg dosing did not fit the analytical results, as the simulation
applying the developed PBPK model yielded threefold lower
concentrations than the mL dosing. Hence, the PBPK model
simulations are in favor of the mL dosing. Nevertheless, even
assuming an administration of morphine in mL, the predicted
morphine concentrations did not match the observed concen-
trations either. To explore physiological explanations for the
underprediction of the model, firstly, a renal failure was as-
sumed during agony as indicated by anuresis 1 day before
death. Thus, a simulation by disabling renal elimination was
performed, but the observed morphine concentrations were still
underestimated. One reason could be that only a negligible
amount of morphine is glomerularly filtrated and excreted into
urine [47]. However, a possible agonal renal failure could have
resulted in increasing uremic toxin blood concentrations, which
could have led to an impaired morphine glucuronidation [48,
49]. Morphine is converted to its main metabolites morphine-3-
glucuronide and morphine-6-glucuronide by uridine 5′-
diphospho-glucuronosyltransferase-mediated glucuronidation
in the liver [50]. In hepatically impaired patients, the action of
these metabolizing enzymes might be decreased as well as he-
patic blood flow leading to an accumulation of the parent com-
pound [22, 23]. Hence, secondly, simulating a hepatorenal syn-
drome by disabling renal and hepatic clearance finally resulted
in good correspondence of the predicted and the observed mor-
phine concentration in femoral blood. However, the calculated
concentration in heart blood as well as the tissue concentrations
were underestimated using the PBPK model. To explain this
discrepancy, postmortem changes have to be taken into consid-
eration as an important issue. After death, processes such as cell
lysis are initiated that can alter blood and tissue concentrations
of a drug depending on its physicochemical properties [6].
Morphine is known to underlie this so-called postmortem re-
distribution (PMR [51]). Increases of 0.4–240% (median 44%)
of the initial morphine concentration were observed in postmor-
tem blood samples depending on various postmortem intervals.
In heart blood concentration changes of − 5–680% (median
37%), in liver changes of − 100–160% (median – 3.1%), and
in lung tissue ranges from − 100 to 300% (median − 8.6%)
were detected [51]. Besides that, heart blood/femoral blood
ratios averaged 1.2 and 2.2 in a series of different cases [43].
Considering a postmortem interval of 6 days, PMRofmorphine
might be a plausible explanation for the higher concentrations
observed in heart blood and tissues.
The PBPK prediction performance for heart blood and tis-
sues could not be tested in living human subjects, hence the
morphine concentrations might not be captured correctly in
the living which subsequently adds uncertainty to the post-
mortem predictions. Due to the fact that data concerning
PBPK modeling on the basis of postmortem tissue specimens
are sparse and to obtain first knowledge, it has been tested
whether the model also predicted the measured morphine con-
centrations in tissue samples. Therefore, future research
should include widened assessment and consideration of
(patho)physiological parameters and postmortem changes in
order to improve the modeling performance.
In addition, morphine-6-glucuronide as well as morphine-
3-glucuronide have been tested to be unstable when stored
above − 20 °C [52]. Thus, the higher free morphine concen-
trations might also be a result of degradation of the
glucuronides.
Morphine was modeled in dependence on age-related
changes in liver size and hepatic blood flow only. Liver size
declines with 6.1% per decade after the age of 40 followed by
a more rapid loss of 11.4% per decade after the age of 60 [53].
The hepatic blood flow in males decreases from 423.0 mL/
min at the age of 30 to 141.6 mL/min at the age of 100 [7]. As
a result, the terminal half-life of morphine after intravenous
administration was reported to be 2.7 ± 3.6 h [54], which is
40% higher than the reported half-life in adult (1.9 h).
However, these age-dependent changes in liver size and he-
patic blood flow were not implemented, because the PBPK
model results are independent of these changes when the he-
patic clearance was is disabled (Fig. 3b, d). In addition,
implementing the physiological and anatomical changes in
the elderly does not impact the predictive performance of the
morphine model in a meaningful manner even if the hepatic
clearance is active [7].
Although PMR, the chemical instability of the morphine
glucuronides, and age-related changes in liver size and hepatic
blood flow were not specifically implemented, the PBPK
model offers a mechanistic explanation for the toxic morphine
concentrations, namely, the physiologically plausible severe
renal and hepatic impairment in this patient. Thus, the PBPK
modeling results argue against the notion of a morphine over-
dose being the only eligible cause of the toxic morphine
concentrations.
In the context of this specific case, there are further uncer-
tainties remaining. In general, due to the abovementioned
postmortem changes, one may argue whether it is adequate
to compare model predictions of the concentrations at the time
point of death with concentrations in specimens obtained
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6 days after. Furthermore, there was no reliable information on
the renal function until death leading to the question, if it is
justified to suppose that there is no renal elimination when
there is no diuresis. In addition, no information on liver func-
tion was available. It remains therefore questionable, whether
it is appropriate to presume that there is no morphine metab-
olism when there is no diuresis. Finally, it has to be kept in
mind that morphine-6-glucuronide is pharmacologically ac-
tive. Thus, in renally impaired patients, a prolonged elimina-
tion of this metabolite can lead to additional severe adverse
effects [55].
Apart from these issues, with respect to the cause of death,
the question arose whether an accidental or intentional dosing
error might have been responsible for a potential lethal mor-
phine concentration. To answer this question, recommenda-
tions about palliative therapy regimes have to be taken into
account. Before establishing an i.v. therapy with morphine on
therapy day 2, oxycodone was orally administered in a dose of
15 mg/day on therapy day 1 and 20 mg/day on therapy day 2
(Table 1). The equianalgesic dose of intravenously adminis-
tered morphine corresponds to 10 mg/day [56]. As document-
ed in the clinical records (Table 1), the daily dose of morphine
amounted to 28 mg (assuming an administration in BmL’) on
therapy day 1 and was continuously increased to 260 mg on
therapy day 4 due to progressive pain. According to literature,
doses of morphine in the range administered in the present
case—assuming an administration in mL—may be medically
indicated in the treatment of severe pain [55, 57] and are also
tolerated in individual cases. Nevertheless, it has to be kept in
mind that elderly patients may be more sensitive to morphine
and that its PK can be altered in this particular population due
to (patho)physiological changes associated with aging [50].
At last, signs of a morphine intoxication, such as respiratory
depression, coma, bradycardia, and urinary retention might
have been disguised by the fact that the patient was
intubated/under anesthesia and in a prefinal state.
Considering the autoptic and forensic toxicological find-
ings in combination with the results of the PBPK modeling,
the cause of death was a cardiovascular failure due to pre-
existing cardiovascular pathology and pneumonia following
a fall, fracture of femur neck, and immobilization, accompa-
nied by a high and potentially toxic morphine concentration,
attributable to the administration under the condition of palli-
ative care.
Conclusion
In this case study, the PBPKmodel simulations argue against a
suspected morphine overdose administered to a 98-year-old
patient by demonstrating that disease-related, physiological
changes in organ functions are a plausible explanation for
the analytically determined toxic morphine concentrations in
various specimens. PBPK modeling and simulation might
qualify as a quantitative in silico tool suited to develop hy-
potheses for forensic questions in the context of a potential
overdosing (e.g., of morphine). Perspectively, future research
should include widened assessment and consideration of
(patho)physiological parameters and postmortem changes as
well as dynamic implementations of disease- and age-related
physiological changes in order to improve analogous model-
ing of further pharmaceuticals and drugs of abuse.
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5 Conclusions 
As of today, drug development and pharmacotherapy face a variety of challenges. Drug 
development is a longsome, complex, costly and risky process. To meet the rightly in-
creasing ethical standards and regulatory expectations, tools to rationalize decision mak-
ing during critical development steps are needed. Pharmacotherapy also tends to increase 
in complexity as it becomes clearer that the “one dose fits all” approach can lead to 
ineffective and unsafe drug therapies. To cope with the high variability in the PK, PD 
and PK/PD relationships of drugs due to differences in anatomy and physiology among 
children, adults and elderly patients and due to additional factors, such as genetics, co-
medications, and diseases, ways of leveraging all the existing drug- and patient infor-
mation are needed. 
An emerging innovative mathematical tool to support drug development and pharma-
cotherapy is PBPK modeling and simulation. By integrating all available drug- and pa-
tient information, these complex models can be used to test hypotheses, waive clinical 
studies and to improve decision making.  
In project I, a PBPK parent-metabolite model was developed to support the drug 
development for the new chemotherapeutic agent zoptarelin doxorubicin and its major 
metabolite doxorubicin. The model helped to rule out the potential of zoptarelin doxo-
rubicin to act as an inhibitor of OATP1B3 and OCT2 by specific DDI simulations with 
simvastatin and metformin in worst-case scenarios and hence increased the confidence in 
moving the drug forward in the development process. In addition, not only did this 
project help to generate knowledge about an IND, but it also provided a new methodol-
ogy to assess the general potential for transporter DDIs when a PBPK model is available 
for the perpetrator drug (e.g. zoptarelin doxorubicin) but not for the victim drugs. This 
approach helps to facilitate earlier DDI potential analyses in drug development. 
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In project II, the first coupled whole-body PBPK DDI model for clarithromycin, mid-
azolam and digoxin was presented to support drug development and pharmacotherapy. 
For the first time, the tissue-specific mechanism-based inhibition of CYP3A4 in the in-
testine and the liver via clarithromycin was correctly described and successfully evaluated. 
This was accomplished by implementing a mechanism-based inhibition model of CAP3A4 
into the MoBi software for the first time. This software enhancement was integrated into 
the software package and is now available for users of this software. Furthermore, this 
project showed the first successful tissue-specific competitive inhibition of digoxin 
transport by P-gp in the intestine and the kidney. The final PBPK DDI model of all 
three compounds was subsequently used to determine safe victim drug doses of midazo-
lam and digoxin during clarithromycin treatment and thus provides rationally designed 
DDI management options to physicians and pharmacists. 
Project III dealt with the development and application a PBPK/PD model for the 
chemotherapeutic agent vorinostat, a HDAC inhibitor, to support pharmacotherapy. The 
model was developed for adult and pediatric patients. As all relevant metabolic enzymes 
were incorporated in the final model, state-of-the-art PBPK fitting algorithms were used 
to determine the enzymatic contributions of the major enzymes to the total clearance of 
vorinostat. For pediatric patients maturation functions for all relevant enzymes were 
incorporated and subsequent dosing simulations identified important dosage reductions 
for very young children to avoid overdosing. This is a significant step towards safer future 
pediatric trials. Furthermore, the adult PBPK model was expanded by pharmacodynamic 
biomarker models of vorinostat, namely, the number of circulating thrombocytes and the 
HDAC inhibition in peripheral mononuclear cells. This again was accomplished by im-
plementing these pharmacodynamic models into the MoBi software for the first time. 
This complex PBPK/PD model was finally used to determine potentially safer and more 
effective drug regimens for adults. Important new drug regimens were identified which 
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could be used in the future design of clinical trials in adults. As PBPK/PD models are 
often a neglected option in PBPK research, this case example may encourage other re-
searchers to intensify their work in this area.  
Finally, in project IV, a PBPK parent-metabolite model was developed for the phar-
macotherapy with morphine and its metabolite morphine-6-glucuronide. In a forensic 
case study, this PBPK model helped to argue against a suspected morphine overdose 
administered to a 98-year-old patient by demonstrating that age- and disease-related 
changes in liver- and renal functions were a plausible explanation for the analytically 
determined toxic morphine concentrations. Project IV is the first attempt to use a PBPK 
model in the area of forensic science. Although the model developer could provide enough 
certainty in the model predictions to rule out the suspected morphine overdose, this 
modeling attempt also revealed major future research directions. Especially the so-called 
postmortem redistribution (PMR) and the decline in organ functions over time should 
be intensely investigated. 
 The presented projects span from drug development to pharmacotherapy and they 
nicely underline the translational character of the PBPK modeling and simulation ap-
proach. Furthermore, the results presented in this doctoral thesis did not only success-
fully overcome major obstacles in the field of PBPK research, but they provided sophis-
ticated, data-driven and rational support for drug development and pharmacotherapy. 
The presented work contributed significantly to the overall undertaking to cut the time 
drug development takes as well as its costs and to offer more patient-specific and, at the 
same time, safer and more effective pharmacotherapies. The PBPK software PK-Sim and 
MoBi has been further developed providing the PBPK research community with a state-
of-the-art foundation for further model development as all presented models are either 
directly available for download via the “Open Systems Pharmacology” community 
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(https://github.com/Open-Systems-Pharmacology) or easily re-built by the provided in-
formation in the project manuscripts. 
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6 Summary 
The Physiologically-based Pharmacokinetic (PBPK) approach was successfully used 
within four projects to meet challenges in drug development and pharmacotherapy. 
Firstly, PBPK modeling and simulation revealed that the chemotherapeutic drug in de-
velopment zoptarelin doxorubicin has no drug-drug-interaction (DDI) potential. It de-
creases the organic anion-transporting polypeptide 1B3 (OAT1B3) and organic cation 
transporter 2 (OCT2) transport rates of metformin and simvastatin by only 0.5 and 2.5%, 
respectively. Secondly, to improve the DDI management during pharmacotherapy, the 
PBPK approach revealed that midazolam and digoxin doses should be reduced by 74 to 
88% and by 21 to 22% during co-medication with 250 or 500 mg of clarithromycin (bid). 
Thirdly, pediatric and adult pharmacotherapy of vorinostat could be improved by spec-
ifying pediatric drug dosages of 80 and 230 mg/m2 at the ages of 0-1 and 1-17 years and 
by specifying an effective and safe adult vorinostat dose of 3000 mg (tid). Finally, the 
PBPK approach helped to refuse a suspected morphine overdose by assessing the impact 
of an impaired hepatic and renal function on morphine. This doctoral thesis has success-
fully overcome major obstacles in PBPK research, enhanced existing PBPK software, 
helped to ease the drug development process and improved pharmacotherapy. 
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7 Zusammenfassung 
Der Ansatz der Physiologie-basierten Pharmakokinetik (PBPK) wurde innerhalb von 
vier Projekten erfolgreich verwendet, um Herausforderungen in der Arzneimittelentwick-
lung und der Pharmakotherapie zu meistern. Erstens enthüllte die PBPK Modellierung 
und Simulation, dass das sich in Entwicklung befindliche Chemotherapeutikum Zoptare-
lin Doxorubicin keine Potenzial für Arzneimittelinteraktionen (DDI) aufweist. Es ver-
mindert die organic anion-transporting polypeptide 1B3 (OAT1B3) und organic cation 
transporter 2 (OCT2) Transportraten von Metformin und Simvastatin um 0,5 und 2,5%. 
Zweitens wurde der Umgang mit DDI während der Pharmakotherapie verbessert. Der 
PBPK Ansatz konnte zeigen, dass die Dosierung von Midazolam und Digoxin während 
der Ko-medikation mit 250 oder 500 mg Clarithromycin (bid) um 74 bis 88% und 21 bis 
22% reduziert werden sollte. Drittens konnte die pädiatrische und adulte Pharmakothe-
rapie mit Vorinostat verbessert werden durch eine Dosisspezifikation für Kinder von 80 
und 230 mg/m2 im Alter von 0-1 und 1-17 Jahren und durch die Spezifikation eine si-
cheren und effektiven Dosis von 3000 mg (tid) für Erwachsene. Schließlich half der PBPK 
Ansatz, durch Simulation des Effekts einer Leber- und Nierenfunktionsstörung auf die 
Morphin Pharmakokinetik, eine vermutete Morphinüberdosierung zurückzuweisen. Diese 
Dissertation hat Hindernisse in der PBPK Forschung beseitigt, bestehende PBPK Soft-
ware verbessert und den Arzneimittelentwicklungsprozess vereinfacht. 
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PBPK model of metformin  1. Introduction  The biguanide metformin is the first-line therapeutic agent for the treatment of type 2 diabetes mellitus. Metformin reduces hepatic gluconeogenesis, reduces intestinal absorption of glucose and increases insulin sensitivity and glucose uptake into peripheral tissues [1].  Because of its hydrophilic structure, metformin shows an exceptionally low lipophilicity (logP = -1.43) and is not bound to plasma proteins [2]. Following oral administration, 50 - 60% of a dose are absorbed and peak plasma concentrations are reached within 2 h. The plasma half-life of metformin is 2.5 - 7 h after intravenous infusion and 4 - 8 h following oral administration [3]. Metformin is not subject to hepatic metabolism and mainly renally excreted. After intravenous administration 80 - 100% of the dose are recovered unchanged in the urine; following oral administration the fraction excreted unchanged alternates between 50 and 75%. The observed renal clearance of metformin is much higher than the glomerular filtration rate (GFR), suggesting active renal secretion [2–4]. Metformin is reported to be a substrate of the organic cation transporter (OCT) 1, the kidney specific OCT2 and of OCT3 [5, 6]. These transporters are localized at the basolateral membranes of renal cells, hepatocytes, enterocytes and cells of many other organs. Metformin is also transported by the H+ organic cation antiporters "multidrug and toxin extrusion protein" (MATE) 1 and MATE2-K [7]. These efflux transporters are primarily expressed in the liver (MATE1) and in the kidney (MATE1, MATE2-K) at the apical (luminal) membranes. In vivo, OCT and MATE transporters form a functional unit to transport organic cations from the blood through hepatocytes and renal tubule cells into the bile and urine, resulting in effective biliary and renal secretion.   2. Materials and Methods  Software PBPK modeling was performed with PK-Sim 7.0.0. Parameter optimization was accomplished using the Monte Carlo algorithm implemented in PK-Sim. Digitization of published plasma concentration-time curves was performed with GetData Graph Digitizer (V 2.26). Graphics and further statistical analyses were generated with R (V 3.3.2) using the graphical interface RStudio (V 1.0.136).  Model development For model development, physicochemical parameters as well as individual and mean plasma concentration-time profiles of metformin after intravenous single dose (250 - 1000 mg), oral single dose (250 - 2550 mg) and oral multiple dose (250 - 1000 mg) administration were obtained from literature. Data was separated into training and test datasets for model development and evaluation, respectively (for a detailed study summary see Suppl. Tab. 1). The training dataset contained a study describing the extent of metformin distribution into erythrocytes [8]. Furthermore, fraction excreted to urine data following intravenous (250 and 500 mg) and oral administration (500 mg) of metformin was used in the training dataset to inform the renal secretion process. For population simulations, a virtual Caucasian population was generated containing 50 male and 50 female individuals, 20 - 50 years of age, with body weights of 40 - 120 kg. The ICRP (International Commission on Radiological Protection) database in PK-Sim was used for generation of this population [9]. For model evaluation, the medians and 90% prediction intervals of population simulation plasma concentration-time profiles were calculated and used to generate visual predictive checks (predicted versus observed plasma concentrations) for the training and test datasets. 
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 3. Results  Metformin modeling To limit the number of parameters to be optimized, only the most important processes were implemented into the final metformin model. These are (1) passive distribution into blood cells and the cells of all organs except renal cells, (2) active uptake from blood into renal cells by OCT2 and (3) renal secretion into urine by MATE2-K. Glomerular filtration and enterohepatic cycling were enabled, as these processes are active under physiological conditions.   Drug-dependent parameters All drug-dependent parameters taken from literature with their references as well as all optimized parameter values are given in Suppl. Tab. 2.   System-dependent parameters Expression of the implemented transporters and the geometric standard deviation of their log-normal distribution in virtual populations are given in Suppl. Tab. 3. No other system-dependent parameters were changed or adjusted.  Model performance Training dataset: The training dataset performance of the final metformin model, predicting plasma concentrations following intravenous (250 mg and 500 mg) and oral (500 - 1500 mg) administration of metformin, is presented in Suppl. Fig. 1, 3 and 5 - 8. Predicted compared to observed fraction exreted to urine following intravenous (250 mg and 500 mg) and oral (500 mg) administration is presented in Suppl. Fig. 2 and 4. Suppl. Fig. 6 shows predicted and observed plasma and erythrocyte concentrations following oral administration of 850 mg metformin. Test dataset: The test dataset performance of the final metformin model, predicting plasma concentrations following intravenous (1000 mg) and oral (250 - 2550 mg) administration of metformin, is presented in Suppl. Fig. 9 - 20.   4. Discussion  Model performance Metformin pharmacokinetics show high inter-individual variability in absorption, apparent volume of distribution (654 +/- 358 L) and renal clearance (335 - 615 mL/min) [1, 10]. The slow absorption of metformin rate-limits its disposition [2, 3] so that variability in absorption causes additional variation during the elimination phase of metformin plasma concentration-time profiles. Evaluation of predicted compared to observed clinical data following intravenous application suggests that the current model overpredicts the velocity of distribution into tissues and underpredicts the rate of excretion of metformin (Suppl. Fig. 1, 2, 9). The model accurately describes the plasma and urine concentrations after single oral administration of 500 mg (Suppl. Fig. 3, 4). The 500 mg multiple dose simulations show a good prediction of the trough concentrations with too rapid absorption and an overprediction of Cmax (Suppl. Fig. 5, 12, 13). The same phenomenon can be observed for some of the other studies, especially with administration of higher doses of metformin in the fasted state (Suppl. Fig. 14, 16 – 18), but there are also simulations that underpredict Cmax (Suppl. Fig. 8, 10, 15), due to the documented inter-individual variability. The model simulations of metformin administration together with food nicely 
4  
predict the plateau-like shape of the measured plasma concentration-time curves around Cmax (Suppl. Fig. 6, 11). Plasma and erythrocyte concentrations of the study of Robert et al. [8] are also very well described (Suppl. Fig. 6).  Model limitations Metformin is recommended by the FDA as OCT2/MATE transport victim drug for the use in clinical DDI studies [11]. The purpose of the presented metformin PBPK model is to accurately incorporate these processes so that this model is fit to be coupled to models of OCT2 and MATE2-K perpetrator drugs and applied for DDI prediction. Metformin is positively charged at physiological pH (pKa = 11.5 (base)) and highly hydrophilic (logP =  -1.43). Therefore, passive diffusion of metformin through lipid bilayers is very slow. Nevertheless, distribution and accumulation into red blood cells has been described, with a much longer elimination half-life from erythrocytes (23 h), than from plasma (3 h) [8]. Furthermore, the apparent volume of distribution of metformin is high, in spite of its exceptionally low lipophilicity. The mechanism of this partitioning into red blood cells is currently not understood. Transport in combination with target-binding, binding to other intracellular components, some kind of trapping within organelles or sticking to the cellular membranes of red blood cells are possible explanations. As the mechanism of this accumulation is unclear, an asymmetric permeability from plasma into red blood cells was incorporated. The wide distribution into body tissues is most probably mediated by active transport processes and was modeled by an overall asymmetric permeability from the interstitial space into the cells of all organs except kidney, as so far, only the kidney specific isoforms of OCT and MATE transporters have been incorporated into this model.  To define the contribution of the two implemented transport processes by OCT2 and MATE2-K, fraction excreted to urine data after intravenous and oral administration of metformin have been included into the training dataset. In addition to an accurate description of unchanged drug recovered in urine, evaluation of this model with measured metformin concentrations in the kidney and by prediction of OCT2 and MATE2-K mediated DDIs is needed.  
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 Suppl. Fig. 1 Training dataset: Population simulations compared to observed data of metformin plasma concentrations following intravenous administration of 250 mg (left panel) and 500 mg (right panel). Clinical data are shown as dots (Pentikainen KL, PP and SR are individual data) [2, 3]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
6  
 Suppl. Fig. 2 Training dataset: Population simulations compared to observed data of metformin fraction excreted to urine following intravenous administration of 250 mg (left panel) and 500 mg (right panel). Clinical data are shown as dots (+/- standard deviation) [2, 3]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 3 Training dataset: Population simulations compared to observed data of metformin plasma concentrations following single oral administration of 500 mg. Clinical data are shown as dots (Pentikainen KL, PP, RL, SR and TK are individual data) [2, 12]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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                               Suppl. Fig. 4 Training dataset: Population simulations compared to observed data of metformin fraction excreted to urine following single oral administration of 500 mg. Clinical data are shown as dots (+/- standard deviation) [2]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 5 Training dataset: Population simulations compared to observed data of metformin plasma concentrations following oral administration of 500 mg, 10 h (left panel) and 12 h (right panel) after a single oral administration of 750 mg metformin. Clinical data are shown as dots (+/- standard deviation) [13, 14]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 6 Training dataset: Population simulations compared to observed data of metformin plasma (left panel) and erythrocyte (right panel) concentrations following single oral administration of 850 mg. Clinical data are shown as dots [8]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 7 Training dataset: Population simulations compared to observed data of metformin plasma concentrations following single oral administration of 1000 mg. Clinical data are shown as dots [15]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 8 Training dataset: Population simulations compared to observed data of metformin plasma (left panel) and whole blood (right panel) concentrations following single oral administration of 1500 mg. Clinical data are shown as dots [3]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 9 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following intravenous administration of 1000 mg. Clinical data are shown as triangles (+/- standard deviation) [16]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 10 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following single oral administration (left panel) and once daily oral administration (right panel) of 250 mg. Clinical data are shown as triangles (+/- standard deviation) [7, 17]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 11 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following single oral administration of 500 mg without meal (left panel) and with meal (right panel). Clinical data are shown as triangles (+/- standard deviation) [3, 18–21]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 12 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following twice daily oral administration of 500 mg without meal (left panel) and with meal (right panel). Clinical data are shown as triangles (+/- standard deviation) [22, 23]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 13 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following oral administration of 500 mg, 12 h after a single oral administration of 750 mg metformin. Clinical data are shown as triangles (+/- standard deviation) [24]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
18  
 Suppl. Fig. 14 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following oral administration of 750 mg, 12 h after a single oral administration of 1000 mg metformin. Clinical data are shown as triangles (+/- standard deviation) [25, 26]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 15 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following single oral administration of 850 mg without meal (left panel) and with meal (right panel). Clinical data are shown as triangles (+/- standard deviation) [21, 27, 28]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 16 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following oral administration of 850 mg, 12 h after a single oral administration of 1000 mg metformin. Clinical data are shown as triangles (+/- standard deviation) [4]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 17 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following three times daily oral administration of 850 mg. Clinical data are shown as triangles [28]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 18 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following once daily oral administration of 1000 mg. Clinical data are shown as triangles (+/- standard deviation) [29]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 19 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following single oral administration of 1700 mg. Clinical data are shown as triangles [28]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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 Suppl. Fig. 20 Test dataset: Population simulations compared to observed data of metformin plasma concentrations following single oral administration of 2550 mg. Clinical data are shown as triangles [28]. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals  
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Suppl. Tab. 1 Studies used for metformin PBPK model development and evaluation Dose (mg) Administration  n Women (%) Age (years) Weight (kg) Food intake Dataset Study reference          250 iv (15 min), SD 4 0 30-36 64-83 no training [3] 500 iv (5 min), SD 3 67 36-39 58-63 no training [2] 1000 iv (bolus), SD 5 20 36-60 64-81 no test [16] 250 po (tab), SD 8 0 22-34 54-77 no test [7] 250 po (tab), QD 7 57 19-23 55-78 no test [17] 500 po (tab), SD 24 0 26 - yes test [18] 500 po (tab), SD 15 53 37 82 yes test [19] 500 po (tab), SD 24 0 18-31 52-80 no test [20] 500 po (tab), SD 5 60 36-51 56-80 no training [2] 500 po (tab), SD 24 0 21-35 - no test [21] 500 po (tab), SD 12 - - - no training [12] 500 po (tab), SD 4 0 30-36 64-83 yes test [3] 500 po (tab), BID 16 0 22-55 71-119 yes test [22] 500 po (tab), BID 18 44 18-37 53-104 no test [23] 500 po (tab), MDa 20 0 23 67 no training [13] 500 po (tab), MDb 24 0 26 71 no training [14] 500 po (tab), MDa 20 0 - - no test [24] 750 po (tab), MDc 20 0 35 - no test [26] 750 po (tab), MDc 12 0 27 71 no test [25] 850 po (tab), SD 12 50 23-33 49-101 no test [27] 850 po (tab), SD 6 33 25-46 - yes training [8] 850 po (tab), SD 9 44 46 76 no test [28] 850 po (tab), SD 24 0 21-35 - no test [21] 850 po (tab), SD 24 0 21-35 - yes test [21] 850 po (tab), MDd 12 33 21-40 - no test [4] 850 po (tab), TID 9 44 46 76 no test [28] 1000 po (tab), QD 27 11 20-55 - no test [29] 1000 po (tab), SD 14 0 20-47 60-106 no training [15] 1500 po (tab), SD 4 0 30-36 64-83 yes training [3] 1700 po (tab), SD 9 44 46 76 no test [28] 2550 po (tab), SD 9 44 46 76 no test [28] a: first dose 750 mg, second dose 12 hours later 500 mg, b: first dose 750 mg, second dose 10 hours later 500 mg, c: first dose 1000 mg, second dose 12 hours later 750 mg, d: first dose 1000 mg, second dose 12 hours later 850 mg, BID: twice daily, iv: intravenous, MD: multiple dosing, n: number of individuals studied, po: peroral, QD: once daily, SD: single dose, tab: tablet, test: test dataset (model evaluation), TID: three times daily, training: training dataset (model development and parameter optimization), -: no data available. Values given for age and weight are arithmetic means, minima and maxima 
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Suppl. Tab. 2 Drug-dependent parameters of the metformin PBPK model  Parameter Unit Metformin model Metformin reference Description      MW g/mol 129.16 - Molecular weight pKa - 11.50 (base)  [30] Acid dissociation constant Solubility g/L 100 not solubility limited Solubility logP - -1.43 [30] Lipophilicity fu % 100 [2] Fraction unbound OCT2 KM µmol/L 22.22 optimized Michaelis-Menten constant OCT2 kcat 1/min 92.79 optimized Transportation rate MATE2-K KM µmol/L 362.00 [7] Michaelis-Menten constant MATE2-K kcat 1/min 184.11 optimized Transportation rate GFR fraction - 1 - Fraction of glomerular filtration EHC continuous fraction - 1a - Fraction of bile bypassing gallbladder Administration - tab [31] Route of administration Perm. (plasma-blood cells) cm/min 6.95E-08 optimized Plasma to blood cell perm. Perm. (blood cells-plasma) cm/min 8.12E-08 optimized Blood cell to plasma perm. Perm. (interstitial-intracellular) cm/min 4.53E-05b optimized Interstitial to intracellular perm. Perm. (intracellular-interstitial) cm/min 2.20E-06b optimized Intracellular to interstitial perm. Partition coefficients - calculated R + R Organ-plasma partitioning Specific intest. perm. (para.) cm/min 3.65E-06 optimized Normalized paracellular intest. perm. Specific intest. perm. (trans.) cm/min 0 [32] Normalized transcellular intest. perm. a: changes to 0.35 after food intake, b: in kidney 0, EHC: enterohepatic circulation, intest.: intestinal, MATE2-K: multidrug and toxin extrusion protein 2-K, OCT2: organic cation transporter 2, para.: paracellular, perm.: permeability, PK-Sim: PK-Sim standard calculation method, R + R: Rodgers and Rowland calculation method [33, 34], tab: tablet - digitized dissolution profile from literature used, trans.: transcellular  
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 Suppl. Tab. 3 System-dependent parameters of the metformin PBPK model  Transporter Reference concentration, tissue of highest expression (µmol/L) Geometric standard deviation in virtual populations Tissue localization  (relative expression, normalized to tissue with highest expression)     OCT2 1.09 [35, 36] 1.28 (≙ 25 %CV) Kidney 1.0 [37] MATE2-K 1.0 [38]  1.28 (≙ 25 %CV) Kidney 1.0 [39] MATE2-K: multidrug and toxin extrusion protein 2-K, OCT2: organic cation transporter 2. If no information on reference concentration was available it was set to 1.0 µmol/L and the transportation rate (kcat) was optimized according to [38]  
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PBPK model of simvastatin lactone and simvastatin acid  1. Introduction  Simvastatin is a 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase inhibitor. It is widely used in the treatment of hypercholesterolemia and belongs to the ten most prescribed drugs in industrial nations [1]. Simvastatin is administered orally as a prodrug in its lactone form (dosing range 5 - 80 mg/day [2]) and is converted to the active acid by a combination of enzyme-mediated hydrolysis and spontaneous chemical conversion [3]. The enzyme predominantly responsible for the hydrolysis of simvastatin lactone to simvastatin acid is paraoxonase 3 (PON3) [4, 5]. Simvastatin lactone is highly lipophilic, resulting in good absorption of approximately 60% of an administered dose, but shows extensive first pass metabolism reducing its oral bioavailability to 5% [3]. Simvastatin lactone is mainly metabolized by CYP3A4 [6], while simvastatin acid is metabolized by CYP3A4 (>80%) and CYP2C8 (<20%) as well as transported by organic anion-transporting polypeptide 1B (OATP1B) [7]. A further process discussed for the pharmacokinetics of simvastatin acid is recyclization to the lactone form, either spontaneously, or via enzymatic formation of an intermediate glucuronide. Suppl. Fig. 1 depicts the metabolization pathways of statins in general.   Objectives The purpose of this work was to establish a whole body parent-metabolite PBPK model of simvastatin lactone (prodrug) and acid (pharmacologically active metabolite) as a CYP3A and OATP1B victim drug model for drug-drug interaction studies 
 that accurately predicts plasma concentrations of simvastatin lactone and acid over a broad dosing range 
 that has been evaluated by showing good prediction of simvastatin lactone and acid plasma concentrations in drug-drug interaction (DDI) studies with rifampicin and clarithromycin as CYP3A4 perpetrator drugs 
 that has been evaluated by showing good prediction of simvastatin lactone and acid plasma concentrations in individuals with different OATP1B1 genotypes   2. Materials and Methods  Software PBPK modeling was performed with PK-Sim 7.0.0. Parameter optimization was  accomplished using the Monte Carlo algorithm implemented in PK-Sim. Digitization of published plasma concentration-time curves was performed with GetData Graph Digitizer (V 2.26). Graphics and further statistical analyses were generated with R (V 3.3.2) and the graphical user interface RStudio (V 1.0.136).  Model development For model development, physicochemical parameters as well as plasma concentration-time profiles of simvastatin lactone and simvastatin acid after oral single dose (SD) and multiple dose (MD) administration (range 20 - 80 mg) were obtained from the literature. Data was separated into training and test datasets for model development and evaluation, respectively (for a detailed study summary see Suppl. Tab. 1). The training dataset contained a study showing the impact of different OATP1B1 genotypes on the plasma concentrations of simvastatin acid [8]. This study was included to define the contribution of this transporter to simvastatin acid pharmacokinetics. For studies that did not specify 
3  
the OATP1B1 genotype, the wild type variant was assumed. Due to the lack of clinical trials of direct administration of simvastatin acid, simvastatin lactone and simvastatin acid model development was performed in parallel.  For population simulations, a virtual Caucasian population was generated containing 50 male and 50 female individuals, 20 - 50 years of age, with body weights of 40 - 120 kg. The ICRP (International Commission on Radiological Protection) database in PK-Sim was used for generation of this population [13]. For model evaluation, the arithmetic means and 90% prediction intervals of population simulation plasma concentration-time profiles were calculated and used to generate visual predictive checks (predicted versus observed plasma concentrations) for the training and test datasets. To test the contribution of the implemented CYP3A4 metabolism, the final simvastatin model was coupled to PBPK models of the CYP3A4 perpetrators rifampicin (CYP3A4 inducer, [9]) and clarithromycin (CYP3A4 inhibitor, [10]). Plasma concentrations of simvastatin lactone and simvastatin acid during co-administration with these perpetrator drugs were predicted and compared to observed data.   3. Results  Simvastatin modeling To limit the number of parameters to be optimized, only the most important processes were implemented into the final simvastatin parent-metabolite model. For simvastatin lactone these are (1) PON3 mediated hydrolysis to generate simvastatin acid and (2) CYP3A4 mediated clearance. For simvastatin acid these are (3) hepatic uptake by OATP1B1 and (4) CYP3A4 mediated clearance. The OATP1B1 transport was implemented with two different KM values and two different transport rates, to describe the impact of the investigated OATP1B1 polymorphism on simvastatin acid plasma concentrations. For both, parent and metabolite, glomerular filtration and enterohepatic cycling were enabled.   Drug-dependent parameters All drug-dependent parameters taken from the literature with their references as well as all optimized parameter values are given in Suppl. Tab. 2.   System-dependent parameters Expression of the implemented enzymes and transporters as well as the geometric standard deviation of their log-normal distribution in virtual populations are given in Suppl. Tab. 3. No other system-dependent parameters were changed or adjusted.  Model performance Training dataset: The training dataset performance of the final model, predicting simvastatin lactone and simvastatin acid plasma concentrations following oral administration of 20, 40, 60 or 80 mg simvastatin lactone, is presented in Suppl. Fig. 2 - 6. Suppl. Fig. 7 shows the predicted compared to observed plasma concentrations following oral administration of 40 mg simvastatin lactone to individuals with different OATP1B1 genotypes [8]. The transport rates of the two homozygous OATP1B1 isoforms (c.521TT wild type and c.521CC) were optimized, the transport rate of the heterozygous isoform (c.521TC) has been predicted. Test dataset: The test dataset performance of the final model, predicting simvastatin lactone and simvastatin acid plasma concentrations following oral administration of 20, 40 or 80 mg simvastatin lactone, is presented in Suppl. Fig. 8 - 10.  
4  
 Model application As a further means of model evaluation, the final simvastatin model was applied to predict clinical DDI studies. Simvastatin plasma concentrations during two different trials studying co-administration of simvastatin lactone and the CYP3A4 perpetrator drugs rifampicin [11] and clarithromycin [12] were predicted and compared to observed data.  In the rifampicin DDI study, a single dose of 40 mg simvastatin lactone was administered 17 h after the last dose of a 600 mg QD, 5 day rifampicin regimen. Thus, no inhibitory effects of rifampicin on CYP3A4 or OATP1B1 are expected, solely pure CYP3A4 induction. In the clarithromycin DDI study, once daily doses of 40 mg simvastatin lactone were administered together with the morning doses of a 500 mg BID, 7 day clarithromycin regimen. Unfortunately, only simvastatin lactone plasma concentrations have been reported from this study, allowing no interpretation of the effect of clarithromycin on OATP1B1 and simvastatin acid. Predicted and observed plasma concentrations are shown in shown in Suppl. Fig. 11 and 12. Predicted and observed AUC ratios (AUC during perpetrator treatment / AUC without co-administration of DDI perpetrator) of these DDIs are compared in Suppl. Tab. 4 and 5.   4. Discussion  Model performance The final parent-metabolite PBPK model accurately describes the plasma concentration-time profiles of simvastatin lactone and simvastatin acid after oral administration of 20 - 80 mg simvastatin lactone. There is a slight terminal overprediction of the lactone, but not of the acid concentrations, following single dose administration of 40 mg simvastatin lactone. Nevertheless, the studies of multiple dose administration of 40 mg simvastatin lactone are well predicted. This phenomenon might be caused by variability in body weight or genetic polymorphisms of involved metabolizing enzymes or transporters of these relatively small study populations that have not been taken into account for the model predictions.  To define the contribution of OATP1B1 to the disposition of simvastatin acid, information of a clinical trial studying the impact of the OATP1B1 c.521 polymorphism on simvastatin acid pharmacokinetics has been included into the training dataset. The final simvastatin model accurately predicts the simvastatin acid plasma concentrations of individuals of the three possible OATP1B1 genotypes.  To evaluate the contribution of CYP3A4 to the metabolism of simvastatin lactone and simvastatin acid, clinical DDI studies with the CYP3A4 perpetrators rifampicin and clarithromycin have been predicted and compared to observed data. During the DDI with rifampicin, simvastatin lactone and simvastatin acid plasma concentrations are adequately predicted. In the DDI study with clarithromycin only simvastatin lactone concentrations have been reported and the effect of clarithromycin on simvastatin lactone peak plasma concentrations is underpredicted. Nevertheless, the predicted AUC ratios of simvastatin lactone and simvastatin acid are within twofold of the observed AUC ratios for both of the tested DDIs (see Suppl. Tab. 4 and 5).   Model limitations Simvastatin is listed by the FDA as a sensitive CYP3A substrate for the use in clinical DDI studies, and simvastatin acid is an approved OATP1B victim drug [13]. The purpose of the presented simvastatin PBPK model is to accurately incorporate these processes so that this model is fit to be coupled to models of CYP3A and OATP1B perpetrator drugs and applied for DDI prediction. 
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Mechanisms not implemented into the final simvastatin model include transport by breast cancer resistance protein (BCRP) or p-glycoprotein (P-gp). Genetic polymorphism in the ABCG2 gene encoding for BCRP has been described to influence the plasma concentrations of simvastatin lactone [14], while genetic polymorphisms in ABCB1 (P-gp) have been described to affect the plasma concentrations of simvastatin acid [15]. Implementation of these transport processes would further diminish the contribution of CYP3A4 and was therefore not retained in the final model. Another possible mechanism involved in simvastatin pharmacokinetics is reabsorption (enterohepatic cycling) following BCRP-mediated transport of simvastatin lactone into the bile, or following P-gp-mediated transport of simvastatin acid into bile with subsequent recyclization to the lactone. Information on the pharmacokinetics of simvastatin lactone and acid after intravenous administration, on bioavailability and on enterohepatic cycling would greatly help to improve our current understanding of the mechanisms affecting the plasma concentrations and DDI behaviour of this widely used lipid-lowering drug.    
6  
 
  Suppl. Fig. 1 General scheme for statin metabolization. Original proposed by [16]   
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 Suppl. Fig. 2 Training dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations following single oral administration of 20 mg simvastatin lactone. Clinical data [15] are shown as triangles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 3 Training dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations following single oral administration of 40 mg simvastatin lactone. Clinical data [8, 17] are shown as triangles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 4 Training dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations on day 6 following once daily oral administration of 40 mg simvastatin lactone. Clinical data [18] are shown as triangles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 5 Training dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations following single oral administration of 60 mg simvastatin lactone. Clinical data [19] are shown as triangles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 6 Training dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations following single oral administration of 80 mg simvastatin lactone. Clinical data [20] are shown as triangles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 7 Simulated compared to observed plasma concentrations of simvastatin lactone (blue) and simvastatin acid (red) in typical individuals of the c.521TT (upper panel), the c.521TC (middle panel) and the c.521CC (lower panel) OATP1B1 genotype following single oral administration of 40 mg simvastatin lactone. Clinical data [8] are shown as triangles (training dataset) or circles (test dataset). Simulations are shown as lines  
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 Suppl. Fig. 8 Test dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations following single oral administration of 20 mg simvastatin lactone. Clinical data [21–23] are shown as circles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals    
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 Suppl. Fig. 9 Test dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations following single oral administration of 40 mg simvastatin lactone. Clinical data [11, 12, 14, 24–31] are shown as circles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 10 Test dataset: Population simulations compared to observed data of simvastatin lactone (upper panel) and simvastatin acid (lower panel) plasma concentrations following single oral administration of 80 mg simvastatin lactone. Clinical data [32] are shown as circles. Population simulation means are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals   
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 Suppl. Fig. 11 Test dataset: Simulated compared to observed plasma concentrations of simvastatin lactone (blue) and simvastatin acid (red) in a typical individual without (upper panel) and following pre-treatment with once daily oral administration of 600 mg rifampicin for 5 days (lower panel). A single oral dose of 40 mg simvastatin lactone was administered 17 h after the last dose of rifampicin. Clinical data [11] are shown as circles. Simulations are shown as lines   
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 Suppl. Fig. 12 Test dataset: Simulated compared to observed plasma concentrations of simvastatin lactone (blue) and simvastatin acid (red) in a typical individual without (upper panel) and during co-treatment with twice daily oral administration of 500 mg clarithromycin for 7 days (lower panel). 40 mg simvastatin lactone were administered orally once daily for 7 days. After a washout phase (3 days), 40 mg simvastatin lactone were administered orally once daily together with the morning dose of clarithromycin for further 7 days. PK samples were collected on day 7 and 17. Clinical data [12] are shown as circles. Simulations are shown as lines   
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Suppl. Tab. 1 Clinical studies used for simvastatin lactone and simvastatin acid model development and evaluation  Dose (mg) Administration n Women (%) Age (years) Weight (kg) Genotype Dataset Study reference          20 po (tab), SD 31 19 38 72 - test [21] 20 po (tab), SD 12 42 22 68 P-gp (TTT) training [15] 20 po (tab), SD 12 42 24 66 P-gp (CGC) training [15] 20 po (tab), SD 7 14 30 77 - test [23] 20 po (tab), SD 4 0 25 69 CYP3A5 (*3/*3) test [22] 40 po (tab), SD 10 50 22 62 - test [26] 40 po (tab), SD 9 0 31 68 - test [24] 40 po (tab), SD 5 60 30a 64a - test [27] 40 po (tab), SD 30 50a 30a 64a - test [12] 40 po (tab), SD 23 52 22 68 BCRP (CC) test [14] 40 po (tab), SD 10 40 24 68 - test [31] 40 po (tab), SD 10 10 30a 64a - test [28] 40 po (tab), SD 10 0 30a 64a - test [29] 40 po (tab), SD 16 50 23 68 OATP1B1 (TT) training [8] 40 po (tab), SD 12 42 24 69 OATP1B1 (TC) training [8] 40 po (tab), SD 4 25 23 84 OATP1B1 (CC) training [8] 40 po (tab), SD 28 29 39 73 - training [17] 40 po (tab), SD 20 0 30a 64a - test [30] 40 po (tab), SD 35 34 30a 64a - test [25] 40 po (tab), MD 18 44 25 73 - training [18] 60 po (tab), SD 10 50 30a 64a - training [19] 80 po (tab), SD 12 0 30a 64a - training [20] 80 po (tab), SD 34 53 24 69 - test [32] 40 po (tab), SD/DDI 10 50 30a 64a - test [11] 40 po (tab), MD/DDI 15 50a 30a 64a - test [12] a: assumed, BCRP: breast cancer resistance protein - included BCRP genotype: c.421CC (high activity), CYP3A5: included genotype: *3/*3 (nonexpressors), MD: multiple dosing, n: number of individuals studied, OATP1B1: organic anion-transporting polypeptide 1B1 - included OATP1B1 polymorphism: c.521TT (high activity), c.521TC (intermediate activity), c.521CC (low activity), P-gp: permeability glycoprotein - included P-gp polymorphisms: c.1236TT-c.2677TT-c.3435TT, c.1236CC-c.2677GG-c.3435CC, po: peroral, SD: single dose, test: test dataset (model evaluation), training: training dataset (model development and parameter optimization), -: no data available. Values given for age and weight are arithmetic means  
19  
Suppl. Tab. 2 Drug-dependent parameters of the final simvastatin lactone and simvastatin acid PBPK model  Parameter Unit Simvastatin lactone model Simvastatin lactone reference Simvastatin acid model Simvastatin acid reference Description        MW g/mol 418.57 - 436.6 - Molecular weight pKa - - - 4.18 (acid) [33] Acid dissociation constant Solubility (pH) mg/L 30.0 (water) [34] 11.0 (7.0) [34] Solubility logP - 4.58 optimized 1.35 optimized Lipophilicity fu % 1.09 [66] 5.66 [35] Fraction unbound  PON3 KM µmol/L 31.7 optimized - - Michaelis-Menten constant PON3 kcat 1/ min 429.0 optimized - - Metabolization rate CYP3A4 KM µmol/L 30.7 [38] 56.7 [7] Michaelis-Menten constant CYP3A4 kcat 1/ min 879.0 optimized 276.0 optimized Metabolization rate OATP1B1 KM c.521TT µmol/L - - 2.09 [36] Michaelis-Menten constant OATP1B1 kcat c.521TT 1/ min - - 331.6 optimized Transportation rate OATP1B1 KM c.521CC µmol/L - - 1.69 [36] Michaelis-Menten constant OATP1B1 kcat c.521CC 1/ min - - 0.67 optimized Transportation rate GFR fraction - 1 - 1 - Fraction of glomerular filtration EHC continuous fraction - 1 - 1 - Fraction of bile bypassing the gallbladder Administration - tab [37] - - Route of administration Partition coefficients - calculated R + R calculated R + R Organ-plasma partitioning Cell permeabilities - calculated PK-Sim calculated PK-Sim Cell membrane permeation Specific intest. perm. cm/min 6.14E-05 optimized 1.49E-04 calculated Normalized transcellular intest. perm. Specific organ perm. cm/min 0.205 calculated 0.029 calculated Normalized to surface area CYP3A4: cytochrome P450 3A4, intest.: intestinal, OATP1B1: organic anion-transporting polypeptide 1B1 with the genotypes c.521TT (high activity) and c.521CC (low activity), perm.: permeability, PK-Sim: PK-Sim standard calculation method, PON3: paraoxonase 3, R + R: Rodgers and Rowland calculation method [38, 39], tab: tablet – digitized dissolution profile from the literature used, trans.: transcellular  
20  
Suppl. Tab. 3 System-dependent parameters of the final simvastatin lactone and simvastatin acid PBPK model  Enzyme/  Transporter Reference concentration, tissue of highest expression (µmol/L) Geometric standard deviation in virtual populations Tissue localization  (relative expression, normalized to  tissue with highest expression)     PON3 1.0 [38] 1.28 (≙ 25 %CV) Liver 1.0, lung 0.18, gonads 0.15, skin 0.13, kidney 0.12, stomach 0.09, small intestine 0.09, bone 0.08, pancreas 0.07, spleen 0.06, large intestine 0.06, brain 0.06, heart 0.05, muscle 0.04 [39] CYP3A4 4.32 [40] PK-Sim ontogeny function Liver 1.0, small intestine 0.07, kidney 0.01 [41] OATP1B1 1.0 [38] 1.28 (≙ 25 %CV) Liver 1.0, gonads 0.01 [42] CYP3A4: cytochrome P450 3A4, OATP1B1: organic anion-transporting polypeptide 1B1, PON3: paraoxonase 3. If no information on reference concentration was available it was set to 1.0 µmol/L and the reaction/transportation rate (kcat) was optimized according to [38]       Suppl. Tab. 4 AUC ratio comparison for simvastatin lactone and simvastatin acid during the DDI with rifampicin Simvastatin Lactone Predicted AUC (h*ng/mL) Observed AUC (h*ng/mL) Ratio Predicted/Observed DDI-Rifampicin 2.7 1.8  Placebo 28.1 16.2  Ratio 0.096 0.111 0.86 Simvastatin Acid    DDI-Rifampicin 1.4 1.1  Placebo 14.4 16.2  Ratio 0.097 0.068 1.43       Suppl. Tab. 5 AUC ratio comparison for simvastatin lactone and simvastatin acid during the DDI with clarithromycin Simvastatin Lactone Predicted AUC (h*ng/mL) Observed AUC (h*ng/mL) Ratio Predicted/Observed DDI-Clarithromycin 258.5 219.0  Placebo 37.4 22.0  Ratio 6.912 9.955 0.69 Simvastatin Acid    DDI-Clarithromycin 204.0 73.0  Placebo 26.9 6.0  Ratio 7.584 12.167 0.62    
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  Suppl. Fig. 1 Zoptarelin doxorubicin parent-metabolite PBPK model structure. CLbiliary: biliary plasma clearance, CLhepatic: hepatic metabolic plasma clearance, iv: intravenous administration, LHRHR: luteinizing hormone-releasing hormone receptor    
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  Suppl. Fig. 2 Training dataset: Population simulations compared to observed data of doxorubicin plasma concentrations (red, semilog scale) and fractions excreted to urine and feces (yellow and brown, linear scale) following intravenous administration of 60 mg/m2 doxorubicin. Clinical data (Study 3, doxorubicin arm, n = 9 and [1]) are shown as dots and squares. Population simulation medians are shown as lines or dashed lines; the shaded areas depict the 5th - 95th percentile population prediction intervals    
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4  
  Suppl. Fig. 3 Training dataset: Population simulations (semilog scale) compared to observed data of doxorubicin concentrations in blood plasma (red) and in nucleated blood cells (black) following intravenous administration of 1x 36 mg/m2 doxorubicin as 96 h long-term infusion (left) or 3x 30 mg/m2 doxorubicin as daily bolus infusions (right). Simulated blood cell concentrations represent free plus DNA-bound doxorubicin in the blood cell compartment. Clinical data ([2], n = 7 and [3], n = 7) are shown as dots and triangles (± SD values). Population simulation medians are shown as lines or dashed lines; the shaded areas depict the 5th - 95th percentile population prediction intervals    
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5  
  Suppl. Fig. 4 Training dataset: Population simulations (semilog scale) compared to observed data of zoptarelin doxorubicin (blue) and doxorubicin plasma concentrations (red) following intravenous administration of 10, 20, 40 or 80 mg/m2 (a, b, c, d) zoptarelin doxorubicin. Clinical data (Study 1, n = 1 for each dose, 2 cycles per patient, one dose every 3 weeks) are shown as dots. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals    
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  Suppl. Fig. 5 Test dataset: Population simulations (semilog scale) compared to observed data of zoptarelin doxorubicin (blue) and doxorubicin plasma concentrations (red) following intravenous administration of 160 or 267 mg/m2 (a, b) zoptarelin doxorubicin. Clinical data (Study 1, n = 6 and n = 5, multiple cycles per patient, one dose every 3 weeks) are shown as dots. Population simulation medians are shown as lines; the shaded areas depict the 5th - 95th percentile population prediction intervals    
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  Suppl. Fig. 6 Model performance: Mean AUClast (a, b) and Cmax (c, d) values of population predictions compared to observed data (log scale) of zoptarelin doxorubicin (blue) and doxorubicin (red) plasma concentrations following intravenous administration of 10 to 267 mg/m2 zoptarelin doxorubicin or of 60 mg/m2 doxorubicin. Each dot represents a dosing group of one clinical study. Number of patients per dosing group and further details are listed in Zoptarelin Doxorubicin Supplementary Tables 1 and 2. The solid line marks the line of identity, the dashed lines show the 0.5 to 2.0-fold prediction success limits. AUClast: area under the plasma concentration-time curve from time 0 to the last measurement, Cmax: peak plasma concentration, D: intravenous administration of doxorubicin    
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 Suppl. Tab. 1 Model performance: Predicted and observed pharmacokinetic parameters of zoptarelin doxorubicin  Dose  [mg/m2] n AUClast obs ± SD [h*ng/mL] AUClast pred ± SD [h*ng/mL] Pred error  [%] Cmax obs ± SD [ng/mL] Cmax pred ± SD [ng/mL] Pred  error  [%] Study reference          Zoptarelin doxorubicin        10 1 202 297 ± 102  47 115 123 ± 43  7 Study 1 (ZEN-008-Z023) 20 1 783 570 ± 168 -27 895 236 ± 69 -74 Study 1 (ZEN-008-Z023) 40 1 965 1223 ± 360  27 828 535 ± 152 -35 Study 1 (ZEN-008-Z023) 80 1 3273 2323 ± 743 -29 3699 1039 ± 332 -72 Study 1 (ZEN-008-Z023) 160 6 3507 ± 2170 5570 ± 1887  59 2667 ± 1732 2688 ± 913  1 Study 1 (ZEN-008-Z023) 267 5 4812 ± 3201 8713 ± 3059  81 2436 ± 974 4329 ± 1532  78 Study 1 (ZEN-008-Z023) 160 3 6975 ± 2932 4421 ± 1552 -37 3722 ± 796 2055 ± 733 -45 Study 2 (AEZS-108-046) 210 7 9001 ± 3400 6685 ± 2614 -26 4379 ± 754 3225 ± 1284 -26 Study 2 (AEZS-108-046) 267 4 8995 ± 2910 7217 ± 2311 -20 4485 ± 1280 3534 ± 1149 -21 Study 2 (AEZS-108-046) 267 21 7647 ± 3109 8152 ± 2948  7 3829 ± 1229 4041 ± 1479  6 Study 3 (AEZS-108-053) AUClast: area under the plasma concentration-time curve from time 0 to the last measurement, Cmax: peak plasma concentration, n: number of individuals studied, obs: observed, pred: predicted, pred error: prediction error, SD: standard deviation. Shown are mean ± SD values     Suppl. Tab. 2 Model performance: Predicted and observed pharmacokinetic parameters of doxorubicin  Dose  [mg/m2] n AUClast obs ± SD [h*ng/mL] AUClast pred ± SD [h*ng/mL] Pred error  [%] Cmax obs ± SD [ng/mL] Cmax pred ± SD [ng/mL] Pred  error  [%] Study reference          Doxorubicin       60 9 2079 ± 441 1958 ± 306 -6 874 ± 128 821 ± 96 -6 Study 3 (AEZS-108-053)          Zoptarelin doxorubicin        10 1 39 81 ± 11  108 24 18 ± 3 -25 Study 1 (ZEN-008-Z023) 20 1 97 145 ± 22  49 104 32 ± 5 -69 Study 1 (ZEN-008-Z023) 40 1 238 401 ± 52  68 164 84 ± 11 -49 Study 1 (ZEN-008-Z023) 80 1 990 616 ± 86 -38 945 145 ± 21 -85 Study 1 (ZEN-008-Z023) 160 6 1201 ± 483 1249 ± 187  4 702 ± 425 374 ± 49 -47 Study 1 (ZEN-008-Z023) 267 5 1676 ± 1179 1894 ± 266  13 712 ± 294 581 ± 66 -18 Study 1 (ZEN-008-Z023) 160 3 1113 ± 155 1377 ± 196  24 333 ± 39 306 ± 38 -8 Study 2 (AEZS-108-046) 210 7 1639 ± 983 1947 ± 309  19 368 ± 41 456 ± 64  24 Study 2 (AEZS-108-046) 267 4 4678 ± 827 2177 ± 341 -53 872 ± 198 524 ± 66 -40 Study 2 (AEZS-108-046) 267 21 1990 ± 479 2549 ± 443  28 497 ± 114 582 ± 78  17 Study 3 (AEZS-108-053) AUClast: area under the plasma concentration-time curve from time 0 to the last measurement, Cmax: peak plasma concentration, n: number of individuals studied, obs: observed, pred: predicted, pred error: prediction error, SD: standard deviation. Shown are mean ± SD values    
9  
 Suppl. Tab. 3 Impact of zoptarelin doxorubicin administration time on victim drug exposure Zoptarelin doxorubicin  co-administration time Victim drug  AUC % increase  Victim drug  Cmax % increase         Simvastatin acid AUC96-120 [h*ng/mL]  Cmax [ng/mL]   No zoptarelin doxorubicin 45.091   3.088   Zoptarelin doxorubicin at 94 h 45.140 0.107  3.090 0.075  Zoptarelin doxorubicin at 96 h 45.139 0.105  3.090 0.070  Zoptarelin doxorubicin at 98 h 45.143 0.114  3.092 0.117  Zoptarelin doxorubicin at 100 h 45.143 0.114  3.090 0.078         Metformin AUC96-104 [h*µg/mL]  Cmax [µg/mL]  No zoptarelin doxorubicin 20.719   4.702   Zoptarelin doxorubicin at 94 h 20.722 0.014  4.701 -0.004  Zoptarelin doxorubicin at 95 h 20.739 0.096  4.708 0.143  Zoptarelin doxorubicin at 96 h 20.730 0.052  4.703 0.036         AUC96-104: area under the plasma concentration-time curve from 96 h to 104 h, AUC96-120: area under the plasma concentration-time curve from 96 h to 120 h, Cmax: peak plasma concentration, co-administration time: start of the zoptarelin doxorubicin infusion (267 mg/m2, infusion duration 2 h). Last administration of simvastatin (80 mg, every 24 h) and metformin (1000 mg, every 8 h) at 96 h   
10  
 Suppl. Tab. 4 Drug-dependent parameters of the final zoptarelin doxorubicin parent-metabolite PBPK model  Parameter Unit Zoptarelin doxo- rubicin model (SE) Zoptarelin doxo- rubicin reference Doxorubicin  model (SE) Doxorubicin  reference Description        MW g/mol 1893.06 - 543.525 - Molecular weight pKa - 6.1 (base) 8.2 (base) 9.5 (acid) 10.1 (acid) 12.1 (base) 
[4] [5] [5] [4] [4] 
8.2 (base) 9.5 (acid) - - - 
[5] [5] - - - 
Acid dissociation constants  
Solubility g/L 25.0 (water) AEZS 20.0 (water) [6] Solubility logP - -3.60 [7]a 1.27 [8] Lipophilicity fu % 2.1 AEZS 26.3 AEZS Fraction unbound LHRHR Kd µmol/L 0.0182 (0.50%) optimized - - Dissociation constant LHRHR koff  1/min 0.0113 (0.0001%) optimized - - Dissociation rate constant Internalization KM µmol/L 7.45E-03 [9] - - Michaelis-Menten constant Internalization kcat 1/min 8.01E-04 (0.53%) optimized - - Internalization turnover Hydrolysis L/(µmol*min) 15.81 (0.59%) optimized - - Hydrolysis rate DNA Kd µmol/L - - 3.23 [10] Dissociation constant DNA koff  1/min - - 509.4 [10] Dissociation rate constant CLhep  1/min - - 2.31 (3.14%) optimized Normalized to liver volume CLbil  1/min - - 2.70 (1.64%) optimized Normalized to liver volume GFR fraction - 1 - 1 - Fraction of glomerular filtration  EHC continuous fraction - 1 - 1 - Fraction of bile bypassing gallbladder Administration - intravenous - intravenous - Route of administration Partition coefficients - calculated R + R  calculated R + R  Organ-plasma partitioning Cell permeabilities - calculated PK-Sim  calculated PK-Sim  Cell membrane permeation Specific intest. perm. cm/min 7.17E-15 calculated 1.46E-07 calculated Normalized transcellular intest. perm. Specific organ perm. cm/min 1.57E-13 calculated 1.32E-04 (0.21%) optimized Normalized to surface area a: DrugBank entry for gonadorelin, AEZS: Aeterna Zentaris in vitro result, CLbil: biliary plasma clearance, CLhep: hepatic metabolic plasma clearance, EHC: enterohepatic circulation, intest.: intestinal, LHRHR: luteinizing hormone-releasing hormone receptor, perm.: permeability, PK-Sim: PK-Sim Standard calculation method, SE: standard error, R + R: Rodgers and Rowland calculation method [11, 12]   
11  
 Suppl. Tab. 5 System-dependent parameters of the final zoptarelin doxorubicin parent-metabolite PBPK model  Protein/  Clearance Reference concentration, tissue of highest expression [µmol/L] (SE) Geometric standard deviation in virtual populations Tissue localization  (relative expression, normalized to tissue with highest expression)     Zoptarelin doxorubicin    LHRHR1 470.77 (1.25%) optimized 1.28 (≙ 25 %CV) Gonads 1.0, lung 0.5  Hydrolysis 1.0 [13] 1.28 (≙ 25 %CV) Plasma 1.0, gonads 1.0, lung 0.5     Doxorubicin    DNA 46050.0 (76.6%) optimized 1.28 (≙ 25 %CV) Heart 1.0, kidney 1.0, liver 1.0, pancreas 1.0, spleen 1.0, intestinal mucosa 1.0, gonads 1.0, lung 1.0, blood cells 0.04 CLhep normalized to liver volume 1.28 (≙ 25 %CV) Unspecific hepatic metabolic clearance CLbil normalized to liver volume 1.28 (≙ 25 %CV) Unspecific hepatic biliary clearance CLbil: biliary plasma clearance, CLhep: hepatic metabolic plasma clearance, LHRHR1: luteinizing hormone-releasing hormone receptor 1. If no information on reference concentration was available it was set to 1.0 µmol/L and the reaction rate constant (kcat) was optimized according to [13]    
12  
Supplementary References   1.  American Society of Health-System Pharmacists (2009) AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD 2.  Speth PA, Linssen PC, Holdrinet RS, Haanen C (1987) Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin Pharmacol Ther 41:661–665 3.  Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C (1987) Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother Pharmacol 20:305–310 4.  Haynes WM (2010) CRC Handbook of Chemistry and Physics. CRC Press, Taylor and Francis, Boca Raton, FL 5.  Munnier E, Tewes F, Cohen-Jonathan S, Linassier C, Douziech-Eyrolles L, Marchais H, Soucé M, Hervé K, Dubois P, Chourpa I (2007) On the interaction of doxorubicin with oleate ions: fluorescence spectroscopy and liquid-liquid extraction study. Chem Pharm Bull (Tokyo) 55:1006–1010 6.  International Agency for Research on Cancer (1976) Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. 10:44 7.  Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668–D672 8.  Hansch C, Leo A, Hoekman D (1995) Exploring QSAR: Hydrophobic, electronic, and steric constants. American Chemical Society, Washington, DC 9.  Halmos G, Nagy A, Lamharzi N, Schally A (1999) Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett 136:129–136 10.  Yao F, Duan J, Wang Y, Zhang Y, Guo Y, Guo H, Kang X (2015) Nanopore single-molecule analysis of DNA-doxorubicin interactions. Anal Chem 87:338–342 11.  Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–1276 12.  Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257 13.  Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J (2012) Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos 40:892–901  
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Fig. 1 Predicted concentration-time profiles of clarithromycin after intravenous application of 
clarithromycin (A,B: ref. (23), C,D: ref. (24)) in comparison with observed mean data. Solid line: 
predicted mean, dash-dotted line: predicted median, gray shaded area: predicted SD, dashed line: 
predicted minimum/maximum, gray circles: observed mean data. 
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Fig. 2 Predicted concentration-time profiles of clarithromycin after oral rising doses of 
clarithromycin (13) in comparison with observed mean data (± standard deviation (SD)). Solid 
line: predicted mean, dash-dotted line: predicted median, gray shaded area: predicted SD, dashed 
line: predicted minimum/maximum, gray circles: observed mean data (± SD). 
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Fig. 3 Predicted CYP3A4 activity after multiple doses of clarithromycin in comparison with 
observed data. Left: CYP3A4 activity in the liver, right: CYP3A4 activity in the duodenum. Solid 
line: predicted median, gray shaded area: predicted 5th–95th percentile, dashed line: predicted 
minimum/maximum, boxplots/point estimates: observed data (94). 
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Fig. 4 Predicted concentration-time profiles of midazolam after single intravenous doses of 
midazolam in comparison with observed mean/individual data. Training dataset A,B: ref. (30,34) 
and evaluation dataset C–E: ref. (32,33,35). Solid line: predicted mean, dash-dotted line: 
predicted median, gray shaded area: predicted SD, dashed line: predicted minimum/maximum, 
gray circles: observed mean and individual data.
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Fig. 5 Predicted concentration-time profiles of midazolam after single oral doses of midazolam in 
comparison with observed mean data. Training dataset A–C: ref. (35,38) and evaluation dataset 
D-F: ref. (33,38). Solid line: predicted mean, dash-dotted line: predicted median, gray shaded 
area: predicted SD, dashed line: predicted minimum/maximum, gray circles: observed mean data. 
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Fig. 6 Predicted concentration-time profiles of digoxin after single intravenous doses of digoxin 
in comparison with observed mean data. Training dataset A–F: ref. (41,46) and evaluation dataset 
G–J: ref. (20,42, 43, 44). Solid line: predicted mean, dash-dotted line: predicted median, gray 
shaded area: predicted SD, dashed line: predicted minimum/maximum, gray circles: observed 
mean data (± SD).
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Fig. 7 Predicted concentration-time profiles of digoxin after single oral doses of digoxin in 
comparison with observed mean data. Training dataset A–C: ref. (44,47,49) and evaluation 
dataset D,E: ref. (41,50). Solid line: predicted mean, dash-dotted line: predicted median, gray 
shaded area: predicted SD, dashed line: predicted minimum/maximum, gray circles: observed 
mean data (± SD).
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Fig. 8 Predicted concentration-time profiles of digoxin after multiple oral doses of digoxin in 
comparison with observed mean data. Training dataset A,B: ref. (52,53) and evaluation dataset C: 
ref. (54). Solid line: predicted mean, dash-dotted line: predicted median, gray shaded area: 
predicted SD, dashed line: predicted minimum/maximum, gray circles: observed mean data (± 
SD). 
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Fig. 9 Predicted concentration-time profiles of digoxin after single intravenous doses of digoxin 
(A,B: (26), C,D: (45)) with and without prior clarithromycin regimens in comparison with 
observed mean data. Solid line: predicted digoxin mean without prior clarithromycin, dashed 
line: predicted digoxin mean with prior clarithromycin, gray circles: observed mean digoxin 
without prior clarithromycin, gray triangles: observed mean digoxin with prior clarithromycin. 
Clarithromycin was administered orally (bid) with 250 mg (A,B) and 200 mg (C,D). 
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Fig. 10 Parameter sensitivity analysis. The x-axis represents the logarithm of the factor by which 
the parameters are multiplied in order to vary them over a range of 0.1 to 10-fold. 
12 / 12 
 
 
 
Table 1. Predicted count of DDI using adapted doses of midazolam and digoxin 
Application and dose [mg] of 
clarithromycin 
Application and dose [mg] of 
victim drug DDI classification* 
CSD 
[%] 
RD 
[%] 
Δ CSD Ref. 
 Midazolam      
po (tab, MD), 500 iv (inf, 30 min, SD), 0.05 /kg No 17.5 42.5 25.0 
(29)   Weak 39.4 26.9 -12.5 
  Moderate 40.0 29.4 -10.6 
  Strong 3.1 1.3 -1.9 
po (tab, MD), 500 po (tab, SD), 4 No 0.0 83.8 83.4 
(29)   Weak 0.6 9.4 8.8 
  Moderate 58.1 6.9 -51.3 
  Strong 41.3 0.0 -41.3 
po (tab, MD), 250 po (tab, SD), 15 No 0.0 66.9 66.9 
(39)   Weak 16.7 6.9 -9.8 
  Moderate 74.2 1.3 -72.9 
  Strong 9.2 0.0 -9.2 
 Digoxin      
po (tab, MD), 500 po (tab, SD), 0.25 No 70.8 86.7 15.8 
(48)   Weak 20.8 10.0 -10.8 
  Moderate 19.2 41.7 22.5 
  Strong 39.2 11.7 -27.5 
po (tab, MD), 250 po (tab, SD), 0.75 No 51.7 54.2 2.5 
(26)   Weak 7.5 8.3 0.8 
  Moderate 8.3 18.3 10 
  Strong 32.5 19.2 -13.3 
* DDI classification is based on FDA Drug Interaction Studies guidance (4): “no”, “weak”, “moderate” and “strong” are used 
according to AUCratio < 1.25, 1.25 ≤ AUCratio < 2.0, 2.0 ≤ AUCratio < 5.0 and AUCratio ≥ 5.0, CSD (clinical study dose) % of 
individuals at clinical study dose, RD (reduced dose) % of individuals at adapted dose 
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Fig. S1 Schematic overview of the PBPK/PD model development process. The sequence of model development is indicated by arrows 
starting with “1. Adult - PBPK”. 
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Fig. S2 Predicted versus observed PK parameters. a AUC0-inf in adults (n = 52). b Cmax in adults 
(n = 52). c AUC0-inf in children (n = 19). Circles indicate adults and triangles children. Dashed 
line: 2-fold acceptance limits. 
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Fig. S3 External evaluation of the vorinostat PBPK model in plasma. Simulated data are 
represented as median (black line), 90% prediction interval (grey shaded area) and minimum and 
maximum values (dotted lines). Observed data are represented whites circles. a,b [1], c-f [2], g-i 
[1], j-m [3], n [4], and o [5]. Single doses: sd, repeated once daily doses: qd. 
5 / 18  
Fig. S4 Maturation of UGT enzymes [6-11]. a Simulated (solid line) versus observed (circles) 
UGT 2B17 maturation. b Available PK-Sim UGT maturation profiles together with the UGT 
2B17 maturation model (solid line, no marker). 
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Fig. S5 Individual single oral vorinostat plasma predictions in pediatric and adult patients [12]. 
Circles and triangles indicate two occasions of vorinostat concentration-time measurements. 
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Fig. S6 Identification of pediatric vorinostat doses from 0 – 17 years. a AUC0-inf and Cmax 
predictions for previously proposed 230 mg/m2. b AUC0-inf and Cmax predictions for doses of 80 
and 230 mg/m2. Boxes: 25th, 50th and 75th of predicted AUC0-inf and Cmax values in the respective 
age groups. Box whiskers: defined as 1.0-times the interquartile range. Blue area: 25th to 75th 
percentile of the adult predictions following the approved adult standard dose of 400 mg. Blue 
solid line: median of the adult predictions. 
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Fig. S7 Comparison of vorinostat PBMC concentration-time profiles simulated using a 1- or 2-
compartmental (cmt) model following a single oral vorinostat dose of 400 mg. Simulated data are 
represented as dashed (1-cmt) and solid (2-cmt) lines. Observed data are represented as white 
circles. 
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Fig. S8 Parameter sensitivity analysis of the vorinostat PBPK model. 
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Table S1 Overview of fitted parameters and applied optimization methods 
Parameter Optimization 
method Parameter description 
Whole-body PBPK model of vorinostat 
CLhydr.,β-ox. Nelder-Mead Clearance via hydrolysis and β-oxidation 
Pintest Nelder-Mead Intestinal permeability 
Pcell Nelder-Mead Cellular permeability 
PRBC->PLS Nelder-Mead Plasma-blood permeability 
PPLS->RBC Nelder-Mead Blood-plasma permeability 
LayerPD,unstirred,water Nelder-Mead Particle dissolution unstirred water layer 
PBMC effect compartment model 
keffect,1 Monte-Carlo Transfer rate constant PlasmaPBMC 
keffect,2 Monte-Carlo Transfer rate constant PBMCPlasma 
keffect,deep,1 Monte-Carlo Transfer rate constant PBMCPBMCdeep 
keffect,deep,2 Monte-Carlo Transfer rate constant PBMCdeepPBMC 
HDAC indirect response model 
Smax Monte-Carlo Maximum inhibition 
SC50 Monte-Carlo Concentration at half maximum inhibition 
kin Monte-Carlo HDAC activity synthesis 
kout Monte-Carlo HDAC activity degradation 
Monte-Carlo settings: Break condition for relative error improvement = 0.001, Scale of 
projection degree (alpha) = 30, Maximum number of iterations = 10000 
Nelder Mead settings: Maximum number of iterations = 1000 
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Table S2 Overview of assumptions 
  Assumption New/established Testable/ 
not-testable Test/approach to assess impact Justification Impact on the results/recommendations 
Pharmacology 
HDAC inhibition turnover model 
can be used for dose identification in 
in silico trials with varying 
vorinostat doses although developed 
with HDAC activity measurements 
following a single 400 mg dose of 
vorinostat only 
new 
Not testable with 
the present dataset 
Development of HDAC inhibition 
model with HDAC activity 
measurements following varying 
single and multiple vorinostat doses 
and compare dose identifications 
Only HDAC activity measurements following a single 
400 mg vorinostat dose was available 
HDAC inhibition might be over- or under-predicted; doses 
identified for adults using the PBPK/PD approach could 
differ from the current ones; dose recommendations for 
children would not differ 
Vorinostat does not accumulate in 
organs and tumors established; new 
Not testable with 
the present dataset 
Measurement of multiple dose 
vorinostat PK in organs and tumors 
Unknown whether vorinostat accumulates in organs or 
tumors, but half-life of vorinostat is very short indicating 
no accumulation 
In case of accumulation of vorinostat in organs or tumors: 
recommended vorinostat doses should be reduced for adults 
The only differences between 
patients with thrombocytosis and 
normal thrombocyte counts are the 
baseline cell counts of proliferating 
and circulating cells 
new 
Not testable with 
the present 
dataset/modeling 
approach 
Combined analysis of the 
thrombocyte counts of both patient 
populations using the population 
approach 
The only dataset available assessing the impact of 
multiple doses of vorinostat was the presented one in a 
thrombocytosis patient population; vorinostat impact on 
platelet count in patient with normal cell counts could be 
successfully predicted 
Platelet counts might be over- or under-predicted in the 
patient population with normal platelet counts. Doses 
identified for adults using the PBPK/PD approach could 
differ from the current ones; dose recommendations for 
children would not differ 
PK/PD (HDAC activity, platelet 
count) relationship is similar in 
adults and children 
new/established Not testable with the present dataset 
Combined analysis of PK/PD 
relationships in adults and children 
Comparable vorinostat doses of 230 mg/m2 for children 
and 400 mg for adults lead to significant accumulation of 
acetylated H3 histones in both populations and to similar 
dose-limiting toxicities; no time-biomarker data available 
for children; PK data in children shows no clear 
relationship between dose and exposure 
Different PK/PD relationships in adults and children might 
change interpretation of dose recommendations for children 
Physiology 
Maturation of UGT 2B17 protein 
abundance can be described by 
mRNA expression profile as 
surrogate 
established Not testable with the present dataset 
Combined analysis of UGT 2B17 
protein abundance over time and 
available mRNA data over time 
In general mRNA correlates adequately with respective 
protein abundance; no age-dependent UGT 2B17 protein 
abundance measurements available 
Dose recommendation for children might change as 
maturation might change using protein data 
The unidentified hydrolytic and 
oxidative enzyme is fully developed 
from birth on 
new 
Not testable with 
the present dataset 
Identification of hydrolytic and 
oxidative enzyme responsible for 
vorinostat metabolism; identification 
of maturation profiles; Assessment 
of dose recommendations for 
children with and without maturation 
profile 
Unidentified enzyme; unknown maturation profile; 
assuming full development from birth on, dose 
recommendations for children can be interpreted as 
maximum doses 
Potential maturation would decrease vorinostat clearance at 
ages with immature enzyme; recommended doses would 
decrease 
Disease 
In patients with hematologic cancer 
or solid tumors, vorinostat has 
similar PK  
established Testable Combined PK analysis of patients 
with hematologic or solid tumors No differences in PK found in clinical studies 
Differences in vorinostat PK in different patient groups could 
lead to disease-dependent PBPK model parameterization 
In patients with hematologic cancer 
or solid tumors, vorinostat has 
similar impact on HDAC inhibition 
new 
Not testable with 
the present dataset 
Combined HDAC inhibition  
analysis of patients with hematologic 
or solid tumors 
HDAC inhibition data only available for patients with soft 
tissue sarcoma only 
Differences in HDAC inhibition in different patient groups 
could lead to disease-dependent dosing regimens 
Data Data BLQ have no impact on 
analysis results new 
Not testable with 
the present dataset 
Model development with and 
without BLQ data followed by 
comparison of model simulations 
No BLQ data were available Vorinostat has a short half-life of 1-2 h, BLQ should have 
negligible impact on dose recommendations 
Statistics PD parameters are distributed with a CV of 20% established 
Not testable with 
the present 
modeling approach 
Development of PD models using 
the population approach PD parameters are known to differ between individuals 
Dose recommendations for adults based on the PBPK/PD 
approach were carried out using a typical individual; 
assumption has no impact on dose recommendations 
BLQ below limit of quantification, CV coefficient of variation, HDAC histone deacetylase, mRNA messenger ribonucleic acid, PBMC peripheral blood mononuclear cells, PD pharmacodynamics, PK pharmacokinetics, UGT Uridine 5'-diphospho-glucuronosyltransferase 
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Table S3 System-related thrombocytopenia model parameters 
Reference Circ0  [109 cells/l] 
MTT  
[h] 
ktr  
[/h] 
γ  
[-] 
δ 
[-] 
[13] 267 97 0.0412 0.288 NA 
[14] NA 60 0.0663 0.118 NA 
[15] 277 104 0.0385 0.239 NA 
[16] 255 37 0.1070 0.135 NA 
[17] 253 110 0.0364 0.203 NA 
[18] 195 95 0.0421 0.498 0.177 
[18] 273 95a 0.0421a 0.498a 0.177a 
[19] NA 142 0.0282 0.176 NA 
[20] 185 112 0.0357 NA NA 
Mean 244 95 0.0486 0.269 0.177 
Circ0 circulating thrombocytes baseline  
MTT mean transit time 
ktr transit rate constant 
γ and δ feedback exponents 
a
 only counted once for the calculation of the mean 
NA not available 
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Table S4 Overall precision and accuracy of the simulated and predicted adult 
and pediatric pharmacokinetic profiles 
Ref. Route of  
administration 
Dose  
[mg] 
Dosing 
schedule 
Internal (in) or 
external (ex) 
dataset 
MPE 
[%] 
[21] iv (inf. 2 h) 75 - 900 /m2 sd in 47 
[1] iv (inf. 2 h) 200, 400 sd ex 35 
[2] po 400 - 1000 qd ex -40 
[3] po 100 - 500 qd in 15 
[22] po 200 - 400 qd ex -7 
[23,24]a po 400 sd in -8 
[4] po 400 qd ex 48 
[5] po 400 qd ex 62 
[12]a po 100 - 500 sd ex 248 
    Mean: 44 
a
 unpublished  
iv intravenous 
inf infusion 
MPE mean prediction error 
po per oral 
qd once daily 
sd single dose 
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Table S5 PBPK/PD model parameter values for the PBMC effect compartment 
model and the HDAC indirect response model 
Parameter Unit Value Parameter description 
PBMC effect compartment model 
keffect,1 1/min 1.58 Transfer rate constant Plasma  PBMC 
keffect,2 1/min 4.00E-3 Transfer rate constant PBMC  Plasma 
keffect,deep,1 1/min 1.19 Transfer rate constant PBMC  PBMCdeep 
keffect,deep,2 1/min 1.26E-3 Transfer rate constant PBMCdeep  PBMC 
HDAC indirect response model 
Smax - 8.35 Maximum inhibition 
SC50 µmol/l 2.38 Concentration at half maximum inhibition 
kin 1/min 0.043 HDAC activity synthesis 
kout 1/min 0.043 HDAC activity degradation 
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Table S6 Overview of in silico trials (part 1) 
In silico 
trial 
Admin. 
route 
Dose 
[mg] 
Infusion 
time [h] Dosing regimen 
Δ HDAC 
activity  
[% APV] 
Δ Acc. time 
HDAC activity 
< 50 %  
[% APV] 
Δ 
Thrombocyte 
count  
[% APV]a 
F1 infusion 900 /m2 2 qd -68 +50 -97 
APV oral 400  qd 0 0 0 
J1 oral 400  bid (every 2nd week) 0 0 -6 
O1 infusion 400  bid (every 2nd week) -54 0 -54 
D oral 800  single dose, every 2
nd
 
day -14 -10 -1 
N1 oral 400  bid; 3 cons. days a 
week 0 -14 +2 
N2 oral 436.56  bid; 3 cons. days a 
week -3 -14 0 
M2 oral 641.74  bid; 2 cons. days a 
week -14 -15 0 
L2 oral 860.32  qd; 3 cons. days a 
week -19 -16 0 
J2 oral 324.23  bid (every 2nd week) 5 -17 0 
E oral 1600  single dose, every 4
th
 
day -24 -22 0 
G infusion 900 /m2 2 qd (every 2nd week) -68 -26 -87 
I2 oral 631.09  qd (every 2nd week) -14 -26 0 
K2 oral 1284.41  qd; 2 cons. days a 
week -22 -27 0 
F2 infusion 120 2 qd -24 -33 0 
O2 infusion 97.11  bid (every 2nd week) -14 -33 0 
H1 infusion 600 /m2 2 qd (every 2nd week) -65 -34 -71 
M1 oral 400  bid; 2 cons. days a 
week 0 -43 +9 
I1 oral 400  qd (every 2nd week) 0 -51 +9 
L1 oral 400  qd; 3 cons. days a 
week 0 -58 +14 
H2 infusion 194.3 2 qd (every 2nd week) -38 -59 0 
H3 infusion 194.3 2.47 qd (every 2nd week) -35 -59 0 
B oral 200  bid +27 -66 +1 
K1 oral 400  qd; 2 cons. days a 
week 0 -72 +18 
C oral 150  tid +38 -100 -2 
Acc. accumulated 
Admin. administration 
APV approved standard treatment 
a
 -74% is equal to the lower thrombocyte constraint of 50*109 cells/l 
qd dosing once daily 
bid dosing twice daily 
tid dosing thrice daily 
cons consecutive 
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Table S7 Overview of in silico trials (part 2) 
In silico 
trial 
Admin. 
route 
Dose 
[mg] 
Infusion 
time [h] Dosing regimen 
Δ HDAC 
activity  
[% APV] 
Δ Acc. time HDAC 
activity < 50 %  
[% APV] 
Δ 
Thrombocyte 
count  
[% APV]a 
C oral 3000  tid -16 +509 -72 
B oral 3000  bid -24 +471 -74 
A oral 3000  qd -27 +283 -62 
J1 oral 3000  bid (every 2nd week) -27 +224 -69 
N1 oral 3000  bid; 3 cons. days a 
week -27 +211 -55 
D oral 3000  single dose, every 2nd day -27 +89 -30 
I1 oral 3000  qd (every 2nd week) -27 +89 -40 
L1 oral 3000  qd; 3 cons. days a 
week -27 +61 -27 
F1 infusion 773 2 qd -62 +33 -74 
O1 infusion 614  bid (every 2nd week) -59 +17 -74 
K1 oral 3000  qd; 2 cons. days a 
week -27 +6 -12 
APV oral 400  qd 0 0 0 
E oral 3000  single dose, every 4th day -27 -6 -7 
G infusion 1230 2 qd (every 2nd week) -65 -34 -74 
M1 oral 3000  bid; 2 cons. days a 
week -27 -43 -37 
Acc. accumulated 
Admin. administration 
APV approved standard treatment 
a
 -74% is equal to the lower thrombocyte constraint of 50*109 cells/l 
qd dosing once daily 
bid dosing twice daily 
tid dosing thrice daily 
cons consecutive 
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